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ABSTRACT 
Background 
Schistosomes are parasitic worms found in tropical and sub-tropical fresh waters.  An estimated 4.5 
million South Africans, mainly in settings of rural poverty, are in need of treatment for urogenital 
schistosomiasis. Women with schistosomiasis are exposed to HIV infection prevalent in African 
countries. Praziquantel is the treatment used in the mainstream healthcare system to manage 
schistosomiasis. Although conventional treatment is available, traditional medicine (TM) has been 
reported to be used for schistosomiasis. This study evaluated the prevalence of the use of traditional 
medicine and prescribed antischistosomal medicines in communities having high prevalence 
schistosomiasis infection in ILembe District, KwaZulu-Natal and established whether the unavailability 
of prescribed antischistosomal medicines led to the use of traditional medicine.   
 
Methods  
This study was a cross-sectional descriptive study using a questionnaire. An exploratory mixed-method 
approach through interviews was conducted from December 2017 to April 2018 in the ILembe District, 
KwaZulu-Natal. In addition, a review of medical chart records of patients with schistosomiasis was 
further carried out to triangulate the information from interviews. Qualitative data were coded and 
analyzed using thematic analysis while descriptive statistics including frequency and percentage were 
used for quantitative data, categorical data were presented as tables. Chi-squared tests were performed 
for the association between continuous variables. A p-value ≤ 0.05 was estimated as statistically 
significant.  
 
Results  
A protocol mapping evidence of the concurrent use of TM and antischistosomal treatment was drafted. 
It anticipated findings on identified gaps in the current literature on this topic and provided direction 
for future research. After mapping for evidence, face-to-face interviews were conducted in phase 1 of 
this study among 22 traditional health practitioners (THPs) who diagnosed and managed 
schistosomiasis symptoms based on their knowledge and experiences using plants either alone or in 
combination with other plants. Senecio serratuloides (Asteraceae) and Hypoxis 
hemerocallidea (Hypoxidaceae) were prominently used in the study area by THPs for the management 
schistosomiasis. THPs provided services to individuals who did not want to be treated in the mainstream 
health care system for schistosomiasis.  
Following the interviews with THPs, 124 healthcare workers (HCWs) were interviewed with the 
majority of them (114/124; 91.9%) reporting that Praziquantel was readily available in healthcare 
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facilities. However, most of HCWs (76/124; 61.3%) did not know whether patients seen by them used 
concurrently TM and Praziquantel for schistosomiasis. No significant relationship between the 
availability of Praziquantel and the concurrent use of TM by patients for schistosomiasis (X2 = 3.042, 
p = 0.551) was found.  
Patients seen by THPs (20) were also interviewed in the same phase 1. They reported that they used 
TM only for schistosomiasis. Patients attending outpatient departments were also interviewed in this 
phase. More than half of them (8/15, 53.3%) crossed from TM to the mainstream healthcare system, 
but they did not disclose their use of TM to HCWs.  
After the interviews in phase 1, a medical chart review was conducted in phase 2 of the study to analyse 
the concurrent use of traditional medicine with conventional medicine for schistosomiasis. None of the 
medical chart records analyzed; documented the concurrent use of TM and Praziquantel.  
Conclusion  
TM played a key role in the management of schistosomiasis in the study area. HCWs indicated that 
although Praziquantel was readily available and free in public sector healthcare facilities, patients used 
TM for schistosomiasis. HCWs reported not to be aware of whether patients used concurrently TM and 
Praziquantel for the treatment of schistosomiasis. Further investigations are needed to establish the 
reasons for use, potential benefits or risks of the concurrent use of modern and traditional medicine for 
schistosomiasis. Biological studies on TM used for schistosomiasis in the study area are warranted to 
confirm the pharmacological properties and active compounds of medicinal plants used by THPs for 
schistosomiasis. 
 
Keywords: Schistosomiasis, Praziquantel, Traditional Medicine, Conventional Treatment, Healthcare 
workers, Patients, Traditional Health Practitioners 
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UKUQALA (ISIZULU) 
Ingemuva 
I-Schistosomes yizibungu ezinamapayipi ezitholakala emanzini ahlanzekile ashisayo nasemanzini 
ashisayo. Kulinganiselwa ukuthi abantu abayizigidi ezingu-4,5 baseNingizimu Afrika, ikakhulukazi 
ezimisweni zobuphofu basemaphandleni, badinga ukwelashwa ye-Abesifazane abanesichenene 
bavezwe ukutheleleka ngegculazi emazweni ase-Afrika. I-Praziquantel yindlela yokwelashwa 
esetshenziswa ohlelweni lwezempilo olulawula isifo sesichenene. Yize ukwelashwa okuvamile 
kuyatholakala, imithi yendabuko ibikwa ukuthi isetshenziselwa isifo sesichenene. Lolu cwaningo 
lwahlola ukusabalala kokusetshenziswa kwemithi yendabuko kanye nemithi enqunywe yi-
antischistosomal emiphakathini enokutheleleka okuphezulu kwesichenene esifundazweni sase-ILembe, 
KwaZulu-Natali futhi yabeka ukuthi ukungatholakali kwemithi enqunyiwe ye-antischistosomal 
kuholela ekusetshenzisweni kwemithi yendabuko. 
Izindlela 
Lolu cwaningo lwaluyinkimbinkimbi echazayo yesigaba esilandelayo besebenzisa emibuzo. Indlela 
yokuhlolisisa indlela eyaxutshwa ngayo ngokusebenzisa izingxoxo yenziwa kusukela ngoDisemba 
2017 kuya ku-Ephreli 2018 esifundeni sase-ILembe, KwaZulu-Natali. Ngaphezu kwalokho, 
ukubuyekezwa kwamarekhodi wezatifiketi zezokwelapha iziguli ezinesichenene kwaqhutshelwa 
phambili ukuze kuhlolisiswe ulwazi oluvela ezinkulumweni. Idatha efanelekayo ibhalwe futhi 
ihlaziywe ngokusebenzisa ukuhlaziywa kwezingqikithi ngenkathi izibalo ezichazayo kufaka phakathi 
imvamisa kanye namaphesenti asetshenziselwa idatha yokulinganisa, idatha yezinhlawulo yanikezwa 
njengamatafula. Ukuhlolwa kwe-Chi-squared kwenziwa ngenhlangano phakathi kwezinguquko 
eziqhubekayo. Inani le-p ≤ 0.05 lalinganiselwa njengenani elibalulekile. 
Imiphumela 
Ubufakazi bokumephulwa kwemithetho yeprotocol yokusetshenziswa okufanayo kwe-TM kanye 
nokwelashwa kwe-antischistosomal kwalungiswa. Kwakulindele ukutholakala kwezikhala 
ezikhonjisiwe ezincwadini zamanje ngalesi sihloko futhi sinikeze isiqondiso socwaningo oluzayo. 
Ngemuva kokumekwa kobufakazi, ukuxoxisana ubuso nobuso kuqhutshwa esigabeni sokuqala salolu 
cwaningo phakathi kwabelaphi bendabuko abangama-22 abathola futhi baphatha izimpawu 
zesichenene ngokusekelwe kolwazi lwabo nokuhlangenwe nakho ngokusebenzisa izitshalo zodwa 
noma zihlangene nezinye izitshalo. I-Senecio serratuloides (i-Asteraceae) ne-Hypoxis hemerocallidea 
(i-Hypoxidaceae) yasetshenziswa ngokucacile endaweni yokucwaninga kwabelaphi bendabuko 
ekulawuleni isichenene. Umulaphi bendabuko inikeze izinsizakalo kubantu ababengafuni ukulashwa 
ohlelweni lokunakekelwa kwempilo olujwayelekile lwesichenene. 
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Ngemuva kokuxoxisana kwabelaphi bendabuko, abasebenzi abangu-124 bezempilo baxoxwa iningi 
labo (114/124; 91.9%) ukubika ukuthi i-Praziquantel yayitholakala kalula ezindaweni zokunakekelwa 
kwezempilo. Kodwa-ke, iningi lakwa-abasebenzi bezempilo (76/124; 61.3%) lalingazi ukuthi iziguli 
zithintana yini n-Imithi yendabuko kanye ne Praziquantel ngesikhathi sesichenene. Akukho buhlobo 
obubalulekile phakathi kokutholakala kwe-Praziquantel kanye nokusetshenziswa okufanayo kwe-
Praziquantel kanye nokusetshenziswa okufanayo kwabelaphi bendabuko iziguli zesichenene (X2 = 
3.042, p = 0.551) okwatholakala. 
Iziguli ezibonwa abelaphi bendabuko (20) nazo zaxoxwa ngesigaba esifanayo sokuqala. Babika ukuthi 
basebenzisa imithi yendabuko kuphela kwisichenene. Iziguli (15) eziya eminyangweni yeziguli 
ezidlulele ngaphandle kwaxoxwa nazo ngalesi sigaba. Abangaphezu kwengxenye yabo (8/15, 53.3%) 
bawela emithonjeni yendabuko baya ohlelweni lwezempilo olujwayelekile, kodwa abazange bakuveze 
ukusebenziswa kwabo imithi yendabuko kwabasebenzi bezempilo. 
Ngemuva kokuxoxisana ngesigaba sokuqala, ukubuyekezwa kweshadi lwezokwelapha kwenziwa 
esigabeni sesibili socwaningo ukuhlaziya ukusetshenziswa okufanayo komuthi wendabuko nemithi 
ejwayelekile yesichenene. Awekho amarekhodi wezeshadi zezokwelapha ahlaziywe asebenzisa 
ukusetshenziswa okufanayo no-Praziquantel. 
Isiphetho 
Imithi yendabuko idlala indima ebalulekile ekuphatheni kwisichenene endaweni yocwaningo. 
Abasebenzi bezempilo abonisa ukuthi nakuba i-Praziquantel isheshe itholakale futhi mahala 
ezindaweni zokunakekela ezempilo zomphakathi, iziguli zisebenzisa imithi yendabuko ukulapha 
isichenene. Abasebenzi bezempilo abike ukuthi angaqapheli ukuthi iziguli ezisetshenziswa 
ngokufanayo imithi yendabuko kanye no-Praziquantel zokwelashwa kweskripthi. Uphenyo 
olwengeziwe luyadingeka ukuze kutholakale izizathu zokusetshenziswa, izinzuzo ezingenzeka noma 
izingozi zokusetshenziswa okufanayo komuthi wesimanje nendabuko we-isichenene. Ucwaningo 
lwezinto eziphilayo ngemithi yendabuko olwenzelwe isichenene endaweni yokucwaninga 
kuqinisekisiwe ukuba kuqinisekiswe izakhiwo zemithi kanye nezinhlanganisela ezisebenzayo 
zezitshalo zokwelapha ezisetshenziswa y-abasebenzi bendabuko ye-isichenene. 
 
Amagama angukhiye: Isichenene, i-Praziquantel, Imithi Yendabuko, Ukwelapha Okuvamile, 
Izisebenzi Zempilo, Iziguli, Abasebenzi Bempilo Yendabuko (Abelaphi Bendabuko) 
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CHAPTER ONE: INTRODUCTION 
This chapter outlines the general topic, gives some background and provides a review of the literature 
related to the topic (section 1.1). Section 1.2 outlines the statement of the problem/justification or 
rationale of the study (evaluate the current situation identifying the gap and the importance of the 
proposed research). Section 1.3 describes the research aim and objectives, section 1.4 states the 
hypothesis, section 1.5 outlines the general methodology and finally, section 1.6 includes an outline of 
the remaining chapters of the thesis or layout of the thesis. 
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CHAPTER ONE: INTRODUCTION 
1.1. Background  
Approximately 750 million people across the world are infected with schistosomiasis and 261 million 
in sub-Saharan Africa (Banhela et al., 2017). Infectious diseases are major public health and 
socioeconomic problems in Africa. Furthermore, in rural and some urban areas of poor countries, there 
are many Neglected Tropical Diseases (NTDs) which are the cause of much suffering (Hotez and 
Kamath, 2009).  Highly prevalent, in Africa alone, schistosomiasis kills about 280,000 people annually 
(Mitra and Mawson, 2017). Even though data have not been updated over the past 20 years (Banhela et 
al., 2017, Barsoum et al., 2013), an estimated 4.5 million South Africans, mainly in surroundings of 
rural poverty, are in need of treatment for urogenital schistosomiasis (Hotez and Kamath, 2009, King 
and Dangerfield-Cha, 2008). Moreover, these NTDs often occur in people who are also infected with 
Human Immunodeficiency virus (HIV), malaria, or Tuberculosis making the problem even more serious 
since co-infections are common (Downs et al., 2012, Hotez and Kamath, 2009). A study showed that 
Schistosoma haematobium prevalence was associated with HIV prevalence in sub-Saharan Africa, each 
S. haematobium infection per 100 individuals was associated with a 2.9% (95% CI: 0.2–5.8%; p=0.038) 
relative increase in HIV prevalence (Christinet et al., 2016). 
 
Different organizations worldwide have tried several methods to bring schistosomiasis infection under 
control (Lai et al., 2015). In many countries, the mass treatment for schistosomiasis has been 
successfully implemented (Sokolow et al., 2016). With over half of South Africa’s population at risk of 
schistosomiasis, regular treatment in transmission areas is required for preventing morbidity and 
secondary infections (Chitsulo et al., 2000, Savioli et al., 2009). Several countries have successfully 
established schistosomiasis national control programs with generic Praziquantel at a price of less than 
0.10 American dollar (USD) per tablet, and there has been no evidence of the development of any 
resistance (Berge et al., 2011). Thus, the generics have proven to be of the same excellent quality at a 
current 1/50th of the South African market’s price of the speciality or trade mark Biltricide®, where  
10 tablets in blister are sold at Rand (R) 4.49/tablet (Lai et al., 2015). This cost of Praziquantel was 
reported to be 50 times higher than the World Health Organization (WHO) standard treatment that is in 
use in the rest of Africa, and hence this mass treatment cannot be implemented (Berge et al., 2011). 
For most of these NTDs, vaccines and medicines are either unavailable, ineffective, or too expensive 
(Boraschi et al., 2008). Since the efficacy of Praziquantel may probably decrease with worm burden 
(Kjetland et al., 2006), a WHO working group was established on urogenital schistosomiasis and HIV 
transmission. The WHO has proposed a prospective study to evaluate the effect of Praziquantel 
treatment on HIV incidence as the next step toward developing a new protocol to treat schistosomiasis 
for HIV prevention (Hotez and Kamath, 2009).   
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In poor constrained settings, plants are used as an alternative to classic vaccines and medicines because 
of their antibacterial, anthelmintic, antischistosomal, anti-amoebic, antioxidant, anti-inflammatory and 
antimalarial activity. Although the use and prescription of traditional medicine are not regulated in 
South Africa, the risk of misadministration of toxic plants in particular always exists (Fennell et al., 
2004). Not much is known about the effectiveness of the management of intestinal or urogenital 
Schistosomiasis by traditional healers as well as the concurrent use of Praziquantel with traditional 
medicine. Due to beliefs and unavailable stock of conventional therapy or the expensive price, people 
mostly in rural areas may not have access to modern treatment for schistosomiasis leading them to 
traditional medicine. Therefore, this study aims to evaluate the prevalence of the use of traditional 
medicine and prescribed antischistosomal medicines in communities having high prevalence 
schistosomiasis infections in ILembe District, KwaZulu-Natal and to establish whether the 
unavailability of prescribed antischistosomal medicines leads to the use of traditional medicine. 
1.2. Literature Review 
This section gives a brief overview of the literature. The local and international literature is reviewed 
with respect to the epidemiology, statistics and availability of antischistosomal drugs, Schistosomiasis 
co-morbidities and treatment option across South Africa. However, a comprehensive literature review 
has been included in the Introduction section of chapter two, chapter three and chapter four presented 
in the format of manuscripts in this dissertation. 
 
1.2.1. Epidemiology, statistics and availability of antischistosomal drugs  
Schistosomiasis is caused by five species of flatworms that live in fresh water in the tropics and sub-
tropics. The Schistosomes are reproduced in snails which release infectious parasites that burrow into 
the skin of individuals in contact with contaminated water. There are often no symptoms at the first 
infection with schistosomes, while some develop a rash or itchy skin, and later fever, chills, cough and 
muscle aches (Chitsulo et al., 2000, Steinmann et al., 2006). The most common of all types is 
Schistosoma mansoni, which is found mostly in Africa and causes intestinal schistosomiasis. 
Schistosoma japonicum and Schistosoma mekongi also cause intestinal schistosomiasis, but mainly in 
Asia and Pacific regions, Africa and the Eastern Mediterranean while Schistosoma haematobium causes 
urinary schistosomiasis (WHO, 2013).  
People are infected with schistosomiasis through contact with contaminated water, as well as while 
swimming, doing personal or domestic cleaning, fishing and cultivating rice. Due to lack of information 
and appropriate sanitation facilities, individuals contaminate their environment by passing out the 
parasites while in the water (WHO, 2015). At least 206.4 million people required preventive treatment 
while more than 89 million people were treated for schistosomiasis in 2016 (WHO, 2018). Its 
transmission has been reported in 78 countries, a review of disease burden estimated that more than 200 
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000 deaths per year are due to schistosomiasis in sub-Saharan Africa (WHO, 2018). The estimated total 
number of people requiring treatment for schistosomiasis in 2014 was 258 875 452, of whom 123 329 
536 (47.6%) were school-age children (5–14 years of age). In 2014, 91.4% of those estimated to require 
treatment for schistosomiasis lived in the African region (WHO, 2016). 
Praziquantel is the recommended treatment against all forms of schistosomiasis due to its safety, 
effectiveness and low-cost making it accessible, and while re-infection may occur after treatment, the 
risk of developing severe disease is diminished and even reversed when treatment is initiated and 
repeated in childhood (WHO, 2018). Praziquantel must be administered repeatedly as potent 
anthelminthic chemotherapy that can reduce schistosomal morbidity and its clinical manifestations 
associated with exacerbated HIV susceptibility (Hatz, 2005, King et al., 2005). The HIV morbidity 
arises from post transmission schistosomiasis often persists as clinical symptoms; even for many years 
after transmission has been interrupted (King and Dangerfield-Cha, 2008). 
While Praziquantel was pledged by the private sector and development partners to treat more than 100 
million children of school age per year in South Africa, a major limitation to schistosomiasis control 
has been its limited availability. Data for 2015 shows that 28.2% of people requiring treatment were 
reached globally, with 42.2% of school-aged children requiring preventive chemotherapy for 
schistosomiasis being treated (WHO, 2018). 
South Africa implemented a mass treatment pilot program in KwaZulu-Natal Province in 1997-2000 
however, since then mass treatment interventions have not been implemented (Appleton et al., 2006).  
That is why an early intervention through mass treatment of the endemic communities can be vital to 
prevent the serious impact of the schistosomiasis, and it has been proved to efficiently reduce this 
disease burden, but only having an effect on the adult worm  (Utzinger and Keiser, 2004). Hence, in 
order to increase the treatment’s effectiveness, mass treatment should be carried out during the low 
transmission season when worms have matured (Anderson et al., 2014). 
Studies in Africa and the Middle East establishing the relationship between inflammation resulting from 
schistosomiasis and squamous cell carcinoma of the bladder have reported that S. mansoni is the chief 
cause of clinical abnormalities, such as hepatomegaly, splenomegaly and periportal fibrosis (Mostafa 
et al., 1994). A study in northern Ethiopia in the Alamata District revealed an alarming 73.9% 
prevalence of schistosomal infection, with presentation of 3.7% hepatomegaly, 7.4% splenomegaly, 
and 12.3% periportal fibrosis (Atalabi et al., 2017). This parasitic disease is responsible for considerable 
morbidity in the east of the region, where both S. hematobium and S. mansoni species cause renal 
disease, while only S. hematobium is encountered in certain foci in the western region (Mostafa et al., 
1994). S. haematobium leads to chronic granulomatous inflammation of the lower urinary tract which 
ultimately gives rise to fibrosis and calcification, resulting in disorders of bladder motility, ureteric 
obstruction and occasionally reflux, which lead to back pressure, infection and secondary stone 
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formation (Atalabi et al., 2017). This kind of scenario is responsible for approximately 7% of renal 
failure in the Egyptian dialysis population (Barsoum, 2002). Early bladder lesions respond well to anti-
schistosomal treatment, late fibrotic lesions of little functional consequence may be left untreated, but 
significant obstructive cases require operative intervention (Barsoum, 1998). Schistosoma mansoni also 
forms granulomata in the gut mucosa and around the hepatic portal tracts, the latter leading to 
progressive fibrosis, portal hypertension and splenomegaly (Barsoum, 1993). Impairment of the hepatic 
macrophage function leads to an escape of antigens into the systemic circulation, generated by the adult 
worms inhabiting the portal veins. Together with specific antibodies, they form immune complexes that 
deposit in the glomeruli, leading to a limited proliferative lesion. In approximately 15% of patients, the 
renal lesions tend to progress into end-stage (Barsoum et al., 2013). 
1.2.2. Schistosomiasis co-morbidities and treatment option across South Africa  
Schistosomiasis is always linked to other infections when left untreated. Thus, female and male genital 
schistosomiasis co-exist in areas with endemic S. haematobium; as do co-infection with agents of 
sexually transmitted infections, which are also frequent in both females and males, as shown in a study 
in Madagascar, where 35% of females and 17% of males with urogenital schistosomiasis had one or 
more sexually transmitted infections (Leutscher et al., 2008). Adding to its direct morbidities, 
schistosomiasis can affect immunological and physiological relationships between the host and co-
infecting pathogens. Thus, better control of schistosomiasis could provide adjunctive benefits in those 
areas. The most compelling example might be the effect of schistosomiasis on susceptibility to HIV 
infection (Downs et al., 2012, Kjetland et al., 2006, Mbabazi et al., 2011). 
Among women with genital schistosomiasis, the inflammation, friability, and neovascularization of the 
genital epithelial tissue can lead to a compromised physical barrier to HIV through sexual activity. In 
population-based studies, female genital schistosomiasis has been associated with three to four times 
increased risk of HIV infection (Downs et al., 2012, Kjetland et al., 2006, Mbabazi et al., 2011). 
Urogenital schistosomiasis is extremely common and a possible risk factor for HIV infection in women. 
There is a need to prevent urogenital schistosomiasis by purchasing generic Praziquantel, which is 
cheaper and can be made available for all South Africans, as there are no locally available alternatives 
to the drug as the treatment of choice of all forms of schistosomiasis (Doenhoff and Pica-Mattoccia, 
2006).  
Estimations show that at least 206.4 million people required preventive treatment for schistosomiasis, 
where, more than 89 million people treated for schistosomiasis in 2016 (WHO, 2018). However, despite 
the effectiveness of Praziquantel, there is a high re-infectivity rate in endemic areas even after mass 
treatment and the cost of this drug, although reduced, remains prohibitive for many control programmes 
in schistosomiasis endemic areas (Jones et al., 2018). A holistic approach is therefore necessary, and 
should not only include reducing the disease burden in infected persons using chemotherapy but also 
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interfering with the life-cycle of the parasite by eliminating the snail vector.  Molluscicides are widely 
considered to be an important part of schistosomiasis control that can be used at selected sites to achieve 
immediate results (Tsepe, 2003). Measures such as improved sanitation and health education are likely 
to take time to reduce the spread and prevalence of the disease, with mollusciciding and traditional 
medicine, therefore, needing to be considered as of important components of schistosomiasis control 
(Jones et al., 2018). 
More than 80% of the population in developing countries depends on plants for their medicinal needs, 
and in South Africa, the prescription and use of traditional medicine is not regulated, with the result that 
when traditional medicine is used concurrently with standard drugs, they impair the activity of the drug 
(Ekor, 2014). ). However, there is also a danger of misadministration, overdose, and the problem of 
toxicity and incompatibility with the prescribed medication (Ekor, 2014, Cock et al., 2018). Some 
medicinal plants with possible anti-schistosomal properties are widely used by traditional healers in 
South Africa, although their effectiveness has not been scientifically evaluated (Cock et al., 2018). 
Knowingly, traditional medicine is an alternative practice in South Africa where 72% of the Black 
African population is estimated to be relying on this type of medicine, accounting almost 26.6 million 
consumers (Mander et al., 2007, Oyedeji, 2018). 
1.2.3. Use of traditional medicine for schistosomiasis and comorbidities  
Traditional medicine (TM) is part of indigenous knowledge (IK), defined by the WHO ‘diverse health 
practices, approaches, knowledge and beliefs incorporating plant, animal, and/or mineral based 
medicine, spiritual therapies, manual techniques and exercises applied singularly or in combination to 
maintain well-being, as well as to treat, diagnose or prevent illnesses (Kasilo and Nikiema, 2014). IK 
continues to play an important role in improving and maintaining health in developing countries 
(Thorsen and Pouliot, 2016). Policies for integrating traditional medicine into public health care systems 
have been formulated to varying extents in a number of countries (Gureje et al., 2015), with the 
approximately 40% of the population using traditional medicine in China and 80% in Africa (Kasilo 
and Nikiema, 2014, Ekor, 2014). As a consequence of the pluralistic nature of health care systems, 
people’s treatment-seeking behaviour is characterized by the use of different treatment types, either 
sequentially or simultaneously (Gureje et al., 2015). 
Regarding diagnosis, IK through TM is a system that is both an art and a method of seeking to discover 
the origins of the disease and determine it. The diagnostic process not only seeks answers to the question 
of how the disease originated (immediate causes), but who or what caused the disease (efficient cause), 
and why it has affected this particular person at this point in time (ultimate cause). Diagnosis consists 
of a combination of information, namely observation, patient self-diagnosis and divination (Tabuti et 
al., 2003). 
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Although, certain plant extracts can interfere with conventional medicine (Karmakar et al., 2012). In 
many developing countries, people living in rural settings often exclusively use traditional medicines 
to treat various, ailments including schistosomiasis (Mander et al., 2007, Cock et al., 2018). A range of 
medicinal plants with possible anti-schistosomal properties has been widely used by traditional healers 
of different ethnic groups in South Africa. The effectiveness of many of them, however, has not been 
scientifically evaluated (Cock et al., 2018). 
The problem of therapeutic failure and drug resistance is being reported from many developing 
countries, and while effective and safe drugs for mass chemotherapy are being developed under these 
circumstances, alternative options must be considered. Plants that have shown molluscicidal and 
antischistosomal activity are indicated in Table 1.0. 
 
Table 1. Plants effective against schistosomes 
Plant name and 
availability 
Biological activity Authors 
Zingiber officinale L. 
(Zingiberaceae) 
native to South East Asia 
but cultivated in many 
tropical countries, including 
Nigeria and Sierra Leone 
Tested using Biomphalaria glabrata and Schistosoma mansoni Adewunmi et al., 
1990 
Two fractions containing pure compounds gingerol and shogaol 
resulted in 80% mortality of Biomphalaria glabrata snails at a 
concentration of 25mg/l 
the Gingerol (5mg/l) arrested the ability of Schistosoma mansoni 
miracidia and cercariae to infect both snails and mice, showing its 
molluscicidal action, supporting use in schistosomiasis control 
Adewunmi et al., 
1990   
Trichilia emetica Vahl 
(Meliaceae) and Berkheya 
speciosa O.Hoffm 
(Compositae) 
Extracts were lethal at 6.25mg/ml while Euclea natalensis 
(Ebenaceae) plant extracts at a concentration of 3.13mg/ml killed 
66% of the schistosomules 
Sparg et al., 2000 
Abrus precatorius L. 
(Fabaceae) 
available in South Africa 
and elsewhere 
Extracts were lethal at concentrations of 0.6mg/ml, killing all 
schistosomules of Schistosoma mansoni 
Mølgaard et al., 
2001 
 
By studying not only the stock available of antischistosomal medicines included in current government 
policy in South Africa but rather the variety of treatments practised by the population for 
schistosomiasis and co-morbidities, this research aimed to improve our understanding of treatment-
seeking behaviour and to thereby inform the development of better-targeted health interventions and 
policies. This study intended establishing the prevalence of the use of traditional medicine and 
prescribed antischistosomal medicines in communities with high Schistosomiasis infection in ILembe 
District, KwaZulu-Natal Province, and to establish whether the unavailability of prescribed 
antischistosomal medicines was a motivating factor in their use. 
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1.3. Statement of the problem/justification or rationale of the study 
The eastern and northern parts of South Africa are endemic for schistosomiasis, with an estimated 2.4 
million school-aged children and 3 million adults requiring treatment with Praziquantel yearly or every 
second year (Baan et al., 2016, WHO., 2013). Urogenital schistosomiasis is a major health problem in 
South Africa, the country has the highest HIV prevalence in the world; the role of female genital 
schistosomiasis in driving the HIV epidemic is yet to be explored ( Downs et al., 2012, Chitsulo et al., 
2004, Doenhoff and Pica-Mattoccia, 2006).   
Cross-sectional studies in Zimbabwe and Tanzania revealed that there is a correlation between female 
genital schistosomiasis and the acquisition of HIV, which have been confirmed elsewhere, and infection 
with some STH species being associated with increasing HIV loading in sexually active women (Downs 
et al., 2011).   
Praziquantel is the recommended treatment against all forms of schistosomiasis, is effective, safe, and 
low-cost, even though re-infection may occur after treatment, with the risk of developing severe disease 
being diminished and even reversed when treatment is initiated and repeated in childhood (WHO, 
2018). Despite the effectiveness of Praziquantel, there is a high re-infectivity rate in endemic areas, 
even after mass treatment, which makes repeated treatment necessary, although it has not been 
established what a suitable interval between such treatments would be (Appleton et al., 2006, Doenhoff 
and Pica-Mattoccia, 2006). In addition, soil-transmitted helminth infections associated with 
schistosomiasis and treated with Albendazole cause a small decrease in HIV load; however, this may 
not represent a direct effect of worms’ removal (Kjetland et al., 2006). 
Despite being reduced, the cost of Praziquantel remains prohibitive for many control programs in 
schistosomiasis endemic areas, highlighting the need for greater commitment to control efforts (Jones 
et al., 2018).  In some countries, traditional medicine has made a contribution to managing 
schistosomiasis (Bah et al., 2006, Cock et al., 2018). In an ethnopharmacological survey conducted in 
Niger and Mali, 55 plant species were reported to be used to treat schistosomiasis either alone or in 
combination, of which Zea mays with Glossonema boveanum were specific for intestinal 
schistosomiasis (Bah et al., 2006). Cissus quadrangularis and Stylosanthes erecta were reported for the 
first time in Mali to be used against the parasite (Bah et al., 2006).  
This research contributed to fill the knowledge gap in exploring the philosophy and IK for treating 
schistosomiasis by traditional healers and understanding issues related to the treatment-seeking 
behaviour among individuals affected by schistosomiasis. The findings of this study are presented in 
the format of manuscripts included in this dissertation in chapters three and four which are targeted for 
publication in scholarly journals. 
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This study aimed to evaluate the prevalence of the use of traditional medicine and prescribed 
antischistosomal medicines in communities having high prevalence schistosomiasis infection in 
ILembe District, KwaZulu-Natal and to establish whether the unavailability of prescribed 
antischistosomal medicines leads to the use of traditional medicine. 
1.4. Research questions, Aim and objectives 
1.4.1. Research questions 
For the purpose of this study, one general research question was developed as follows: “What is the 
prevalence of the use of traditional medicine or/and prescribed antischistosomal medicines for the 
management of schistosomiasis in ILembe District?” 
To answer this general research question, specific research questions were formulated as follows:   
1. How do traditional healers diagnose the mentioned diseases and what types of traditional medicines 
are used to treat them?  
2. What is the prevalence of patients consulting THPs and using prescribed schistosomal medicines for 
urogenital and intestinal schistosomiasis?  
3. Does the unavailability of stock of prescribed medicines lead to the use of traditional medicine for 
schistosomiasis, helminthiasis and HIV/AIDS?  
4. How do healthcare workers perceive the use of TM for the management of schistosomiasis, 
helminthiasis and HIV/AIDS?  
5. What are the effects on patients using concurrently both prescribed medicines and traditional 
medicines for schistosomiasis, helminthiasis and HIV/AIDS? 
1.4.2. Aim or purpose of the study 
This study aimed to evaluate the prevalence of the use of traditional medicine and prescribed 
antischistosomal medicines in communities having high prevalence schistosomiasis infection in 
ILembe District, KwaZulu-Natal and to establish whether the unavailability of prescribed 
antischistosomal medicines leads to the use of traditional medicine. 
1.4.3. Hypothesis 
Individuals infected with schistosomiasis also used TM due to unavailability of prescribed medicines. 
1.4.4. Objectives 
The objectives for conducting this study were as follows: 
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1. To explore and understand the way THPs diagnosed Schistosomiasis and the types 
of traditional medicines used to treat the disease. 
2. To determine the prevalence of patients consulting THPs and using prescribed 
antischistosomal medicines for schistosomiasis. 
3. To establish to what extent the unavailability of prescribed medicines resulted in 
the patients’ use of traditional medicine for schistosomiasis, helminthiasis and 
HIV/AIDS. 
4. To establish the perceptions of Healthcare workers about the use of TM for 
managing schistosomiasis, helminthiasis and HIV/AIDS. 
5. To describe the effects on patients of using prescribed medicines and traditional 
medicines for schistosomiasis, helminthiasis and HIV/AIDS. 
 
1.5. General methodology  
This is an overview of the methodology of this study. Chapters two, three and four have each a detailed 
methodology section. This research was a quantitative and qualitative study (mixed method). It used an 
exploratory survey to obtain facts in an attempt to learn about and describe the perceptions and 
knowledge in the treatment of schistosomiasis from a perspective of traditional treatment comparing to 
the conventional one. This survey explored the characteristics of the targeted population and identified 
what issues were important to their understanding of the topic (Katzenellenbogen, et al., 1999). The 
chosen methodology generated useful information through the collection and analysis of data on the 
perceptions about the use of TM and the availability of prescribed antischistosomal medicines in the 
management of schistosomiasis. 
1.5.1. Study design  
  This study was a cross-sectional descriptive study, using an exploratory mixed-method 
approach. The study was carried out into two phases as described below:   
Phase 1 included both qualitative and quantitative descriptive studies divided into four parts: 
Phase 1.A. Qualitative descriptive study:  a self-developed questionnaire was administered to 
understand THPs’ experiences about the management of schistosomiasis. This questionnaire probed 
concepts about different methods used by THPs to diagnose and treat schistosomiasis (see Appendix 
6.A). 
Phase 1.B. Qualitative descriptive study: patients seen by THPs were interviewed to understand their 
experiences about the use of traditional medicine in the management of schistosomiasis. The 
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questionnaire used in this phase was slightly different from the THPs’ questionnaire (see Appendix 
6.B). 
Phase 1.C. Quantitative approach: health care workers (HCWs) were interviewed in their facilities 
regarding the management of schistosomiasis using antischistosomal prescribed medicines as well as 
their thoughts on the use of TM. Through a written questionnaire respondents were interviewed on the 
availability of antischistosomal medicines and the use of TM in the management of schistosomiasis   
(see Appendix 6.C). 
Phase 1D: Qualitative-Quantitative survey: patients seen by HCWs and those who have visited THPs 
were interviewed on the concurrent use of conventional antischistosomal medicines with TM. A 
questionnaire was developed to collect respondents’ perceptions of the concurrent use of 
antischistosomal medicines and the use of TM in the management of schistosomiasis (see Appendix 
6.D). 
Phase 2: Quantitative descriptive: Medical chart records of patients were reviewed to establish the 
documented use of conventional antischistosomal treatment as well as the use of TM for the 
management of schistosomiasis and comorbidities. A data collection tool was developed to collect 
information about conventional medicines prescribed to patients and other relevant information related 
to the documented use of TM (see Appendix 6.E). 
 1.5.2. Study area 
Located on the eastern coast of KwaZulu–Natal (KZN), ILembe District Municipality was the study 
area due to its history of schistosomiasis prevalence in KZN (Saathoff et al, 2004). It is bordering the 
Indian Ocean, surrounded by Umzinyathi in the north, the Indian Ocean in the east, eThekwini in the 
south (Durban), and Umgungundlovu in the west and Uthungulu in the north- east. It is the smallest 
municipality in the province, with a population of 630 464 and an area of 3269 km2; it is about 75 km 
from Durban. The majority of rural areas inland are tribal areas, characterized by subsistence farming. 
ILembe has four local municipalities between Durban and Richards Bay: Mandeni, KwaDukuza, 
Maphumulo and Ndwedwe. The town stretches along the Tugela River, the traditional border between 
the former Colonial Natal and the Kingdom of Zululand, the site of historical and cultural events. The 
ILembe seat is KwaDukuza (formerly Stanger). The border of the district is the unicity of Durban in 
the immediate south, connected to Richards Bay in the north by the coastal highway, giving access to 
both harbours for commercial purposes. It is also a leading tourism industry due to its rich heritage in 
the Zulu Kingdom, as it was named in recognition of King Shaka. The ILembe district has 90.8% Black 
African, 9.6% Native English speakers, 3.3% Native Xhosa and 2.4% White people in its population. 
The majority of people (82 per cent) speaks Zulu. ILembe Health District has four hospitals: District 
Hospital of Montebello, Provincial Hospital of Stanger, District Hospital of Umphumulo, District 
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hospital of Untunjambili (http://www.kznonline.gov.za/index.php/government/ 2016-08-02-09-42-
02/ilembe-district-municipality). 
 
Figure 1. 1:  A geographic map showing the study area in ILembe  
(Http: //www.kznonline.gov.za/index.qphp/government/2016-08-02-09-42-02/ilembe-district-
municipality)   
1.5.3. Study population, inclusion and exclusion criteria  
1.5.3.1. Study population  
The study population consisted of THPs, patients seen by them (THPs), HCWs treating schistosomiasis 
and patients with schistosomiasis who have visited outpatient departments of healthcare facilities 
included in this study.  
1.5.3.2. Inclusion and exclusion criteria 
 This study included THPs, HCWs treating schistosomiasis and patients with schistosomiasis, 
irrespective of gender. Participants were aged 18 years old and above. Participants eligible for inclusion 
but not available at the time of data collection for face-to-face interviews were excluded from this study. 
Patients with doubtful information about schistosomiasis were excluded as well from this study. 
 
 
Study area: Maphumulo 
and KwaDukuza 
13 
 
1.5.3.3. Sampling technique and sample size  
Sampling technique 
A purposive sampling technique was used to draw participants namely THPs, patients seen by them 
(THPs), HCWs and patients with schistosomiasis at outpatient departments. The different categories of study 
participants were purposively sampled from the study area (Fig. 1).  
Sample size 
Here was the sample size for each phase of this research: 
Phase 1A: based on the principle of saturation, this study recruited 22 THPs who treated patients with 
schistosomiasis in the study area. 
Phase 1B: THPs seen in phase 1A referred researchers to patients seen by them. 20 participants were 
included at this stage. 
Phase 1C: 124 HCWs treating schistosomiasis in the public health care facilities under the study area 
were included. This sample size was divided among the 10 facilities visited in the study area, ILembe 
district, KwaZulu-Natal.  
 Phase 1D: 15 patients with schistosomiasis seen by HCWs were recruited from outpatient departments. 
Phase 2. The population in the study area was estimated at 657 612 
(https://municipalities.co.za/demographic/117/ilembe-district-municipality). Thus, the minimum 
recommended sample size was 139 respondents. The sample size of respondents was determined using 
the formula as described by Lwanga (1991) and Daniel (1999) (Naing et al., 2006):  
𝑁 =
𝑍2P(1 − P)
2𝑑2
 
Where Z statistic as 1.96 for the confidence level of 95%, P is 0.8 as the expected proportion of the 
characteristics were measured in the study area (Lankford et al., 2010, Jacobs and Viechtbauer, 2017); 
d is the precision of 0.05 for 95% confidence interval. Since it was a prospective study, attritions were 
expected for various reasons, unsigned consent and assented forms, the absence of respondents, failure 
to provide information or not being available during subsequent survey; an increase of 10-20% was 
added to the minimum sample size of 139 yielding 159 respondents included in the final analysis.  
 
1.5.4. Recruitment and selection of study participants 
The recruitment started with THPs seen initially for interviews about schistosomiasis management. 
Community heads and leaders of THPs associations were contacted for identification of THPs treating 
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schistosomiasis. THPs were visited during their business hours at their workplaces (Phase 1A). Patients 
seen and identified by those THPs were contacted and recruited in the next step of the study (Phase 1B). 
HCWs involved in the management of schistosomiasis were seen and recruited during business hours 
in public healthcare facilities (Phase 1C) and finally, patients with a history of consulting both THPs 
identified from phase 1B and who also crossed the mainstream healthcare system for schistosomiasis 
were included in this step of the study (phase 1D). In phase 2, medical chart records of patients were 
purposively analyzed. 
 
1.5.5. Data collection techniques and research tools  
Research-administered face-to-face interviews were carried out in phase 1 while phase 2 consisted of a 
medical chart review of patients. In phase 1, questionnaires were used to collect data. In phase 2, a 
checklist was developed to collect relevant information. Data were collected four days a week over the 
data collection period from January to April 2018. Questionnaires used in phase 1A, 1B, 1C and 1D 
were translated into IsiZulu. An expert for content validity tested the translated questionnaire.  
 
1.5.6. Data analysis 
Data collected was captured cleanly and accurately in a spreadsheet. Quantitative data were entered into 
and analyzed statistical package for social sciences (IBM SPSS Statistics) statistical software version 
25.0 package for Windows.  The phase with the qualitative approach was analyzed using thematic or 
content analysis while phases with the quantitative approach used descriptive statistics including 
frequency, percentage, and categorical data represented as tables.  
Qualitative data: based on a thematic analysis in which the translated for those in the local language, 
IsiZulu and transcribed interviews were read and reread entirely. They were summarized; keeping in 
mind that more than one of them might exist in a set of interviews. If identified, the themes that appeared 
to be significant and concepts linking substantial portions of the interviews were written down and 
entered on the computer (Morse and Field, 1995). Each of the selected respondents gave their point of 
views in the management of schistosomiasis. This approach was used to generate an in-depth 
understanding of the issue (Pearson et al., 2010). 
Quantitative data: An analysis of variables was carried out. Associations between continuous variables 
were analyzed using Chi-squared tests. A p-value ≤ 0.05 was estimated as statistically significant.  
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1.5.8. Ethics and permissions  
The permission for the study was sought from the University of KwaZulu-Natal Biomedical Research 
Ethics committee (BREC) under reference number BE477/17 (see Appendix 1). Gatekeeper permission 
was secured from the KZN Provincial Department of Health reference number HRKM451/17 (see 
Appendix 2). Letters of support from study sites were secured (see Appendix 3). Eligible participants 
were given an information letter/sheet about the study (see Appendix 5A). Those willing to participate 
were requested to give a written consent form before being interviewed (see Appendix 5B). 
Participation in the study was voluntary. Participants were free to withdraw at any time with no further 
obligation. The main ethical principles that were considered in conducting this research study were 
respect for persons, confidentiality and beneficence /non-maleficence. Study aims and procedures were 
explained to participants in English and the local language, IsiZulu. Anonymity and guaranteed 
confidentiality about information collected were maintained. No name, no ID of participants were 
disclosed to the third party or displayed on questionnaires and data collection forms. Questionnaires 
and data extraction form were coded and codes are known to the team of researchers. Data collected 
were kept in a locked cupboard in the supervisor’s office. Information on the computer used for the 
study was password protected. 
 
1.6. Layout of the thesis 
This thesis is presented in a manuscript format, as per the UKZN requirements, with the Results and 
Discussion being described in manuscripts that have been prepared for publications. It is structured as 
follows: 
Chapter 1. Introduction: This chapter gives a background of the study, a brief overview of the 
literature on schistosomiasis, the statement of the problem/justification or rationale of the study, aim 
and objectives, hypothesis, general methodology and the layout of the thesis. 
Chapter 2. Manuscript 1- Review Protocol: “Mapping evidence of the concomitant management of 
schistosomiasis by Traditional Health Practitioners and Health care Professionals in communities with 
high prevalent infections: A systematic scoping review protocol”. This is a systematic review protocol 
on the concomitant management of schistosomiasis by THPs and HCPs in communities with high 
prevalent schistosomiasis infection. A manuscript was written and submitted to BMC Systematic 
Reviews. 
 
Chapter 3. Manuscript 2 - Research article: “Knowledge, perceptions and experiences of traditional 
health practitioners about the management of female urogenital schistosomiasis: the Case of ILembe 
District, KwaZulu-Natal, South Africa”. This chapter provides an original research manuscript on 
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perceptions of participants about the management of schistosomiasis using TM. A manuscript was 
written and submitted to BMC Ethnobiology and Ethnomedicine.  
Chapter 4. Manuscript 3 - Research article: “A Triangulation of information from Healthcare 
workers and patients about the concurrent use of traditional medicine and conventional prescribed 
medicines for schistosomiasis in ILembe district, KwaZulu-Natal, South Africa”. This chapter is an 
original research manuscript on participants perceptions about the management of schistosomiasis and 
analyzed information documented in medical chart records of patients with schistosomiasis. 
Chapter 5. Synthesis chapter: This chapter provides general discussions of major findings, general 
conclusions of the study and recommendations for future studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
 
1.7. References list for chapter one 
Adewunmi, C. O., Oguntimein, B. O. & Furu, P. 1990. Molluscicidal And Antischistosomal Activities 
Of Zingiber Officinale. Planta Medica, 56, 374-376. 
Anderson, R., Truscott, J. & Hollingsworth, T. D. 2014. The Coverage And Frequency Of Mass Drug 
Administration Required To Eliminate Persistent Transmission Of Soil-Transmitted Helminths. 
Philosophical Transactions Of The Royal Society Of London. Series B, Biological Sciences, 
369(1645), 435. 
Appleton, C., Kvalsvig, J. & Infection 2006. A School-Based Helminth Control Programme 
Successfully Implemented In KwaZulu-Natal. Southern African Journal Of Epidemiology, 21, 
55-67. 
Atalabi, T. E., Adubi, T. O. & Lawal, U. 2017. Rapid Mapping Of Urinary Schistosomiasis: An 
Appraisal Of The Diagnostic Efficacy Of Some Questionnaire-Based Indices Among High 
School Students In Katsina State, Northwestern Nigeria. Plos Neglected Tropical Diseases, 11, 
E0005518. 
Baan, M., Galappaththi-Arachchige, H. N., Gagai, S., Aurlund, C. G., Vennervald, B. J., Taylor, M., 
Van Lieshout, L. & Kjetland, E. F. 2016. The Accuracy Of Praziquantel Dose Poles For Mass 
Treatment Of Schistosomiasis In School Girls In Kwazulu-Natal, South Africa. Plos Neglected 
Tropical Diseases, 10, E0004623. 
Bah, S., Diallo, D., Dembélé, S. & Paulsen, B. S. 2006. Ethnopharmacological Survey Of Plants Used 
For The Treatment Of Schistosomiasis In Niono District, Mali. Journal Of 
Ethnopharmacology, 105, 387-399. 
Banhela, N., Taylor, M., Gift Zulu, S., Sund Strabo, L., Floerecke Kjetland, E. & Gunnar Gundersen, 
S. 2017. Environmental Factors Influencing The Distribution And Prevalence Of Schistosoma 
Haematobium In School Attendees Of Ilembe And Uthungulu Health Districts, Kwazulu-Natal 
Province, South Africa. Southern African Journal Of Infectious Diseases, 32, 132-137. 
Barsoum, R. S. 2002. Overview: End‐Stage Renal Disease In The Developing World.  Artificial Organs, 
26, 737-746. 
Barsoum, R. S., Esmat, G. & El-Baz, T. J. 2013. Human Schistosomiasis: Clinical Perspective. Journal 
Of Advanced Research, 4, 433-444. 
Berge, S. T., Kabatereine, N., Gundersen, S. G., Taylor, M., Kvalsvig, J. D., Mkhize-Kwitshana, Z., 
Jinabhai, C. & Kjetland, E. F. 2011. Generic Praziquantel In South Africa: The Necessity For 
Policy Change To Provide Cheap, Safe And Efficacious Schistosomiasis Drugs For The Poor, 
Rural Population. Southern African Journal of Epidemiology and Infection, 26, 22-25. 
Boraschi, D., Alemayehu, M. A., Aseffa, A., Chiodi, F., Chisi, J., Del Prete, G., Doherty, T. M., 
Elhassan, I., Engers, H. & Gyan, B. 2008. Immunity Against Hiv/Aids, Malaria, And 
Tuberculosis During Co-Infections With Neglected Infectious Diseases: Recommendations For 
The European Union Research Priorities. Plos Neglected Tropical Diseases, 2, E255. 
18 
 
Chitsulo, L., Engels, D., Montresor, A. & Savioli, L. 2000. The Global Status Of Schistosomiasis And 
Its Control. Acta Tropica, 77, 41-51. 
Chitsulo, L., Loverde, P. & Engels, D. 2004. Schistosomiasis. Nat Rev Microbiol, 2, 12-3. 
Christinet, V., Lazdins-Helds, J. K., Stothard, J. R. & Reinhard-Rupp, J.J. 2016. Female Genital 
Schistosomiasis (Fgs): From Case Reports To A Call For Concerted Action Against This 
Neglected Gynaecological Disease. International Journal For Parasitology, 46, 395-404. 
Cock, I., Selesho, M. & Van Vuuren, S. 2018. A Review Of The Traditional Use Of Southern African 
Medicinal Plants For The Treatment Of Selected Parasite Infections Affecting Humans. Journal 
Of Ethnopharmacology. 
Doenhoff, M. J. & Pica-Mattoccia, L. 2006. Praziquantel For The Treatment Of Schistosomiasis: Its 
Use For Control In Areas With Endemic Disease And Prospects For Drug Resistance. Expert 
Review Of Anti-Infective Therapy, 4, 199-210. 
Downs, J. A., Mguta, C., Kaatano, G. M., Mitchell, K. B., Bang, H., Simplice, H., Kalluvya, S. E., 
Changalucha, J. M., Johnson, W. D., Jr. & Fitzgerald, D. W. 2011. Urogenital Schistosomiasis 
In Women Of Reproductive Age In Tanzania's Lake Victoria Region. Am J Trop Med Hyg, 84, 
364-9. 
Downs, J. A., Van Dam, G. J., Changalucha, J. M., Corstjens, P. L. A. M., Peck, R. N., De Dood, C. J., 
Bang, H., Andreasen, A., Kalluvya, S. E., Van Lieshout, L., Johnson, W. D., Jr. & Fitzgerald, 
D. W. 2012. Association Of Schistosomiasis And Hiv Infection In Tanzania. The American 
Journal Of Tropical Medicine And Hygiene, 87, 868-873. 
Ekor, M. 2014. The Growing Use Of Herbal Medicines: Issues Relating To Adverse Reactions And 
Challenges In Monitoring Safety. Frontiers In Pharmacology, 4, 177-177. 
Fennell, C. W., Lindsey, K. L., Mcgaw, L., Sparg, S. G., Stafford, G., Elgorashi, E., Grace, O. & Van 
Staden, J. 2004. Assessing African Medicinal Plants For Efficacy And Safety: Pharmacological 
Screening And Toxicology. Journal of Ethnopharmacology. 94(2-3):205-17. 
Gureje, O., Nortje, G., Makanjuola, V., Oladeji, B. D., Seedat, S. & Jenkins, R. 2015. The Role Of 
Global Traditional And Complementary Systems Of Medicine In The Treatment Of Mental 
Health Disorders. The Lancet Psychiatry, 2, 168-177. 
Hatz, C. F. 2005. Schistosomiasis: An Underestimated Problem In Industrialized Countries? Travel 
Med, 12, 1-2. 
Hotez, P. J. & Kamath, A. 2009. Neglected Tropical Diseases In Sub-Saharan Africa: Review Of Their 
Prevalence, Distribution, And Disease Burden. Plos Neglected Tropical Diseases, 3, E412. 
Jacobs, P. & Viechtbauer, W. 2017. Estimation Of The Biserial Correlation And Its Sampling Variance 
For Use In Meta‐Analysis. Plos Neglected Tropical Diseases, 8, 161-180. 
Jones, I., Lund, A., Riveau, G., Jouanard, N., Ndione, R.A., Sokolow, S.H. and De Leo, G.A., 2018. 
Ecological control of schistosomiasis in Sub-Saharan Africa: restoration of predator-prey 
19 
 
dynamics to reduce transmission. Ecology and Evolution of Infectious Diseases: Pathogen 
Control and Public Health Management in Low-Income Countries, 236. 
 
Karmakar, P., Islam, M. M., Kibria, M. G., Hossain, M. S. & Sattar, M.M. 2012. Prevalence, Belief 
And Awareness Of Preferring Traditional Healthcare System In Urban And Rural People Of 
Noakhali District, Bangladesh. International Current Pharmaceutical Journal, 1, 229-234. 
Kasilo, O. M. & Nikiema, J. B. 2014. World Health Organization Perspective For Traditional Medicine. 
Novel Plant Bioresources: Applications In Food, MedicineCosmetics, 23-42. 
King, C. H. & Dangerfield-Cha, M. 2008. The Unacknowledged Impact Of Chronic Schistosomiasis. 
Chronic Illness, 4, 65-79. 
King, C. H., Dickman, K. & Tisch, D. J. 2005. Reassessment Of The Cost Of Chronic Helminthic 
Infection: A Meta-Analysis Of Disability-Related Outcomes In Endemic Schistosomiasis. 
Lancet, 365, 1561-9. 
Kjetland, E. F., Ndhlovu, P. D., Gomo, E., Mduluza, T., Midzi, N., Gwanzura, L., Mason, P. R., 
Sandvik, L., Friis, H. & Gundersen, S. G. 2006. Association Between Genital Schistosomiasis 
And Hiv In Rural Zimbabwean Women. Aids, 20, 593-600. 
Lai, Y.-S., Biedermann, P., Ekpo, U. F., Garba, A., Mathieu, E., Midzi, N., Mwinzi, P., N'goran, E. K., 
Raso, G. & Assaré, R. K. 2015. Spatial Distribution Of Schistosomiasis And Treatment Needs 
In Sub-Saharan Africa: A Systematic Review And Geostatistical Analysis. The Lancet 
Infectious Diseases, 15, 927-940. 
Lankford, B., Pringle, C., Dickens, C., Lewis, F., Mander, M., Chhotray, V., Goulden, M., Nxele, Z. 
and Quayle, L., 2011. Hydrological modelling of water allocation, ecosystem services and 
poverty alleviation in the Pongola floodplain, South Africa. Journal of environmental planning 
and management, 54(9), 1237-1260. 
Leutscher, P. D., Ramarokoto, C. E., Hoffmann, S., Jensen, J. S., Ramaniraka, V., Randrianasolo, B., 
Raharisolo, C., Migliani, R. & Christensen, N. 2008. Coexistence Of Urogenital 
Schistosomiasis And Sexually Transmitted Infection In Women And Men Living In An Area 
Where Schistosoma Haematobium Is Endemic. Clin Infect Dis, 47, 775-82. 
Mander, M., Ntuli, L., Diederichs Mander, N. & Mavundla, K. 2007. Economics Of The Traditional 
Medicine Trade In South Africa. South African health review,(1),189-196. 
Mbabazi, P. S., Andan, O., Fitzgerald, D. W., Chitsulo, L., Engels, D. & Downs, J. A. 2011. Examining 
The Relationship Between Urogenital Schistosomiasis And Hiv Infection. Plos Negl Trop Dis, 
5, E1396. 
Mitra, A. & Mawson, A. 2017. Neglected Tropical Diseases: Epidemiology And Global Burden. 
Tropical Medicine Infectious Disease, 2, 36. 
20 
 
Mølgaard, P., Nielsen, S. B., Rasmussen, D. E., Drummond, R. B., Makaza, N. & Andreassen, J. 2001. 
Anthelmintic Screening Of Zimbabwean Plants Traditionally Used Against Schistosomiasis. 
Journal Of Ethnopharmacology, 74, 257-264. 
Morse, J. M. & Field, P. A. 1995. Nursing Research: The Application Of Qualitative Approaches, 
Nelson Thornes. 2nd Ed, 124-131 
Mostafa, M. H., Helmi, S., Badawi, A. F., Tricker, A. R., Spiegelhalder, B. & Preussmann, R. 1994. 
Nitrate, Nitrite And Volatile N-Nitroso Compounds In The Urine Of Schistosoma 
Haematobium And Schistosoma Mansoni Infected Patients. Carcinogenesis, 15, 619-25. 
Naing, L., Winn, T. & Rusli, B. 2006. Practical Issues In Calculating The Sample Size For Prevalence 
Studies. Archives of Orofacial Sciences,1, 9-14. 
Oyedeji, O.O., Tanga, M., Lewu, F.B., Oyedeji, OA., 2018. Cultivation Of Medicinal Plants In South 
Africa: A Solution To Quality Assurance And Consistent Availability Of Medicinal Plant 
Materials For Commercialization. Academia Journal of Medicinal Plants 6(7): 168-177 
Pearson, P., Steven, A., Howe, A., Sheikh, A., Ashcroft, D. & Smith, P. 2010. Learning About Patient 
Safety: Organisational Context And Culture In The Education Of Healthcare Professionals. 
Journal of Health Services Research & Policy, 15(1_suppl),4-10. 
Savioli, L., Gabrielli, A., Montresor, A., Chitsulo, L. & Engels, D. 2009. Schistosomiasis Control In 
Africa: 8 Years After World Health Assembly Resolution 54·19. Parasitology, 136, 1677-1681. 
Saathoff E, Olsen A, Magnussen P, Kvalsvig JD, Becker W, Appleton CCJBid: Patterns of Schistosoma 
haematobium infection, the impact of praziquantel treatment and re-infection after treatment in 
a cohort of schoolchildren from rural KwaZulu-Natal/South Africa. 2004, BMC infectious 
diseases. 4(1):40. 
Sokolow, S. H., Wood, C. L., Jones, I. J., Swartz, S. J., Lopez, M., Hsieh, M. H., Lafferty, K. D., Kuris, 
A. M., Rickards, C. & De Leo, G. A. 2016. Global Assessment Of Schistosomiasis Control 
Over The Past Century Shows Targeting The Snail Intermediate Host Works Best. Plos 
Neglected Tropical Diseases, 10, 794. 
Sparg, S., Light, M. & Van Staden, J. 2004. Biological Activities And Distribution Of Plant Saponins. 
Journal Of Ethnopharmacology, 94, 219-243. 
Steinmann, P., Keiser, J., Bos, R., Tanner, M. & Utzinger, J. 2006. Schistosomiasis And Water 
Resources Development: Systematic Review, Meta-Analysis, And Estimates Of People At 
Risk. The Lancet Infectious Diseases, 6, 411-425. 
Tabuti, J., Dhillion, S. & Lye, K. 2003. Traditional Medicine In Bulamogi County, Uganda: Its 
Practitioners, Users And Viability. Journal Of Ethnopharmacology, 85, 119-129. 
Thorsen, R. S. & Pouliot, M. 2016. Traditional Medicine For The Rich And Knowledgeable: 
Challenging Assumptions About Treatment-Seeking Behaviour In Rural And Peri-Urban 
Nepal. Health Policy Plan, 31, 314-24. 
21 
 
Utzinger, J. & Keiser, J. 2004. Schistosomiasis And Soil-Transmitted Helminthiasis: Common Drugs 
For Treatment And Control. Expert Opinion On Pharmacotherapy, 5, 263-285. 
WHO. 2016. Schistosomiasis: Number Of People Treated Worldwide In 2014. Available From: 
Https://Www.Who.Int/Neglected_Diseases/Resources/Who_Wer9105/En/ [Accessed On 17 
January 2019]. Weekly Epidemiological 91, 53-60. 
WHO. 2018. Schistosomiasis, Fact Sheet No 115. Available From:  Http://Www. Who. 
Int/Mediacentre/Factsheets/Fs115/En. [Accessed 17 January 2019]. 
WHO. 2013. Schistosomiasis: Progress Report 2001-2011, Strategic Plan 2012-2020. Available From: 
Http://Apps.Who.Int/Iris/Handle/10665/78074 [Accessed On 17 January 2019]. 
WHO. 2015. Geneva: Who. Schistosomiasis. Fact Sheet N°115. Available From: 
Http://Www.Who.Int/Mediacentre/Factsheets/Fs115/En/ [Accessed 17 January 2019]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2: FIRST MANUSCRIPT 
Mapping evidence of the concomitant management of schistosomiasis by 
Traditional Health Practitioners and Health care Professionals in communities 
with high prevalent infections: A systematic scoping review protocol  
 
 REVIEW AUTHORS INFORMATION  
Gloire-Aimé Aganze Mushebenge1*, Tivani Mashamba-Thompson2, Manimbulu Nlooto1 
1Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal  
2Discipline of Public Health Medicine, University of KwaZulu-Natal  
*Corresponding author: Gloire-Aimé Aganze Mushebenge Email: aganzedar@Gmail.com, alternative 
e-mails: nlooto@ukzn.ac.za, Mashamba-Thompson@ukzn.ac.za  
 
Taking into consideration the literature on the use of traditional medicine and the orthodox medicine in 
schistosomiasis management, this review was entitled: “Mapping evidence of the concomitant management of 
schistosomiasis by Traditional Health Practitioners and Health care Professionals in communities with high 
prevalent infections: A systematic scoping review protocol”. It aimed to map publications on the evidence of the 
concurrent use of orthodox and traditional medicine management of schistosomiasis infection in Low and Middle 
Income Countries (LMICs). This review was developed following the BMC Systematic reviews guidelines and 
submitted to the same Journal. It is under second review (Manuscript number SYSR-D-17-00336R1). 
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Abstract 
Background 
Schistosomiasis is one of the most prevalent parasitic diseases in low-and-middle-income countries 
(LMICs), being regarded as a neglected tropical disease in sub-Saharan Africa. Praziquantel is the 
conventional treatment recommended for schistosomiasis in mainstream healthcare systems. In many 
poor settings, while many people reportedly use both traditional medicine and public-sector mainstream 
healthcare systems, little is known if those infected with schistosomiasis use both African traditional 
and prescribed antischistosomal medicines. This review aims to map evidence of the concomitant 
management of schistosomiasis by traditional health practitioners (THPs) and health care professionals 
(HCPs) in communities with a high prevalence schistosomiasis infection in LMICs.   
Methods/Design 
Guided by Arksey and O’Malley scoping review framework and Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA), we will map the evidence from relevant studies 
dating from 2007 to September 2017 published on LMICs. An electronic keyword search of the 
following databases will be conducted: PubMed; Cochrane Library and the Cumulative Index to 
Nursing and Allied Health Literature (CINAHL) and MEDLINE via EBSCOhost, Google Scholar and 
WILEY online Library. Peer-reviewed articles, grey literature sources and reference lists will be 
included to identify for eligible studies. Following title screening, two reviewers will independently 
screen the abstracts and full-texts. Any study that focuses on managing schistosomiasis will be included.  
The data will be analysed using thematic analysis with the help of NVIVO software version 11, with 
the Mixed Method Appraisal Tool (MMAT) being used to assess the quality of the included studies.  
Discussion 
 This review will map the evidence in the literature of the concomitant management of schistosomiasis 
by THPs and HCPs in communities with a highly prevalent infection in LMICs. The review findings 
will be important for policymakers across the healthcare continuum and be used to inform stakeholders’ 
consensus process to explore the development of a generic set of patient-centered quality indicators that 
are applicable to multiple care settings. It will also identify research gaps in schistosomiasis 
management in LMICs and provide direction for future research. The results will be disseminated 
through a peer-reviewed publication and presented in relevant conferences. 
Systematic review registration: CRD42017078198 
(https://www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42017078198) 
Keywords: Schistosomiasis; Neglected tropical diseases; Collaboration; Investigation, Traditional 
Health Practitioners; Health Care Professionals; Access; Low-and-Middle Income Countries 
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BACKGROUND 
Infectious diseases are both a major public health concern and a socioeconomic problem in tropical 
regions within most low-and-middle-income countries (LMICs), where neglected tropical diseases 
(NTDs), such as schistosomiasis, are cause for concern [1]. These NTDs often occur in people who are 
also infected with human immunodeficiency virus (HIV), malaria or tuberculosis, making the problem 
even more serious, as co-infections are common [2]. Globally, more than 250 million people are 
infected with schistosomiasis, with approximately 700 million at risk of infection [3]. Schistosomiasis 
is a parasitic disease caused by schistosomes, worms that are found in tropical and sub-tropical 
freshwaters [4].  An estimated 206.4 million people needed preventive treatment for schistosomiasis in 
Africa in 2016, of whom approximately 89 million (43%) were reportedly treated [5]. More than five 
million people in South Africa, mainly in rural areas, required treatment in 2014 for urogenital 
schistosomiasis [6]. 
Praziquantel, the recommended treatment against all forms of schistosomiasis [7], is inexpensive and 
regarded as effective and safe, although re-infection may occur after treatment. The risk of developing 
the severe disease is reduced when treatment is initiated and repeated in childhood [8].  Many countries, 
such as Mozambique, Zambia, Nigeria and Uganda, have implemented mass treatment campaigns since 
the 1980s with generic medicines, including Praziquantel, with some having attained countrywide 
coverage the last few years [9-11]. The cost of Praziquantel in South Africa is 50 times higher than the 
World Health Organization (WHO) standard treatment that is in use in the rest of Africa, making it 
costly to provide mass treatment, which cannot be implemented [12]. None of the companies producing 
generic Praziquantel in other countries has the right to sell them in South Africa, due to the time-
consuming, expensive, “scientifically unnecessary” an elaborate registration process [13]. However, the 
cost of Praziquantel in South Africa, despite having been reduced, remains prohibitive for many control 
programs in schistosomiasis endemic areas [14].  
Alternatively, traditional medicine has demonstrated its contribution to managing schistosomiasis [15]. 
In an ethnopharmacological survey conducted in Niger and Mali, 55 plant species were reported to be 
used for treating schistosomiasis either alone or in combination, of which Zea mays with Glossonema 
boveanum were specific for intestinal schistosomiasis, while Cissus quadrangularis and Stylosanthes 
erecta were reported for the first time in Mali to be used against urogenital schistosomiasis [16]. A 
range of medicinal plants with anti-schistosomiasis properties has been widely used by traditional 
healers of different tribes in South Africa, although their effectiveness has not been scientifically 
evaluated [14].  A study conducted on mice in Zimbabwe showed no significant difference between a 
herbal preparation (Schitozim) and Praziquantel in managing schistosomiasis. However, the authors 
warranted further investigation to determine the toxic levels and effective doses of Schitozim in clinical 
settings [17].  
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Due to the unavailability of conventional therapy, or the expensive cost of Praziquantel and other 
antischistosomal medicines, people in rural areas may not have access to modern treatment for 
schistosomiasis, which results in them using traditional medicine [18, 19]. Collaboration between the 
two medical traditions can provide appropriate care for diseases management, for example, through 
mutual referral [20].  
This review aims to map the evidence of the concomitant management of schistosomiasis by traditional 
health practitioners and health care professionals in communities with a high prevalence of 
schistosomiasis infection in LMICs.  Thus, the purpose of this review is to provide evidence to enable 
the implementation of policies and guidelines to manage schistosomiasis with traditional medicine 
contributing to primary healthcare. 
 
METHODS/DESIGN 
Scoping review framework  
This review will be based on the framework originally proposed by Arksey and O’Malley [21] and 
further improved by Levac et al. (2010), which are presented in Table 1 [21-23]. There are six steps 
involved in the framework, although the last step about consulting experts/stakeholders will not be 
conducted for this review due to funding constraints.  Consulting additional sources of information, 
perspectives, meaning and applicability will be covered with grey literature. This review follows the 
six steps outlined by the Arksey and O’Malley framework but will incorporate enhancement suggested 
by the later authors. 
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Table 1. 1: Scoping review framework for this review [21-23].  
Arksey and O’malley 
framework  
Enhancements proposed by Levac, Colquhoun and 
O’brien  
1. Identify the research 
Question 
 
Clarify and link the purpose and research 
question 
2. Identify relevant studies Balance the feasibility with breadth and 
comprehensiveness of the scoping process 
 
3. Select the study Use an iterative team approach to select studies and extract 
data 
 
4. Chart the data Incorporate a numerical summary and qualitative thematic 
analysis 
 
5. Collate, summarize and report 
the results 
 
Identify the implications of the study findings for policy, 
practice or research 
6. Consult experts/stakeholders 
(optional) 
Provide opportunities for consumer and stakeholder 
involvement to suggest additional references and provide 
insights beyond those in the literature. 
 
1. Identify the research questions 
The following research questions were formulated to guide the review in meeting its aims and 
objectives. The general research question is: “What is the evidence about the concomitant management 
of schistosomiasis by THPs and HCPs in communities with a high prevalence schistosomiasis 
infection?” The specific research questions are as follows: 
1. What is the evidence of the healthcare seeking behaviour among individuals in communities 
with high prevalent infections of schistosomiasis?  
2.  What is the evidence of the use of traditional, complementary and alternative medicine for 
managing schistosomiasis?  
3. Is there a bidirectional referral of patients between THPs and HCPs for managing 
schistosomiasis? 
 
Eligibility of research questions 
The Population, Intervention, Comparison and Outcomes (PICO) for the research questions has been 
used to break down the clinical questions into searchable keywords [24]. 
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Table 1. 2: Research questions eligibility (PICO) Framework 
Framework Evidence-based practice 
 
P: Population THPs and HCPs, aged 18 years old and above regardless of gender. 
 
I: Intervention Traditional remedies for schistosomiasis management, Praziquantel and 
LMICs. 
 
C: Comparison Schistosomiasis management by THPs and HCPs. 
 
O: Outcomes Access to treatment and improvement of the management of schistosomiasis 
in communities with high prevalent infection. 
 
2. Identify relevant studies 
Relevant literature will be searched from the following databases: PubMed; EBSCOhost (the 
Cumulative Index to Nursing and Allied Health Literature (CINAHL) and MEDLINE); Google Scholar; 
Cochrane Library, WILEY online Library and grey literature. Reference lists of included studies will 
also be searched. The keywords search will include the following: schistosomiasis; neglected tropical 
diseases; collaboration; investigation, traditional health practitioners; health care professionals; access; 
low and middle-income countries, schistosomiasis or collaboration or traditional medicine or neglected 
tropical diseases (NTDs) or natural products or leads. The Boolean search terms (AND and OR) and 
MeSH terms ("therapy", "therapeutics", "schistosomiasis", "health personnel", "residence 
characteristics", "infection", …) will be included in the search. Grey literature will be identified through 
website source links in references. Peer review studies and grey literature reporting on the evidence of 
managing schistosomiasis by THPs and HCPs in LMICs published between 2007 and 2019 will be 
included. Authors of primary studies or reviews will be contacted for further information or to access 
missing studies where relevant. If the authors do not respond, then their publications will be excluded. 
  
3. Select the study  
Inclusion criteria 
The following criteria provide a guide to clearly understand what is proposed by the reviewers and, 
more importantly, a guide for the reviewers themselves upon which to base decisions about the sources 
to be included in this review [25]. As explained above, regarding the review types, there must be clear 
congruency between the title, objectives, question/s, and inclusion criteria of a scoping review. They 
are as follows: 
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1.  Evidence of the population of interest in this review (THPs and HCPs)  
2.  Evidence of the intervention (Schistosomiasis treatment and co-morbidities)  
3.  Evidence of the comparison of treatment by THPs and HCPs 
4.  Evidence on the outcomes of managing schistosomiasis 
5.  Articles published in English and French will be included.  
 
Exclusion Criteria 
1. Articles published before 2007. 
2. Articles not addressing the treatment of schistosomiasis and comorbidities. 
3. Articles not addressing integration and collaboration between Traditional Medicine and 
Conventional Medicine. 
4. Studies that are not reporting evidence from LMICs 
 
Search strategy  
 The search strategy for this review aims to be comprehensive to identify both published and 
unpublished (grey literature) primary studies and reviews [25, 26]. A pilot search was conducted with 
the database results provided in Appendix 1. A three-step search strategy will be utilized. The first step 
is an initial limited search of the electronic databases. This initial search will be monitored, exported on 
Endnote X8 reference manager for abstract and full article screening. The duplicated article will be 
deleted. A second search using all identified keywords and index terms will then be undertaken across 
all included databases. Thirdly, the reference list of all identified reports and articles will be searched 
for additional studies [25]. For abstract and full article screening, the endnote library will be shared with 
a second reviewer.  Any discrepancies in the results of abstract screening will be resolved through a 
discussion until a consensus is reached. A third screener will help to resolve discrepancies in full article 
screening results [26].   
Publications duplicated in the research results will be treated as a single study for the review. To 
maintain transparency in the review selection process, a PRISMA Flow Diagram will be followed in 
each stage of the selection process. In addition, a list of the studies excluded during the full-text review 
will be documented as an appendix, with brief reasons for their exclusion [26]. A PRISMA Flow 
Diagram will be used to report the screening results (see Figure 1). EndNote will help to manage the 
search results including downloading all results, removing duplicate records, and screening for 
potentially relevant studies. 
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Figure 2. 1: The PRISMA Flow Diagram for a scoping review screening process [25]. 
 
Quality appraisal 
For the quality appraisal of the included studies, we will use a Mixed Methods Appraisal Tool (MMAT), 
version 2011[27]. The MMAT will allow us to assess the appropriateness and quality of the research. 
Studies can be scored following specific criterion using a certain score to describe them from 50% and 
above. 
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4. Chart the data 
We will conduct data extraction to enable a logical and descriptive summary of the search results 
(Appendix 1) of our systematic scoping review [25, 26]. A table of characteristics for included studies 
will be developed at this stage to record the key information of the source, such as author, reference and 
results or findings relevant to the review question/s (Appendix 3). This may be further refined at the 
review stage and the sample extraction form updated accordingly. From the key information chart, data 
in the selected articles will be in data extraction form and synthesized into different themes for 
interpretation to identify key findings.  
5. Collate, summarize and report the results 
The results will be presented in a data extraction form or table and will be further refined towards the 
end of the review when the authors will have the greatest awareness of the contents of their included 
studies to manage schistosomiasis. The results will be mapped in the existing thematic framework, 
which will consist of the included papers in a diagrammatic or tabular form, and/or in a descriptive 
format that aligns with the objective/s and scope of the review related to outcomes. The PICO elements 
for inclusion criteria will be useful to guide how the data will be mapped most appropriately.  
 A narrative summary will accompany the tabulated and/or charted results and should describe how 
they relate to the review objective and question/s according to the management of schistosomiasis and 
its co-morbidities by THPs and HCPs. The synthesis of important findings across the included studies 
will be classified by identifying prominent themes under the main conceptual categories, such as: 
“intervention type”, “review population” (and sample size, if it is the case), “duration of intervention”, 
“aims”, “methodology adopted”, “key findings” (evidence established), and “gaps in the research”. For 
each category reported, a clear explanation will be provided. 
 
Synthesis 
Throughout this research, we will examine the above-mentioned themes and critically identify their link 
to the research question. Reviewers will analyze the significance of the findings according to the aim 
of this research and their implications for future studies, practice and policy. 
 
DISCUSSION  
This review is part of larger studies evaluating the management of schistosomiasis by THPs and HCPs 
in South Africa. There is little evidence to support the current South African policy to manage 
schistosomiasis. This systematic scoping review aims to build on the work of the existing Cochrane 
study [20] by further describing the participant inclusion criteria and utilizing a wider range of evidence 
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on this topic. A key strength is that it can provide a rigorous and transparent method for mapping areas 
of research according to the treatment of schistosomiasis with comorbidities. We wish to be able to 
illustrate the field of interest, that being the management of schistosomiasis, in terms of the volume, 
nature and characteristics of the primary research.  
Articles not addressing integration and collaboration between traditional and modern medicine will not 
be part of this research, as it intends finding a way to manage schistosomiasis via bidirectional referral 
of patients between THPs and HCPs.  Due to the prevalence of schistosomiasis, a collaboration of THPs 
and HCPs could help to manage the infection, as traditional medicine is available to most people in 
LMICs, with not less than 80% of people worldwide depending on it [28]. 
It is anticipated that this review will identify gaps in the current literature on this topic and provide 
direction for future research in this area of this review. The summary and dissemination of this research 
findings may be of interest for policymakers and stakeholders (practitioners and consumers) who are 
involved in the NTDs management, especially those involved in schistosomiasis management using 
either the mainstream healthcare systems or African traditional medicine. 
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APPENDICES 
Appendix 1. Table 2: Results of the pilot database search  
Keyword Search Date of search Search Engine 
used 
Number of 
publications 
retrieved 
(Results) 
Mapping[All Fields] AND evidence[All 
Fields] AND concomitant[All Fields] AND 
("therapy"[Subheading] OR "therapy"[All 
Fields] OR "treatment"[All Fields] OR 
"therapeutics"[MeSH Terms] OR 
"therapeutics"[All Fields]) AND 
("schistosomiasis"[MeSH Terms] OR 
"schistosomiasis"[All Fields]) AND 
Traditional[All Fields] AND 
("health"[MeSH Terms] OR "health"[All 
Fields]) AND Practitioners[All Fields] AND 
("health personnel"[MeSH Terms] OR 
("health"[All Fields] AND "personnel"[All 
Fields]) OR "health personnel"[All Fields] 
OR ("health"[All Fields] AND "care"[All 
Fields] AND "professionals"[All Fields]) OR 
"health care professionals"[All Fields]) AND 
("residence characteristics"[MeSH Terms] 
OR ("residence"[All Fields] AND 
"characteristics"[All Fields]) OR "residence 
characteristics"[All Fields] OR 
"communities"[All Fields]) AND high[All 
Fields] AND prevalent[All Fields] AND 
("infection"[MeSH Terms] OR 
"infection"[All Fields] OR "infections"[All 
Fields]) AND low[All Fields] AND middle[All 
Fields] AND ("income"[MeSH Terms] OR 
"income"[All Fields]) AND countries[All 
Fields] 
September 18th 2017 Google Scholar, 
PUBMED 
8370 
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Appendix 2. Table 3: PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to 
address in a systematic review protocol*  
Section/topic # Checklist item 
Information 
reported  Line 
number(s) 
Yes No 
ADMINISTRATIVE INFORMATION   
Title  
  Identification  1a Identify the report as a protocol of a systematic review   P1 
  Update  1b 
If the protocol is for an update of a previous systematic review, identify as 
such 
   
Registration  2 
If registered, provide the name of the registry (e.g., PROSPERO) and 
registration number in the Abstract 
  P3 
Authors  
  Contact  3a 
Provide name, institutional affiliation, and e-mail address of all protocol 
authors; provide physical mailing address of corresponding author 
  P1&P14 
  Contributions  3b 
Describe contributions of protocol authors and identify the guarantor of the 
review 
  P14 
Amendments  4 
If the protocol represents an amendment of a previously completed or 
published protocol, identify as such and list changes; otherwise, state plan for 
documenting important protocol amendments 
   
Support  
  Sources  5a Indicate sources of financial or other support for the review   P14 
  Sponsor  5b Provide name for the review funder and/or sponsor    
  Role of 
sponsor/funder  
5c 
Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in 
developing the protocol 
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Section/topic # Checklist item 
Information 
reported  Line 
number(s) 
Yes No 
INTRODUCTION  
Rationale  6 Describe the rationale for the review in the context of what is already known   P4&P5 
Objectives  7 
Provide an explicit statement of the question(s) the review will address with 
reference to participants, interventions, comparators, and outcomes (PICO) 
 
   P7 
METHODS  
Eligibility criteria  8 
Specify the study characteristics (e.g., PICO, study design, setting, time 
frame) and report characteristics (e.g., years considered, language, 
publication status) to be used as criteria for eligibility for the review 
  P7, P8&P9 
Information sources  9 
Describe all intended information sources (e.g., electronic databases, contact 
with study authors, trial registers, or other grey literature sources) with 
planned dates of coverage 
  P8 
Search strategy  10 
Present draft of search strategy to be used for at least one electronic 
database, including planned limits, such that it could be repeated 
  P9&P10  
STUDY RECORDS  
  Data 
management  
11a 
Describe the mechanism(s) that will be used to manage records and data 
throughout the review 
  P11&P12 
  Selection 
process  
11b 
State the process that will be used for selecting studies (e.g., two 
independent reviewers) through each phase of the review (i.e., screening, 
eligibility, and inclusion in meta-analysis) 
  P8-P10 
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Section/topic # Checklist item 
Information 
reported  Line 
number(s) 
Yes No 
Data collection 
process  
11c 
Describe planned method of extracting data from reports (e.g., piloting forms, 
done independently, in duplicate), any processes for obtaining and confirming 
data from investigators 
  P9&P10 
Data items  12 
List and define all variables for which data will be sought (e.g., PICO items, 
funding sources), any pre-planned data assumptions and simplifications 
  P7&P14 
Outcomes and 
prioritization  
13 
List and define all outcomes for which data will be sought, including 
prioritization of main and additional outcomes, with rationale 
  P12&P13 
Risk of bias in 
individual studies  
14 
Describe anticipated methods for assessing risk of bias of individual studies, 
including whether this will be done at the outcome or study level, or both; 
state how this information will be used in data synthesis 
  P8 – P12 
DATA 
Synthesis  
15a Describe criteria under which study data will be quantitatively synthesized   P12 
15b 
If data are appropriate for quantitative synthesis, describe planned summary 
measures, methods of handling data, and methods of combining data from 
studies, including any planned exploration of consistency (e.g., I 2, Kendall’s 
tau) 
   
15c 
Describe any proposed additional analyses (e.g., sensitivity or subgroup 
analyses, meta-regression) 
   
15d 
If quantitative synthesis is not appropriate, describe the type of summary 
planned 
  P12 
Meta-bias(es)  16 
Specify any planned assessment of meta-bias(es) (e.g., publication bias 
across studies, selective reporting within studies) 
  P9 
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Section/topic # Checklist item 
Information 
reported  Line 
number(s) 
Yes No 
Confidence in 
cumulative 
evidence  
17 
Describe how the strength of the body of evidence will be assessed (e.g., 
GRADE) 
  P11 
*
 
It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for 
important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including 
checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0. 
 
 
From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic 
review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2; 349(jan02 1):g7647
41 
 
Appendix 3. Table 4: Sample extraction form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key information chart  
a. Title 
b. Author(s)  
c. Year of publication  
d. Origin/country of origin (where the study was published or conducted)  
e. Aim (s) /purpose(s)  
f. Summary of the study results 
g. Study population and sample size (if applicable)  
h. Methodology/methods (recruitment and sampling) 
i. Study design 
j. Data collection method 
k. Data analysis 
l. Intervention type, comparator and details of these  
(e.g. duration of the intervention) (if applicable)  
m. Duration of the intervention (if applicable)  
n. Outcomes and details of these (e.g. how measures) (if applicable)  
o. Relevant Key findings that relate to the scoping review question/s. 
p. Conclusions  
q. Comments 
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Chapter 3 explored the way traditional health practitioners’ diagnosed schistosomiasis and types of traditional medicines 
used to treat this disease in communities with high prevalence infection. Reportedly, THPs are playing a key role in the 
management of schistosomiasis in individuals in rural settings of ILembe District, KwaZulu-Natal; they consulted 
individuals with schistosomiasis who did not accept to be treated in the mainstream health care system. Different plants 
species either alone or in combination were used in the management of schistosomiasis. A manuscript entitled 
“Knowledge, perceptions and experiences of traditional health practitionners about the management of female urogenital 
schistosomiasis: The case of ILembe District, KwaZulu-Natal, South Africa” was written following the guidelines of 
the journal “BMC Complementary and Alternative medicine.” This manuscript is actually under review (Manuscript 
number BCAM-D-19-00253). 
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ABSTRACT  
 
Background: Schistosomiasis is the third most important Neglected Tropical Disease, with more than 
4 million South Africans being infected. Cases of re-infection with schistosomiasis after being treated 
using modern medication has opened ways to seeking alternative treatment modalities using medicinal 
plants. This study aimed to explore and understand ways traditional healers diagnosed schistosomiasis, 
the types of traditional medicines used to treat it in communities with a high prevalence of the infection, 
and established whether the unavailability of prescribed anti-schistosomal medicines led to the use of 
traditional medicine. 
 
Methods: A qualitative exploratory study was conducted using a questionnaire from December 2017 
to March 2018 in the ILembe District, KwaZulu-Natal Province, South Africa. In-depth interviews were 
carried out among traditional health practitioners (THPs) involved in managing female urogenital 
schistosomiasis (FUS). Recorded narrative data was transcribed verbatim, read through thoroughly and 
coded, and analyzed using thematic analysis. 
 
Results: THPs provided services to many women who did not want to be treated in the mainstream 
healthcare system for their FUS. The disease was perceived and understood the same way by most of 
the respondents, that being caused by the use of fresh water. Plants species, either alone or in 
combination, were used to manage schistosomiasis in women. Senecio serratuloides (Asteraceae) and 
Hypoxis hemerocallidea (Hypoxidaceae) were prominently used by THPs in FUS management.  
 
Conclusion:  Traditional Health Practitioners are playing a key role in managing schistosomiasis in 
women in rural areas of the ILembe District; this study reported that THPs diagnosed schistosomiasis 
symptoms based on their knowledge and experiences. Respondents indicated that modern conventional 
treatment was readily available and free in public sector healthcare facilities; however, they consulted 
patients suffering from FUS.  Traditional herbal medicines were reportedly used by THPs to manage 
schistosomiasis in the women. Further studies are needed to investigate the views and experiences of 
clients regarding the success of the treatments used and why they do seek care from THPs.   
 
Keywords: Female urogenital schistosomiasis, Traditional health practitioners, Traditional medicine, 
Management, South Africa, qualitative study 
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BACKGROUND 
The World Health Organization (WHO) estimated that a minimum of 206.4 million people was in need 
of treatment for schistosomiasis in 2016, with almost 91.4% living in Africa [1]. Being the third most 
important Neglected Tropical Disease, schistosomiasis, or Schistosomiasis, is an infectious, water-
borne parasitic disease in many tropical settings that is caused by worms falling under the Schistosoma 
genus [1-3]. People engaging in various activities in contact with fresh/untreated water infected by 
Schistosoma during activities such as laundry, plate washing, water fetching for domestic use, bathing, 
paddling, diving, swimming or drinking as well as fishing and farming, are at risk of contracting the 
disease. Women and children are the most exposed [4],  as they are often involved in activities 
associated with water. Female urogenital schistosomiasis is presented as inflammation and ulceration 
of the genital mucosa and is listed by the WHO as a research priority [5-7].  
More than four million South Africans are infected with schistosomiasis [6], and while Praziquantel is 
used effectively to control current infections, often through mass-treatment programs, it may also 
worsen the symptoms and will not prevent future infections [8-10]. Treatment is also provided by 
traditional health practitioners (THP) who use traditional medicine (TM) in rural communities of South 
Africa, with many people using them as their primary healthcare provider of choice [11]. In southern 
African countries, TM has played a key role in managing schistosomiasis, also known as 
schistosomiasis, making it important to document to establish its efficacy [12].  
Various studies carried out in South Africa have reported that several plants are recognized as having 
anti-schistosomal activity (Cock et al., 2018, Sparg et al., 2000). The following species have been 
widely used to manage the disease: Acacia karroo, Maytenus senegalensis, Peltophorum 
africanum and Ziziphus mucronata, Abrus precatorius, Boswellia carteri, Cissampelos murconata, 
Euclea natalensis, Sclerocarya birrea, Rumex nepalensis, Protasparagus buchananii, Maytenus 
senegalensis, Faurea saligna [12-16]. Moreover, cases of re-infection with schistosomiasis following 
the use of modern medication to treat it has opened ways to seeking alternative treatment modalities 
based on indigenous knowledge (IK) holders through the use of medicinal plants.  
There has been little research on THPs knowledge, perceptions and practices regarding the process of 
traditional healing of schistosomiasis in women in South Africa. To address this gap, this present study 
was conducted among THPs from the ILembe District in KwaZulu-Natal Province, South Africa. This 
study aims to explore and gain an understanding of the way THPs diagnose female urogenital 
schistosomiasis (FUS), identify the types of traditional medicines used to treat it in communities with 
a high prevalence of infection, and to establish whether the unavailability of prescribed anti-
schistosomal medicines in the public health sector leads to the use of traditional medicine.  
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METHODS 
Study settings 
The ILembe District Municipality is located on the east coast of KwaZulu-Natal Province north of the 
city of Durban, and is the smallest of the provincial municipalities, with a population of 630 464 in an 
area of 3,269 km². Most of the interior rural areas are tribally controlled and characterized by 
subsistence agriculture.  ILembe consists of four sub-districts: Mandeni, KwaDukuza, Maphumulo and 
Ndwedwe (Figure 1), its main town being Stanger, which lies on the Tugela River [17]. The study area 
was chosen due to its history of schistosomiasis prevalence in KZN (Saathoff et al, 2004). 
 
 
Figure 3. 1:   The four sub-districts of the ILembe district municipality  
 
 Study design 
An exploratory qualitative study was undertaken from December 2017 to March 2018 and consisted of 
eight weeks of fieldwork. A BREC validated semi-structured questionnaire with open questions 
administered to participants, using face-to-face interviews to obtain qualitative data [18]. 
 
Study sample  
This study enrolled 22 THPs (saturation in the recruitment) who were recruited from the Traditional 
Health Organization (THO) in the ILembe District using purposeful sampling, followed by snowball 
sampling, with referrals being made to identify suitable participants [19]. Male and female THPs who 
were aged 18 years old and above were included who had managed FUS in women for at least one year.  
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Procedure for recruiting and selecting study participants 
The Biomedical Research Ethics Committee of the University of KwaZulu-Natal under reference 
BE477/17 approved this study, and informed consents were sought from all participants. They agreed 
on the findings being published to raise awareness on the contribution of traditional medicine to manage 
FUS. Contacts were made through the University of KwaZulu-Natal’s Centre in Indigenous Knowledge 
Systems with THO leaders to identify registered THPs. After being introduced by community leaders, 
the research team approached THPs at their workplace during business hours, with those being willing 
to participate were interviewed.  
 
Data collection methods 
A semi-structured questionnaire with open- and closed-ended questionnaire was administered to 
participants using face-to-face interviews until saturation was reached [20]. The design of the 
questionnaire reduced possible bias and misunderstanding between the western and indigenous 
conception of FUS and its bio-medical definition [21, 22]. THPs were interviewed at their houses or 
any place of their choice and lasted from 15-60 minutes. Study aims and procedures were explained to 
participants in English and the local language, IsiZulu. The questionnaire was divided into four sections: 
demographic data, and their knowledge, perceptions and practices about managing FUS, and is 
presented in Additional File 1. The interview was recorded with the participant’s permission, with notes 
being taken and observations made throughout.   
 
Data analysis  
The statistical package for social sciences (IBM SPSS Statistics) statistical software version 25.0 
package for Windows was used for demographic data [23]. The recorded narrative qualitative data were 
collected using Giorgi’s phenomenological framework [24, 25], and transcribed verbatim, read through 
thoroughly and coded for thematic analysis for step-wideness [19, 26, 27]. The transcripts were cross-
checked with the records, and meaning units corresponding to the study objective extracted, coded, 
grouped in sub-categories and thematic categories following the deductive technique, and substantiated 
by quotes [28].  The body language, silences and other non-verbal communications are considered in 
analyzing the data [29]. 
 
This study followed the guidelines proposed by Lincoln and Guba [30] for the trustworthiness of the 
findings, with more than one researcher being involved in the study and the voluntary participation of 
respondents. The research procedure and design enhanced transparently to provide transferability.  
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RESULTS 
The participants’ demographic details are followed by the themes relating to the THPs knowledge, 
perceptions and practices of managing FUS.   
 
Demographic details  
The 22 participants who agreed to be interviewed (Table 1) were aged between 26 and 70 years old, 
with a mean age of 41.05 ± 13.075 (SD). The majority were females (14/22, 63.6%) and married (14/22, 
63.6%) and participants completed their high schooling (10/22, 45.5%). Most respondents practised as 
diviners (Izangoma) (17/22, 77.2%), were Christians (15/22, 68.2%), and had a mean of 13 years’ 
experience (±10.170). 
Table 2. 1: Respondents’ background characteristics 
 
Variables Category No. % Proportion 
(95% Confidence interval) 
Gender  
 
                              Female 
                                Male 
14 63.6 40.7 – 82.8 
8 36.4 17.2 – 59.3 
Marital status      
 
                         Married 
 Not married 
14 63.6 40.7 – 82.8 
8 36.4 17.2 – 59.3 
Level of 
Education 
  High School completed  
None specified  
Prim. School completed 
Postsecondary certificate  
Degree 
10 45.5 24.4 – 67.8 
7 31.8 13.9 – 54.9 
3 13.6 2.9 -34.9 
1 4.5 0.1 – 22.8 
1 4.5 0.12 – 22.8 
Profession  
 
Diviner (Sangoma) 
Both (Sangoma/Inyanga) 
Herbalist (Inyanga) 
17 77.2 54,6 - 92,2 
3 13.6 2,9 – 34,9 
2 9.1 1.1 – 29.2 
Religion  
 
Christian 
Traditional religion 
Hinduism 
None specified 
15 68.2 45.1 – 86.1 
5 22.7 7.8 – 45.4 
1 4.5 0.1 – 22.8 
1 4.5 0.1 – 22.8 
Mean years of work experience, SD: 13 (10.170)  
Age (years) Mean age, SD, Range:  41.05 (13.075), 26 – 70 
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Traditional health practitioners’ perceptions, knowledge and experiences in diagnosing of FUS  
A thematic content analysis was carried out that yielded seven major themes:  (1) source of knowledge, 
(2) diagnosing female urogenital schistosomiasis, (3) acceptability and affordability of treatment, (4) 
locally used plants to manage FUS, (5) availability of TM treatment in FUS management, (6) concurrent 
use of TM with prescribed conventional antischistosomal medicines, and (7), knowledge of side effects 
and perceptions of efficacy of treatment provided by THPs. 
Theme 1. Source of knowledge  
Respondents were questioned about their source of knowledge about healing FUS. They reported that 
a special calling from ancestors is a requirement of becoming a traditional healer. In most cases, this 
calling can come in dreams/visions, where trainees are instructed to avail themselves into helping the 
community by becoming THPs. If they agree, they go through training after verification of the calling. 
In addition, THPs who train new ones are called to do so as well. They are not only traditional healers 
but trainers, as with the ancestors giving orientation to the newly called person, sending them to a 
trainer. When asked about their source of the healing process for FUS, a respondent noted that: 
 “… I didn’t just have knowledge of being sangoma (traditional healer), my ancestor came 
to me and took me to training of ukuthwasa (which is to accept the calling of becoming a 
traditional healer).”   THP21. 
They reported having learnt from old THPs, identified as trainers, in their respective areas. In the 
learning process, they go through different healing practices for a period of time. When asked about 
how he learnt the healing process a respondent said:  
“… We use to wake up early morning and go to inyanga houses where we had to pass the 
whole day studying Traditional Medicine and I did it for a year…” THP18. 
 
Theme 2. Diagnosing female urogenital schistosomiasis  
THPs mentioned that FUS occurs when engaging in various activities close to fresh water and diagnose 
the symptoms based on their knowledge and experience, specifically by checking the patient’s urine 
colouration. A Respondent reported the following that: 
“… If the person is urinating constantly blood or if their urine changing colour. The same 
thing happens in women when they have this disease (FUS)…” THP18. 
Some respondents indicated that there was a natural process of diagnosing FUS in women. It involved 
mainly physical symptoms. A respondent reported that:  
 “ … Urine have an unusual temperature, tension on the bladder, prostate feels itchy for 
man, it is swollen near the bladder, and bladder feels pain for male and female.  If the 
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person is urinating constantly blood or if their urine changing colour and itching when 
urinating. The same thing happens in women when they have this disease…” THP2. 
Some reported that they relied on spiritually diagnosing FUS by consulting their ancestors and that 
people sometimes had a curse tossed at them that is why they need spiritual assistance. A participant 
mentioned the following: 
“…We perform the practice called Ukumhlola ngoko moya (spiritual divination) to 
diagnose schistosomiasis in patients…” THP9. 
Some used both natural and spiritual ways to diagnose schistosomiasis in women, the one method 
confirming the other:  
“… Ucama igazi (urinating blood) after swimming in rivers then I throw bones to confirm 
the diagnostic…” THP15. 
 
Theme 3. Acceptability and affordability of treatment  
The respondents noted that although modern treatments were readily available and free in public sector 
healthcare facilities, they consulted many women who did not want to be treated in the mainstream 
health care system (acceptability), preferring to first consult THPs:  
“I treat the patient who comes to me with schistosomiasis (isichenene) because they think 
that it is only for children. They are feeling bad to tell to the doctors that they are urinating 
blood (ukucama igazi)… “THP1. 
THPs, as IK holders, contended that traditional medicine is affordable and accessible to community 
members, with no standard price for consultations and payment being done after being treated. The cost 
of medicine depended on the level of confidence between the healer and his patients and varies from 
healer to healer as well as being based on the severity of the infection. A respondent reported that: 
“… I am not sure of how much it would cost to treat schistosomiasis at the hospital but 
traditionally I make the price of all my medicines almost similar, for Ischenene its R150 
for the complete treatment…” THP18. 
In comparing traditional treatment to orthodox treatment, a few participants argued that their treatment 
price could depend on how and where it was collected from, as well as its price at the Muti market, all 
of which contribute to the price they charge the patients, which can make some treatment expensive. 
Participants said:  
“… Traditional healers medicine is quite expensive, traditional healers are more expensive 
than the scientific people…”  THP3. 
The acceptability and affordability of the treatment depend on whether the infection is severe, or the 
patient is newly infected. The more medication they take the more money they will have to pay. A 
respondent said:  
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“.. Depends on the person sickness and the person intensity to be healed, as well as what 
the person needs, also on the healer’s payment rate…” THP7.  
Some infections can be beyond the THPs knowledge and understanding, including FUS, for which they 
refer a patient to healthcare facilities. They advanced that it is not about treatment payment but the 
patient well-being, and reported that: 
“… We cannot say a patient has to choose what they afford or what they see cheaper 
between traditional medicine and modern medicine. Doctors’ medicines have chemicals 
that reduce pains quicker, that’s why I recommend them if I can’t manage the disease…” 
THP 17.  
THPs combine practices by executing the spiritual part and leaving the treatment to healthcare workers 
in a collaborative way: 
“There are sicknesses that are based on witchcraft, that’s where a traditional healer is 
needed. When I see that my patient’s sickness is not of witchcraft I then advise them to go 
to hospitals…” THP21. 
Both western and unorthodox practitioners can collaborate when needed, as they can complement each 
other, including for FUS management: 
“… Modern doctors and traditional doctors should work here hand-in-hand. Modern 
doctors are very important. The collaborative approach is good for the wellbeing of the 
patient in managing this disease (FUS)…” THP20. 
Traditional healers testified that they discuss their treatment fees with their patients who give them 
feedback on the efficacy of the treatment before payment. 
 
Theme 4. Locally used plants to manage FUS  
The THPs indicated that they used a combination of traditional medicinal plants to treat FUS, which 
most (n= 12; 54.5%) indicated were not easily accessible. They used various plants to manage FUS in 
rural areas of KwaZulu-Natal Province, some of which are well-known by community members who 
used them on their own, only sometimes consulting THPs. They reported that the main sources of 
treatment were plants.  Doses were measured depending on the severity of the disease and the 
experience of each THP. Most of the respondents were sceptical about sharing knowledge with the 
researchers.  Table 2.2 presents a list of the plants used to manage FUS.
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Table 2 2: Traditional treatments used individually or in combination to manage FUS 
Botanical name  Family 
 
isiZulu (Z)/isiXhosa 
(X), Tshivenda (V) 
vernacular name (s) 
given by 
interviewees 
Number 
of times 
quoted 
by 
THPs 
Previous report of ethnomedical uses (reference) 
Adenostemma caffrum DC. Asteraceae Umahogo (Z) 1 Used as a love charm and for influenza. The infusion is 
taken as an emetic given to children as enemas [13].  
Albuca fastigiata Dryand. Hyacinthaceae uMaphipha (Z) 1 Traditionally used as emetics for protection against sorcery 
and as general protective charms [31].  
Aloe marlothii A.Berger/ Aloe ferox 
Mill. 
 
Asphodelaceae iNhlaba, uMhlaba 
(Z) 
2 Used in southern African for infections, particularly 
sexually transmitted infections and internal parasites, 
genito-urinary system, injuries, digestion, pregnancy, skin 
complaints, sensory system, inflammation, pain, 
respiratory system, muscular-skeletal system, nutrition 
[32]. 
Anemone fanninii Harv. ex Mast. 
 
Ranunculaceae Emyama/ 
nManzamnyama (Z) 
1 The plant has antitumor, antimicrobial, anti-inflammatory, 
sedative, analgesic activities, anti-convulsant and anti-
histamine effects [33]. 
Bowiea volubilis Harv. Ex Hook.f. 
subsp. volubilis 
 
Hyacinthaceae UGibisisila or 
uGibisila; iguleni 
(Z); uMgaqana (X) 
2 Plant widely used against numerous ailments including 
headache, muscular pains, infertility, cystitis and venereal 
diseases in southern Africa [34]. 
Callilepis laureola DC. 
 
Asteraceae Amafuthomhlaba, 
ihlamvu, impila (Z) 
2 Used for stomach problems, tapeworm infestations, 
impotence, cough, and to induce fertility. Impila is also 
administered to pregnant women by traditional birth 
attendants to “ensure the health of the mother and 
child” and to facilitate labour. It is also taken by young girls 
in the early stages of menstruation [35]. 
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Botanical name  Family 
 
isiZulu (Z)/isiXhosa 
(X), Tshivenda (V) 
vernacular name (s) 
given by 
interviewees 
Number 
of times 
quoted 
by 
THPs 
Previous report of ethnomedical uses (reference) 
Carpobrotus edulis (L.) L. Bolus Mesembryanthem
aceae (Aizoaceae) 
mthombozi/Umgong
ozi (Z) 
1 The plant is used in soothing itching caused by spider and 
tick bites. It contains astringent antiseptic juice which can 
be taken orally for treating sore throat and mouth 
infections. It has an antimicrobial activity [36] 
Combretum 
erythrophyllum (Burch.) Sond. 
Combretaceae 
 
Umdubu (Z) 1 Used for the treatment of abdominal pains and venereal 
diseases due to antibacterial compounds in the leaves [13]. 
Combretum vendae A.E.van Wyk Combretaceae Gopo (gopo-gopo, 
gopokopo-bani (V). 
1 Used for the treatment of bacterial related infections and 
oxidative related diseases by indigenous people of South 
Africa [37].  
Eucomis autumnalis (Mill.) Chitt.  Hyacinthaceae uBuhlungu 
eSimathunzi (X), 
uMathunga (Z) 
4 Greatly valued in traditional medicine for the treatment of 
a variety of ailments, predominantly those involving pain, 
fever and inflammation [38]. 
Gunnera perpensa L. 
 
 
Gunneraceae iPhuzi lomlambo, 
iGhobo (X); uGobhe, 
uGobho (Z) 
 
4 Used in folk medicine to relieve rheumatoid pain, facilitate 
childbirth and healing wounds. Zulu traditional healers use 
it to induce labor, expel the placenta after birth and to relief 
menstrual pains [39]. 
Hypoxis hemerocallidea    Fisch., 
C.A.Mey. & Avé-Lall. 
 
Hypoxidaceae iNkomfe (Z), 
iLabatheka (Xhosa) 
5 Southern African ‘wonder’ plant medicine being claimed 
to be an effective remedy against HIV/AIDS-related 
diseases, arthritis, yuppie flu, hypertension, diabetes 
mellitus, cancer, psoriasis, gastric and duodenal ulcers, 
tuberculosis, urinary tract infections, asthma, and some 
central nervous system (CNS) disorders, especially 
epilepsy and childhood convulsions [40]. 
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Botanical name  Family 
 
isiZulu (Z)/isiXhosa 
(X), Tshivenda (V) 
vernacular name (s) 
given by 
interviewees 
Number 
of times 
quoted 
by 
THPs 
Previous report of ethnomedical uses (reference) 
Knowltonia bracteata Harv. ex 
J.Zahlbr. 
Ranunculaceae nguthuza or 
uMvuthuza (Z) 
1 Used for sexually transmitted diseases [41]. 
Maytenus undata (Thunb.) 
Blakelock 
Celastraceae  Undubula 
/iNdabulaluvalo (Z) 
2 Widely used in folk medicine as anti-tumour, anti-
asthmatic, analgesic, anti-inflammatory, antimicrobial and 
anti-ulcer agents, and as a treatment for stomach problems 
[42]. 
Myrothamnus flabellifolius Welw. 
 
Myrothamnaceae uVuka kwa bafile (Z) 2 Used for respiratory ailments, nosebleeds and fainting, 
alleviate backache, kidney problems, haemorrhoids and 
menstrual pains, abrasions, dressings for burns and 
wounds, chest pains and asthma, treat infections and pains 
in the uterus. In central Africa, it is used as a tonic and to 
treat breast complaints. Shona healers have used the plant 
to treat epilepsy, madness and coughs [43]. 
Nidorella Sp. Schimper, G.W. Asteraceae uMhlabelo 2 Useful in embrocation for fractures, sprains and snakebites 
[13]. 
Ranunculus multifidus Forssk, Ranunculaceae Uxhaphozi (Z) 1 It used for sexually transmitted infections [44] 
 
 
Rhoicissus sp. Wild & 
R.B.Drumm), 
 
 
 
 
 
 
Vitaceae 
 
 
iSinwazi (Z) 
 
 
4 
 
 
Medicinal plants used to treat burns, swelling and malaria, 
one can expect that they might possess anti-microbial and 
anti-inflammatory activities as well [13]. 
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Botanical name  Family 
 
isiZulu (Z)/isiXhosa 
(X), Tshivenda (V) 
vernacular name (s) 
given by 
interviewees 
Number 
of times 
quoted 
by 
THPs 
Previous report of ethnomedical uses (reference) 
Sclerocarya birrea (A.Rich.) 
Hochst. 
Anacardiaceae umGanu (Z) 1 It is used in treating proctitis. The Vhavenda use it to treat 
fevers, stomach ailments and ulcers and for many purposes 
including sore eyes in Zimbabwe. In East Africa, it is an 
ingredient in an alcoholic medicine taken to treat an 
internal ailment known as kati, it is used for stomach 
disorders. The Hausas in West Africa use it as a remedy for 
dysentery. It could show that extracts inhibit diarrhoea in 
mice [42]. 
Senecio serratuloides var. gracilis 
Harv., 
 
Asteraceae uNsukumbili (Z) 7 A traditional herbal remedy used to treat skin wounds in 
South Africa [45]. 
Solanum aculeastrum Dunal 
subsp. aculeastrum 
Solanaceae Imbuna/iNtuma and 
water 
 
1 The plant used in traditional medicine to treat various 
human and animal diseases, specifically stomach disorders 
and various cancers, in the Eastern Cape, South Africa [46]. 
Tylophora flanaganii Schltr. Apocynaceae iNhlanhlemhlophe 
(iNhlanhla) (Z) 
4 It is taken in Asia and Africa for allergies, asthma, cancer, 
congestion, constipation, cough, inflamed skin, diarrhoea, 
bloody diarrhoea, gas, haemorrhoids, tender joints (gout), 
yellowed skin (jaundice), joint disorder (rheumatoid 
arthritis), whooping cough, to make someone vomit, and to 
cause sweating [47]. 
*THPs reported that the treatment period might vary from one to three weeks depending on the patient condition 
*Botanical names of the following local plants were not found. They are as follows:  Igwalagwala, Impizo, Ukuse kukleneke, Isinya, Imbizani, Iqabunga, 
Impande/Oyimpande, Oyilitshe, Cigunzi, Umopho and Indonye.  
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Theme 5. Availability of TM treatment in FUS management 
To treat their patients, traditional healers have to find the components, including the plants. The 
availability of plants varies widely, with some being found in the traditional medicine market where 
they have to buy them, or they need to go into natural areas to find them.  There is substantial variability 
in the availability of plants treating schistosomiasis, depending on the season that they collect them or 
their availability in the market. A respondent said:  
“It is very easy to get these plants. I get them from the forest and I buy some of them from 
Durban Berea Market…” THP21. 
Some participants declared that the ease of finding the plants could be related to the frequency of their 
use and therefore availability. If they use them regularly, they know where to find them, either in the 
market or in nature.   THPs sometimes share their ideas and knowledge among themselves, this 
collaboration enabling them to get what they do not have from another healer, in this way contributing 
to the well-being of the community:  
“… Yes, we find them easily, depending on experience on using them or got them from 
other THPs or go at the market… ” THP15. 
Some participant said that the treatments could be difficult to find for those who are new to the working 
area. Some need to go back to where they come from to look for plants to treat schistosomiasis as said 
the following participant: 
“… Some plants are easy to find while others are very hard to find. I find some plants on 
the other side of the road and to get others I have to travel to far place …” THP19. 
 Some plants are seasonal and must be collected at a specific time of year, which may not be easy to if 
it requires going in the bush to collect them, some of which are in limited supply:  
“It’s not easy to get these cures because we have to go and look for them in the forest, 
especially in winter; it is very hard to find them…” THP18. 
Theme 6. Concurrent use of TM with prescribed conventional anti-schistosomal medicines 
Two-thirds of the respondents (n=15, 68.2%) reported that their patients did not use TM concurrently 
with conventional anti-schistosomal medicines. This may suggest that their patients do not always 
disclose the concurrent use of the two types of medicines. One of the respondents indicated this:   
“Patients go to modern doctors most of the time on their own initiative, not mine; they go 
to medical doctors without telling you…” THP8. 
Some THPs indicated that their patients consulted mainstream practitioners if they were not satisfied 
with the treatment from THPs, as indicated by a respondent: 
 “… No, concurrent use of traditional and modern medicine unless if TM does not work, 
the patient himself goes there…” THP16. 
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THPs in this study had referred patients to modern healthcare facilities for FUS treatment when the 
infection was beyond their professional capacities and skills. One of the respondents stated: 
“… I am aware that my patients use sometimes both modern and traditional medicine for 
managing FUS. As traditional healers, it is important for us to work with modern doctors 
because we are not after money, but we want to see our patients better. There is a stage of 
the FUS infection that we cannot treat and there are diseases that modern doctors cannot 
treat, so I send my patients there if they need to use both medicines… ” THP21. 
The THPs mentioned that they have sent patients to healthcare facilities for a medical examination if 
they were not experienced in schistosomiasis management. A respondent said: 
“… I usually send them to hospitals for checking up if the cure that I used worked or not. 
Sometimes I send them to the hospital when I don't know how to treat certain diseases…” 
THP18. 
Another group of THPs reported that they did not get help from biomedically trained healthcare 
professionals and did not initiate any collaboration with them. They advanced reasons such as the 
absence of motivation in communication and collaboration with these professionals and vice versa due 
to cultural basis and people’s beliefs.  
“… No, I do not mix or allow both uses, but they can rather start with one, if it does not 
work, the patient takes another one. I can do for lab test but not the treatment because I 
trust it… Patients use both, but I don't easily send them to hospitals due to cultural base…” 
THP12.  
In addition to the above statement, another respondent reported:  
“… Medical doctors ease the pain but do not permanently remove the problem of FUS…”  
THP10. 
THPs showed confidence in their treatment and indicated that they were of the opinion that western 
medicine does not heal the infection, while their treatment has shown its success in managing FUS.  A 
respondent reported that:  
“… They do use modern medicine, although doctors do not really get rid of this infection 
in women. Only traditional medicine can help get rid of schistosomiasis …” THP20. 
They do believe that concurrent use of Western medicine (WM) and TM is not wise to avoid 
uncontrollable side effects.  
Theme 7. Knowledge of side effects and perceptions of the efficacy of treatment provided by THPs 
The THPs were asked if they knew anything about side-effects experienced by women seeking 
treatment from them for FUS. They indicated that the treatment for FUS was helpful even though side 
effects could occur sometimes, depending on different factors and dosages.  Half of the respondents 
(11/22; 50.0%) argued that there were side effects when using TM, while the other half (11/22; 50.0%) 
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indicated the absence of significant side effects, which they contended were due to the non-respect of 
the prescribed dose. Some patients need to have quick results to stop ongoing bleeding. Patients said 
that it relieved the pain and took more medication than was indicated, or they used it concurrently with 
conventional prescribed medicines. A respondent said: 
“… Yes, there can be some side effects sometimes. It depends on the patient’s health. Some 
of my treatments can be dangerous if a patient is suffering severely from schistosomiasis, 
big quantities cause that, but we lower the dosage to avoid those effects…” THP15.  
The respondents reported that side effects could result from patients having diseases other than FUS 
that was also being treated by THPs. In the provision of care for FUS, they also treated other diseases 
to make sure that patients recovered fully, with a respondent reporting: 
“.. It happens that when a person has schistosomiasis, he is also having other diseases, but 
if they manifest after a person has been treated and then I must deal with them too. So, my 
medicine does not give side effects…” THP20. 
Regarding the referral system, a respondent argued that in case of complications, he referred patients to 
healthcare facilities for follow-up when they were difficult to manage with his traditional treatment. He 
further stated that: 
“… There is no side effect so far. But if there are side effects arising, I would treat them 
too. If I fail to do so I would take my patient to clinic…” THP22. 
With regards to side effects, other respondents argued that they have not had side effects appearing after 
giving treatment to women with FUS.  From their experience, some of the side effects appearing in the 
course of the traditional treatment, such as constipation, were beneficial to the wellbeing of the women 
with FUS. One respondent stated that: 
“… There are no side effects after taking the medicine of treating Ischenene. The patient 
does not go to the toilet a lot and the urine changes back to its normal colour…” THP18. 
THPs said that it happened that patients were scared, that led them to try different healing processes 
from different THPs to fasten their wellbeing, which could affect negatively on their treatment. A 
respondent stated: 
: “… Yes, sometimes due to people having different spiritual lives (behaviour of using 
weather TM or WM with TM combined)…”  THP7. 
 
DISCUSSION 
This exploratory study was an investigation on the knowledge, practices and experiences of THPs in 
managing one of the neglected tropical diseases, specifically female urogenital schistosomiasis, in 
women in the ILembe District, KwaZulu-Natal Province, South Africa. Little is known about the 
prevalence of schistosomiasis in this district over the last 20 years, with few studies having been 
conducted since the 1980s [10, 48].  
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Theme 1. Source of Knowledge 
The findings revealed that THPs received a call from their ancestors to join the healing practice, leading 
them to the initiation (Ukuthwasa), which is the training to become a THP.  This has been documented 
in another study, which reported training to be a lengthy process of months to years’ duration [49]. Peek 
[50] reported that in African traditional healing, this training depended on the trainee’s learning skills.  
 
Theme 2. Diagnostic of female urogenital schistosomiasis 
Findings on the diagnostic of FUS showed that the THPs were not limited to cultural practices in this 
process, with symptoms widely known. They are as follows: change in the colour of urine to red, locally 
called urinate blood (ucama igazi), or the presence of blood in the urine (hematuria), change of urine 
temperature, painful bladder and itching when urinating being reported as the main symptoms by THPs. 
Some relied on spiritual practices to confirm the diagnostic of the disease which occurred by throwing 
bones for spiritual divination (ukumhlola ngoko moya). The findings are consistent with other studies 
carried out with THPs in Mali, which reported that hematuria was the main symptom in urogenital 
schistosomiasis [51, 52]. However, Cock et al. [12] reported that the FUS signs and symptoms can be 
unspecific and might be confused with other inflammatory diseases of the urinal tract.  
 
Theme 3.  Acceptability and affordability of treatment 
The study showed that the THPs felt that traditional medicine was affordable and effective for whoever 
needed it, depending on the patients’ possibility and level of FUS infection.  The THPs reported that 
they did not have a standard price for treatment and patients did not pay anything until after they had 
received their formulation. The finding on the cost of TM was supported by another study arguing that 
there was a need for regulation regarding appropriate costing of TM [53]. The price varied from one 
healer to another, depending on the availability of the treatment and how it was collected or obtained 
by the THP. Treatment cost depended on where (distance, place) the medicinal products were collected 
and the ease of finding them. In their study, Mander et al. [54] found that the pricing of traditional 
product depended on the fact that several species were extinct in the wild due to their over-collection, 
which resulted in their being inaccessible to the TM industry. The THPs emphasized that they looked 
after their clients until the healing process had finished, and were open to easing the treatment process 
(confidence). In contrast, a study conducted in South Africa by Nxumalo et al. [55] showed that three-
quarters of the poorest quintile spent more than 10% of their income on traditional medicine due to the 
lack of any regulations regarding the availability and costs medicinal plants. A policy protecting the 
community from excessive out-of-payments needs to be implemented from the parallel healthcare 
systems perspective.  
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Theme 4. Locally treatment used to manage FUS 
Our findings reported medicinal plants were the main source of treatment for FUS in rural areas of the 
ILembe District and were used alone or in combination. The THPs felt that they had adequate 
knowledge about FUS symptoms as has been reported in other studies on managing schistosomiasis 
across Africa [12, 13, 51, 52, 56-59]. The twenty-two plant species cited in this study belonged to 
fourteen families, with the Asteraceae and Hyacinthaceae being often cited. These findings are in line 
with a study conducted by Sparg et al. and Yineger et al. [60, 61]on the anti-schistosomal activity of 
Hyacinthaceae and Asteraceae species.  
In this study, more than two plant species were commonly combined in herbal treatment preparations, 
as such combined treatments worked better when taken according to THPs requirements. These findings 
are aligned with a study conducted in Pakistan by Adnan et al. [62], which showed that the combination 
of herbal medicine can enhance their effect.  Where plants were given in combination, Senecio 
serratuloides (Asteraceae) and Hypoxis hemerocallidea (Hypoxidaceae) were the two most frequently 
used species, as was reported by Naidoo et al. [63], their use for urinary tract infections being due to 
their antimicrobial properties.  
THPs outlined that the length of the management of FUS varied from one to three weeks, depending on 
whether or not the patients had taken the treatment as prescribed and not mixed it with other 
formulations without letting them know what they were taking. The successfulness of the treatment also 
depended on the THPs experience in managing FUS, these findings being consistent with a study by 
Zuma et al. [11], which reported that THPs as knowledge holders played a key role in diseases 
management in rural South Africa. Details regarding the specifics of the treatment were not revealed 
by the THPs, the secrecy issue being a consequence of their fear that orthodox scientists or people not 
related to them would take their ideas, modifying and use them for commercial gain [49], hence the 
need to protect their knowledge [64]. Plants species reported in this study were documented previously 
in other studies [13, 32, 34, 35, 38-40, 45, 47] for being used in folk medicine to treat ailments.  
 
Theme 5. Availability of TM treatment  
It was reported that TM plants were widely used in FUS management, their treatment were obtained in 
“muti” market or collected in nature, depending on the THP experience and the plant's availability. A 
study conducted by Chinsamy et al. [65] found that medicinal plants used to manage diseases, including 
schistosomiasis, were traded on markets in different areas of South Africa. Some of them were bought 
from neighbouring countries, such as Mozambique and Swaziland [54]. A study conducted by Cock et 
al. [12] gave an overview of various medicinal plants that were available and used for managing 
schistosomiasis in the southern African region.  
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Theme 6. Concurrent use of TM with conventional orthodox medicine 
This study found that the THPs were certain about the efficacy of TM used in FUS management in rural 
South Africa. However, some did acknowledge that inputs from HCPs might be useful to treat severe 
cases that they were unable to cure. Thus, a collaboration between THPs and HCPs should be a reality 
for saving people lives. In their study, Zuma et al., [11] showed that traditional medicine was known as 
the common treatment of people in rural areas of South Africa. The authors suggested further that it 
was important to identify the role played by THPs and HCPs in diseases management to improve the 
quality information on the disease and its management. This is in relation to the findings of a study by 
Stanifer et al. [66], which reported the importance of sharing information to improve patients’ quality 
of healthcare, avoid reports of medical non-compliance and adverse medical outcomes, and prevent 
poorer individual disease understanding. Reportedly, patients were treated first with TM and could only 
be sent in healthcare facilities when complications occurred, or where they could collect medication to 
complete the TM treatment. Studies conducted by Peltzer [67] and Nlooto and Naidoo [68] showed that 
the use of TM was prevalent even though the medication was free in the South African public health 
care system. The concurrent use of conventional orthodox and traditional medicine could have an 
impact on treatment adherence, drug interaction and disease management outcomes, with the integration 
of TM and WM systems possibly improving the outcomes of managing neglected diseases.  
 
Theme 7. Side effects and assessment of the efficacy of medicines by THPs  
This study finding reported that some side effects were perceived to be a good result of the treatment 
given to patients. These findings were similar to a study conducted in Limpopo Province in South Africa 
by Semenya and Potgieter [69], which showed that side effects could be results of the TM effectiveness. 
However, comorbidities could lead to the appearance of other symptoms that were also being managed 
by THPs. In their study, Van Wyk et al. [43] reported that experienced THPs had remedies to manage 
the side effects of TM. This study found that feedback from a patient not urinating blood but 
experiencing constipation were some signs of healing, while some patients were sent to modern 
facilities to establish if the disease had been cured. This correlates with Semenya and Potgieter [69], 
who reported that the validity of efficacy relied on reported positive feedback from the patient.  
In line with our findings, THPs self-assessment of their TM efficacy was not taken seriously as a 
potential health issue within low- and middle-income countries, but could be very beneficial to local 
communities that relied on traditional treatment to manage infectious diseases [12]. It was reported that 
side effects also depended on the dosage being respected as prescribed, or by consulting various people 
instead of taking one treatment. Very little is known about the side effects of the use of medicinal plants 
for managing FUS, with Kamsu-Foguem and Foguem [70] reporting that adverse drugs reactions of 
TM were a consequence of an inappropriate preparation or use. In their study, Aremu et al. [56] 
suggested that there was a need to undertake further evaluation of the plant's toxicity to determine their 
safety. 
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Limitations of the study  
In light of the results findings, this study should be seen within its methodological context of THPs’ 
perceptions, knowledge and practices in managing FUS. In their study, Cock et al. [12] found that THPs 
played a key role in managing various infectious diseases in women. The purposive sampling method 
was used for this study whereby respondents were selected in regard to the fact that they have treated 
or were currently treating patients with schistosomiasis condition. The sampling methods may have 
introduced a risk of bias, with purposive and snowball sampling being used due to the problems of 
identifying THPs who have managed FUS in women through the official organization.  The study was 
also conducted in one District in KZN, with the results possibly not being generalizable to other areas 
in the province or in the country, due to the variations in plant types across the affected areas. The 
occurrence of schistosomiasis is restricted to low lying areas along the eastern seaboard with eastward 
flowing rivers. The small sample size may have limited the variations in responses, but in the absence 
of other studies on the topic in South Africa, forms a base for future research, the qualitative nature of 
the study providing sufficient details on which to build further qualitative and quantitative research.     
 
CONCLUSION 
THPs are playing a key role in managing FUS in rural areas of the ILembe district and can diagnose 
FUS symptoms based on their knowledge and experience. Respondents indicated that while 
conventional treatment was readily available and free in public sector healthcare facilities, many women 
wanted to be treated with traditional remedies. Traditional herbal medicines were reportedly used by 
THPs to manage FUS in women and included Senecio serratuloides (Asteraceae), Hypoxis 
hemerocallidea (Hypoxidaceae), Tylophora flanaganii (Apocynaceae), Rhoicissus digitata (Vitaceae), 
Gunnera perpensa (Gunneraceae) and Eucomis autumnalis (Hyacinthaceae). The Asteraceae and 
Hyacinthaceae were the most cited by THPs as a source of TM treatment. Very little is known by THPs 
about the side effects of using medicinal plants to manage FUS. However, more research is needed, 
specifically as some women may take them concurrently with western medication.  Further studies are 
needed to investigate the views and experiences of clients seen by THPs to establish their opinions 
about the effectiveness of the treatments used for FUS, and to thereby contribute to the larger body of 
research on the role of traditional medicines in the pursuit of keeping communities health.  
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Chapter 4 is a manuscript, which assessed Healthcare workers (HCWs), and patients’ perceptions about the concurrent 
use of African traditional medicine and conventional prescribed medicines for the management of schistosomiasis in 
ILembe district, KwaZulu-Natal. Results presented focused not only on perceptions of participants but medical chart 
records of patients were analyzed for a triangulation of information about the management of schistosomiasis. A 
manuscript entitled “A Triangulation of information from Healthcare workers and patients about the concurrent use of 
traditional medicine and conventional prescribed medicines for schistosomiasis in ILembe district, KwaZulu-Natal, 
South Africa” was written following the guidelines of the journal “BMC Complementary and Alternative medicine.”  
This manuscript is actually under review (Manuscript number: BCAM-S-18-02495) 
70 
 
ABSTRACT 
Background 
Praziquantel is the commonly used conventional treatment recommended for schistosomiasis in the 
mainstream healthcare system. Although Praziquantel may be free in healthcare facilities, many 
individuals may resort to the use of traditional medicine. This study aimed to assess perceptions of 
participants on the availability of Praziquantel and to ascertain whether individuals infected with 
schistosomiasis used concurrently African traditional medicines with this treatment. 
Methods 
A cross-sectional descriptive study, using face-to-face interviews, was conducted from January to April 
2018 among healthcare workers (HCWs) and patients. A review of medical chart records of patients 
was further carried out to triangulate the information from interviews. Descriptive statistics including 
frequency and percentage were used; categorical data were represented as tables. Chi-squared tests were 
performed for the association between continuous variables. A p-value ≤ 0.05 was estimated as 
statistically significant.  
 
Results 
Most of HCWs (114/124; 91.9%) reported that Praziquantel was available in healthcare facilities. 
Majority of HCWs (76/124; 61.3%) did not know whether patients seen by them used concurrently 
traditional medicine and Praziquantel for schistosomiasis. There was no significant relationship 
between the availability of Praziquantel and the concurrent use of TM by patients for schistosomiasis 
(X2 = 3.042, p = 0.551).  
Patients seen by THPs (8/20, 40%) did not use Praziquantel for schistosomiasis. Those patients (8/15, 
53.3%) who crossed from TM to the mainstream healthcare system did not disclose their use of TM to 
HCWs. Their main reason was that concurrent use of TM and Praziquantel could destroy organs or 
make Praziquantel not to work properly. None of the medical chart records analyzed documented the 
concurrent use of TM and Praziquantel.  
Conclusion 
Most of the HCWs were not aware of the concurrent use of TM and Praziquantel by patients for the 
treatment of schistosomiasis. Patients seen by THPs relied solely on TM for schistosomiasis. Although 
patients indicated crossing from TM to the mainstream healthcare system, there was no evidence of 
documented use of TM in medical chart records of patients. Further studies are needed to contribute to 
the knowledge of medicinal plants used by THPs for schistosomiasis. 
 
Keywords: Schistosomiasis, Praziquantel, Conventional Medicine, Traditional Medicine, Healthcare 
workers, Patients 
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BACKGROUND 
Schistosomiasis also is known as bilharzia remain a public health threat. The disease co-morbidities 
including HIV and other STIs are common in poor settings [1-3]. The control of schistosomiasis remains 
a public health issue with a global estimate of 200,000 annual death rate [4]. About 25% of people with 
HIV are reported to be co-infected with helminths including schistosomiasis [5]. Praziquantel treatment 
has shown great progress for urinary schistosomiasis into the therapeutic arsenal [6]. The benefits of 
this drug are its easy administration, low toxic effects and low side effect intensity [7]. These significant 
factors have contributed to the tolerance of individualized and mass treatments and their easy 
application. However, the failure of various proportions of Praziquantel treatment was reported [8-10]. 
Traditional medicine (TM) has been widely used for schistosomiasis in Africa [11]. People living in 
low and middle-income countries (LMICs) tend to use traditional medicine in complementary and 
alternative medicines (CAMs), including schistosomiasis and comorbidities according to their attitudes 
and beliefs [12, 13]. This study aimed to assess perceptions of participants on the availability of 
Praziquantel and to ascertain whether individuals infected with schistosomiasis used concurrently 
African traditional medicines with this treatment. 
An increase in the incidence of non-communicable diseases contributes greatly to the burden of 
schistosomiasis and adds burden to already strained health systems due to the high prevalence of 
infectious diseases [14]. For mass treatment to prevent co-morbidities in schistosomiasis management, 
the World Health Organization (WHO) suggested preventive chemotherapy in primary healthcare 
systems for elimination of the infection [15, 16]. Traditional medicine has played an important role in 
rural areas where many plants are alternatively used to treat infectious diseases including 
schistosomiasis but not well documented [17]. About 70 and 80 per cent of South Africans are estimated 
to use traditional medicine [18]. 
South Africa, like many developing countries, has a pluralistic health care system where a modernized 
healthcare system coexists with a variety of non- conventional medical systems, including traditional 
practices and beliefs [19]. TM has demonstrated its contribution to the management of schistosomiasis, 
the reason for the increased use of TM, including dissatisfaction with the effectiveness of Praziquantel, 
with certain concerns about adverse effects and misconceptions that TM is seen as natural and therefore 
safer, even if used with prescription drugs or, in particular, when used [20]. Therefore, it is assumed 
that the referral system will play a crucial role in health and well-being through cooperation between 
health professionals and traditional health Practitioners [21, 22]. The role of CAM in the provision of 
primary health care is recognized in the health policy documents of some Sub- Saharan African 
countries in the context of limited access to essential health services, especially in poor settings [23]. 
The concurrent use of conventional treatment with medicinal plants is not well documented. The 
documentation through patients personal medical records (PMR) should allow people to track their 
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medical information. Preserving a PMR promotes greater personal involvement in healthcare and 
emphasizes communication between individuals and clinicians [24].  
The perceptions of the concurrent use of Praziquantel with herbal medicine in the management of 
schistosomiasis is not well documented. This study assessed respondents’ views and perceptions in the 
use of Praziquantel and traditional medicine to treat schistosomiasis. The collected data will serve as a 
reference for evaluating the impact of the concurrent use of traditional end modern medicine in the 
management of schistosomiasis. 
METHODS  
Ethical considerations  
The Biomedical Research Ethics of the University of KwaZulu-Natal under reference BE477/17 and 
the KwaZulu-Natal Department of Health under reference number HRKM451/17 approved this study 
and informed consents was sought from all respondents.  
Study design  
This study was a cross-sectional descriptive study, using an exploratory approach. This approach was 
used to bring additional insights in understanding the management of schistosomiasis in rural 
communities of KwaZulu-Natal. Three sources of data were used citing HCPs, Patients seen by THPs 
and patients who might have crossed the conventional and traditional treatment.  
 
 Study sites 
ILembe District Municipality is situated on the east coast of KwaZulu-Natal bordering the Indian 
Ocean, it is surrounded by Umzinyathi to the north,  the Indian Ocean to the east, eThekwini to the 
south (Durban), Umgungundlovu to the west and Uthungulu to the north-east. ILembe consists of four 
local municipalities located between Durban and Richards Bay: Mandeni, KwaDukuza, Maphumulo 
and Ndwedwe. The town straddles the Tugela River [25]. This study was conducted in areas 
surrounding Kwadukuza and Mamphumulo municipalities where healthcare facilities visited citing 
Primary Healthcare Centre (PHC): Amandlalathi, Mpise, Otimati, Oqaqeni, Mpumelelo and 
Shakaskraal Clinics, one Community Healthcare centre (CHC): Kwadukuza Clinic,   Level one of 
Healthcare: Umphumulo and Untunjambili Hospitals, Level two of healthcare: Stanger Hospital. A 
previous study in ILembe district reported that schistosomiasis was prevalent over the past years [26]. 
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Figure 4. 1.  A geographic map of the in ILembe district 
Study population, inclusion and exclusion criteria 
Study population 
This study recruited healthcare workers including medical doctors, pharmacists, nurses and pharmacist 
assistants from 10 healthcare facilities. Traditional health practitioners interviewed in a previous study, 
as well as patients recruited from the five different facilities during the data collection period from 
January to April 2018, referred patients included in this study to the researchers.  
 
Inclusion criteria 
 Respondents who have had the infection between 2016 and early 2018 were included to generate key 
findings [27, 28]. Ten patients who had the disease outside the study period (2016 to early 2018) were 
included to gather their perceptions about the concurrent use of traditional medicine and conventional 
prescribed antischistosomal medicines. Male and female respondents aged 18 years old and above with 
schistosomiasis history were included.  
 
Exclusion criteria 
Healthcare workers managing schistosomiasis and patients who had the disease but not available at the 
time of data collection were excluded from this study. Patients with doubtful information about 
schistosomiasis were excluded as well from this study. 
 
 
Study area: Maphumulo 
and KwaDukuza 
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Sampling technique and study size calculation 
A purposeful sampling method was used to gather data from respondents who have treated, either 
managed or suffered from schistosomiasis during the study period. 
This study aimed to detect at least 10% difference in the concurrent use of traditional medicine and 
conventional antischistosomal treatment, thus the sample size calculation was based on an expected 
prevalence of 10% considered as a response distribution, a margin of error of 5% and 95% confidence 
intervals [29]. The population in the study area was estimated at 657 612 
(https://municipalities.co.za/demographic/117/ilembe-district-municipality). Thus, the minimum 
recommended sample size was 139 respondents. The sample size of respondents was determined using 
the formula as described by Lwanga (1991) and Daniel (1999) [29]:  
𝑁 =
𝑍2P(1 − P)
2𝑑2
 
Where Z statistic as 1.96 for the confidence level of 95%, P is 0.8 as the expected proportion of the 
characteristics were measured in the study area [30]; d is the precision of 0.05 for 95% confidence 
interval. Since it was a prospective study, attritions were expected for various reasons, unsigned consent 
and assented forms, the absence of respondents, failure to provide information or not being available 
during subsequent survey; an increase of 10-20% was added to the minimum sample size of 139 
yielding 159 respondents included in the final analysis. 
Procedure for recruitment and selection of respondents 
Three categories of respondents were recruited in this study. THPs from the previous study directed the 
researchers to their patients in their different locations in the study area. The researchers approached 
them during the day, for those not available interviews were done via phone calls. An isiZulu speaking 
person assisted with translation for those respondents who could not express themselves in English. 
Healthcare workers who have treated schistosomiasis were recruited in the 10 facilities and were 
interviewed at their workplace during business hours. HCWs directed the researchers to patients who 
had a history of schistosomiasis in the outpatient department. Researchers went to check the patients’ 
medical records as per healthcare workers’ directions. 
Data collection methods and tools 
Information was gathered using an open-ended and closed questionnaire using purposeful sampling 
[31].  Questions were on the impact and treatment seeking behaviour in schistosomiasis management.  
THPs and those who have visited the mainstream healthcare system divided this study into two phases 
whereby phase one consisted of interviews with respondents including healthcare workers and patients 
seen. The study enrolled 20 patients referred to researchers by THPs in the previous study, 124 HCWs 
in healthcare facilities selected in the study as well as 15 patients who have been using the conventional 
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treatment for the management of schistosomiasis. Among those 15 respondents, two of them have used 
concurrently conventional and traditional treatment for schistosomiasis following reports of HCWs.  In 
phase two, medical records of patients with schistosomiasis were purposively assessed and analyzed 
for the potential use of conventional and traditional treatment. Thirty-nine patients medical record were 
retrieved. A special note concerns the fact that the disease being part of neglected ones, patients files 
could not be traced due to the use of registry system where they just reported cases and notification of 
medical conditions (NMC) forms for patients seen in phase one. Two patients out of 39 were specifically 
identified by HCWs in phase one of the study following concurrent use of traditional and conventional 
treatment for schistosomiasis management. However, no mention of the use of traditional medicine was 
found in their medical records. 
 
Data analysis  
All data were first entered twice in an Excel spreadsheet, cross-checked and then transferred to data 
were entered into and analyzed by the statistical package for social sciences (IBM SPSS Statistics) 
statistical software version 25.0 package for Windows. Descriptive statistics were used including 
frequency, percentage, and categorical data represented as tables. Analysis of associations between 
continuous variable used Chi-squared tests. A p-value ≤ 0.05 was estimated as statistically significant. 
Each of the selected respondents gave their point of views in the management of schistosomiasis. This 
approach was used to generate an in-depth understanding of the issue [28]. Data were reviewed, 
individual components were analyzed and compared to other cases as a requirement of collective case 
studies [32]. 
 
RESULTS  
Demographic assessments of respondents 
 Socio-demographic characteristics of respondents showed that the majority were recruited in Stanger 
Hospital (46/159 (28.9%)  [22 – 36.6]). Most of them were females (120/159 (75.5%)  [68 – 81.9]), and 
where not married (98/159 (61.6%)  [53.6 – 69.2]), 56/159 (35.2%)  [27.8 – 43.2] had a degree as the 
highest study level. On respondents’ profession 93/159 (58.5%)  [50.4 – 66.2] were nurses. The majority 
(104 (65.4%) [57.5 -72.8]) were christians.  See Table 3.1 below for details. 
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Table 3. 1. Background characteristics of respondents (n=159) 
 
Category (variables) 
HCPs, n=124 Patients seen 
only by THPs, 
n=20 
Patients seen 
by both THPs 
and HCPs, 
n=15 
Frequency, Total, N= 159 N (%) [CI 95%] 
Facility  Amandlalathi / 
Mpise/Otimati/Oqaqeni/ 
Mpumelelo Clinics 
17 Nil 4 21 (13.2% )  [8.4 – 19.5] 
Kwadukuza Community 
Health Clinic 
5 Nil 5 10 (6.3% )  [3.1 – 11.3] 
Mobile Clinics 1&2/ 
KwaDukuza Health Dpt 
15 Nil 5 20 (12.6%)  [7.9 – 18.8] 
Stanger Hospital 46 Nil Nil 46 (28.9%)  [22 – 36.6] 
Umphumulo and 
Untunjambili Hospitals 
41 Nil 1 42 (26.4%)  [19.7 - 34] 
Sex Female 93 15 12 120 (75.5%)  [68 – 81.9] 
Male 31 5 3 39 (24.5%)  [18.1 - 32] 
Marital 
status 
Married 52 5 4 61 (38.4%)  [30.8 – 46.4] 
Not married 72 15 11 98 (61.6%)  [ 53.6 – 69.2] 
 
Study level 
/Degree 
Primary Nil 1 1 2 (1.3%)  [0.2 – 4.5] 
Matric Nil 3 4 7 (4.4%)  [ 1.8 – 8.9] 
Certificate/Diploma 27 6 Nil 33 (20.8%)  [ 14.7 – 27.9] 
Degree 55 1 Nil 56 (35.2%)  [27.8 – 43.2] 
None Nil 9 10 19 ( 11.9%)  [7.4 - 18] 
 
Occupation
/Profession 
Nurses 93 Nil Nil 93 (58.5%)  [50.4 – 66.2] 
Medical Doctors 16 Nil Nil 16 (10.1%)  [5.9-15.8 ] 
Pharmacists 12 Nil Nil 12 (7.5% )  [4 – 12.8] 
Pharmacist assistants 3 Nil Nil 3 (1.9%) [ 0.4-5.4 ] 
Traditional healer Nil Nil 1 1 ( 0.6% )  [ 0-3.5 ] 
Little business Nil 5 2 7 ( 4.4% )  [1.8 – 8.9 ] 
Cashier Nil 2 Nil 2 (1.3% )  [0.2 – 4.5] 
Counsellor Nil 1 Nil 1 (0.6% )  [ 0-3.5 ] 
Packer Nil 1 Nil 1 (0.6% )  [ 0-3.5 ] 
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Social worker Nil 1 Nil 1 (0.6% )  [ 0-3.5 ] 
Student Nil 3 Nil 3 (1.9%)  [ 0.4-5.4] 
None Nil 7 12 19 (11.9%)  [7.4 - 18] 
Religion Christian 85 15 4 104 (65.4%)  [57.5 -72.8] 
Hinduism 12 Nil 1 13 (8.8% )  [4.4-13.6] 
Traditional religion 10 5 3 18 (11.3%)  [6.8-17.3] 
Others 17 Nil 7 24 (15.1% )  [9.9-21.6 ] 
*This study enrolled 124 HCWs recruited as follows: Level 2 healthcare (46/124, 37.1%), Level 1 healthcare (41/124; 33.1%), community healthcare clinics (CHC) (7/124, 
5.6%) and primary healthcare clinics (PHC) (30/124; 24.2%).  
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Phase 1: Assessment of healthcare professionals and patients’ perception towards the use of TM 
and orthodox medicine for the treatment of Schistosomiasis with co-morbidities  
The phase one enrolled 20 patients referred to researchers by THPs in the previous study, 124 HCWs 
in healthcare facilities selected in the study as well as 15 patients who have been using the mainstream 
healthcare system for the management of schistosomiasis.  
Self-reports of HCWs on the availability of Praziquantel (Biltricide®)   
The comparison of the availability of Praziquantel (Biltricide®) and the level of healthcare facilities 
shows that out of the 124 respondents, the majority (106/124; 85.5%) indicated that Praziquantel 
(Biltricide®) was available in the facilities. Most of the respondents (114/124; 91.9%) reported that 
medicines were purchased directly by the facilities for free distribution to patients. Although, about 
(10/124; 8.1%) of the respondents mentioned that they did not know if medicines were purchased 
directly by the facilities for distribution to patients. More so, out of the 91.9% of the respondents that 
stated that medicines were purchased directly by the facilities for distribution to patients, 49.2% of them 
worked in rural areas and 42.7% of them worked in semi-urban areas.  
A correlation has been found with a p-value set at < 0.05, suggesting that there is a strong relationship 
between the level of healthcare facilities and the availability of Praziquantel (Biltricide®). The level of 
healthcare facilities is a key factor that determines the availability of Praziquantel (Biltricide®) in rural 
area facilities (p = 0.006). Refer to table 3.2 below for details. 
Table 3. 2. Assessment of HCWs perception on Praziquantel (Biltricide®) availability  
Praziquantel (Biltricide®)  Availability by respondents(n) 
Healthcare 
Facilities/ 
Number of 
facilities (10) 
Yes No Don’t Know Total, n= 124, N,(%), [CI 95%] 
PHC (6) 29 Nil 1 30 (24.2%) [17 – 32.7] 
 
CHC (1) 7 Nil Nil 11 (5.6%) [2.3 – 11.3] 
Level 1 (2) 28 4  9 41 (33.1%) [24.9 – 42.1] 
 
Level 2 (1) 42 Nil 4 46 (37.1%) [28.6-46.2] 
 
Total 106                       4                             14 124 (100.0%) 
*PHC (Amandlalathi, Mpise, Otimati, Oqaqeni, Mpumelelo, Shakaskraal Clinics), CHC (Kwadukuza Clinic), 
Level1 of Healthcare (Umphumulo and Untunjambili Hospitals), Level 2 of healthcare (Stanger Hospital) 
When testing the relationship between the Praziquantel (Biltricide®)  availability perception and the 
concurrent use of TM and conventional treatment (CT) perception for the treatment of Schistosomiasis, 
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there was no significant relationship between the concurrent use of TM and CT by patients for the 
treatment of schistosomiasis in the study area (X2 = 3.042, p = 0.551). 
Self-reports by HCWs about patients’ record keeping and visits to healthcare facilities for 
schistosomiasis 
It is indicated that all respondents working in the different level of healthcare facilities kept a record of 
patients suffering from schistosomiasis using patients’ files in most cases (105/124; 84.7%). Most of 
the 124 respondents (111/124; 89.5%) always retrieved and consulted patients’ files to follow up each 
time they visit facilities. See table 3.3 below for details. 
Table 3. 3. Assessment of record keeping and visits to healthcare facilities for schistosomiasis 
Types of Record Keeping 
Facilities Filing  System Registry 
System 
Notification 
form 
(NMC) 
Others Total N, (%),[CI 95%] 
PHC 18 Nil 12 Nil 30 (24.2%) [17– 32.7] 
CHC 7 Nil Nil Nil 7 (5.6%) [2.3 – 11.3] 
Level 1 36 Nil Nil 5 41 (33.1%) [24.9 – 42.1] 
Level 2 44 2 Nil Nil 46 (37.1%) [28.6 – 46.2] 
Total  105 2 12 5 124 (100.0%) 
*PHC (Amandlalathi, Mpise, Otimati, Oqaqeni, Mpumelelo, Shakaskraal Clinics and Mobile clinics 1 and 2), 
CHC (Kwadukuza Clinic), Level1 of Healthcare (Umphumulo and Untunjambili Hospitals), Level 2 of healthcare 
(Stanger Hospital) 
Perceptions of HCWs about the concurrent use of traditional medicine and conventional prescribed 
medicines 
Majority of healthcare professionals (76/124; 61.3%) reported that they did not know whether their 
patients used concurrently TM and CT for the treatment of Schistosomiasis. In comparing the 
availability of Praziquantel (Biltricide®) in facilities with its concurrent use with TM, showed that most 
of the respondents (62/124; 50.0%) argued positively on the availability of the Praziquantel 
(Biltricide®) in the facility reported that their patient did not concurrently use TM and CT for the 
treatment of schistosomiasis.  
Knowledge and prevalence of schistosomiasis among patients seen by both THPs and HCWs 
On views and experiences of respondents on the treatment of schistosomiasis, 12 respondents out of 15 
who visited healthcare facilities and met THPs were women. The maximum duration of the disease 
reported was a month as reported the majority of respondents using TM and those using CT. A 
treatment, which consisted of antibiotics (15 days prescription) and Praziquantel (Biltricide®) (single 
dose), was reported by respondents. Patients referred by THPs to the researchers indicated the use of 
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medicinal plants in the management of schistosomiasis. They all reported that they did not use 
conventional treatment for schistosomiasis. Respondents (8/20, 40%) seen by THPs used TM 
occasionally while the ones who crossed the two systems used TM only once.  
On the other side, patients seen by HCPs reported that schistosomiasis was frequent in women (10/15, 
66.7%), they reported as well that the disease duration was a month (11/15, 73.3%). It is reported that 
8/15, 53.3% have crossed CT and TM but they used the mainstream healthcare facility to be examined 
as asked by the THPs to find out if the disease was treated well. The majority of respondents reported 
having been on Biltricide®, single dose and Antibiotics (12/15, 80%). Results showed that 10/15, 66.7% 
agreed to have used TM for schistosomiasis not on a regular basis but only once. Refer to table 3.4 
below for details. 
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Table 3. 4. Knowledge and prevalence of schistosomiasis among patients 
Category (variables) Patients seen by only 
by THPs, n=20 
Patients seen by 
HCPs, n=15 
Total, N= 35 N (%) [CI 95%] 
Type of Schistosomiasis Bilharzia in women Nil 12  12 (34.3%)  [19.1-52.2] 
Bilharzia in man Nil 3  3 (8.6% )  [1.8-23.1] 
 
Disease duration 
Two weeks  Nil 2  2 (5.7% )  [0.7-19.2] 
Almost month  Nil 1  1 (2.9% )  [0.1-14.9] 
A month  14  11  25 (71.4%)  [53.7-85.4] 
Two months  6  1  7 (20%)  [ 8.4-36.9] 
Treatment duration  No modern treatment, I went to the facility to be 
examined as asked me the THP to find out if the disease 
was treated well 
 
 
Nil 
 
 
8  
8 (22.9%)  [10.4-40.1] 
15 days 10  Nil 10 (28.6%)  [14.6-46.3] 
One day 10  1  11 (31.4%)  [16.9-49.3] 
Types of treatment 
received in the past for 
this disease 
Biltricide Nil 3  3 (8.6% )  [1.8-23.1] 
Imbiza Nil 12  12 (34.3%)  [19.1-52.2 ] 
Current treatment  for the 
disease 
Imbiza (Herbal medicine mixture) 18  15  33 (94.3%)  [80.8-99.3] 
Modern medicine (didn't use TM after consulting the 
THP) 
2  Nil 2 (5.7%)  [0.7-19.7] 
Other treatment used than 
conventional medicines for 
schistosomiasis 
Yes Nil 12  12 (34.3%)  [19.1-52.2 ] 
No Nil 3  3 (8.6%)  [1.8-23.1] 
Conventional medicine 
used for schistosomiasis 
Biltricide, single dose Nil 2  2(5.7% )  [0.7-19.7] 
Biltricide, single dose and Antibiotics Nil 12  12(34.3%  )  [19.1-52.2] 
None Nil 1  1(2.9%)  [0.1-14.9] 
Frequency of use of TM/ 
CT for schistosomiasis 
Occasionally 8  5  13(37.1%)  [21.5-55.1] 
Only once 5  10  15 (42.9% )  [26.3-60.6] 
Weekly 7   Nil 7 (20%)  [8.4-36.9] 
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Perceptions about the use of TM either alone or in combination with conventional medicines among 
patients seen by both THPs and HCWs 
 
Respondents reported that they used TM only when they had stopped the use of modern medicine for 
those who have crossed the two healthcare systems (9/15, 60%), they were motivated by their curiosity 
and belief on the choice of the use of traditional medicines (12/15, 80%). They reported having used 
TM because it stopped the bleeding for those who visited healthcare facilities and used TM (12/15, 
80%).  
The majority (12/15, 80%) of respondents reported that TM can be recommended to be used widely 
against schistosomiasis. Patients (8/15, 53.3%) who crossed the two systems mentioned that they did 
not disclose to HCPs that they used TM because they usually tell them to avoid the use of TM because 
it destroys organs or makes the modern treatment not work properly when using conventional treatment 
with traditional herbs. The overall yearly cost for TM used was R1000 or 84.75$ (Rate 1$=11.8R at the 
time of data collection) reported by the majority (8/15, 53.3%) of patients who have used CT and TM. 
Respondents who consulted THPs self-reported a particular perceived benefit obtained from the use of 
TM including a good treatment of the disease and relief of its symptoms (18/20, 90%). Few respondents 
(8/20, 40%) reported experiencing unwanted effects after the use of TM  such as running stomach 
(diarrhoea), vomiting and nausea; however, they were satisfied on the performance of TM used for 
schistosomiasis. The majority of respondents seen by THPS (18/20, 90%) reported that TM can be 
recommended to be used widely against schistosomiasis. See table 3.5 below for details. 
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Table 3. 5. Perceptions on the use of TM either alone or in combination with conventional medicines 
Category (variables) Patients seen only 
by THPs, n=20 
Patients seen by 
HCPs, n=15 
Total, N= 35 N (%) [CI 
95%] 
 
Explanation of the use of conventional 
and  Traditional medicine 
The respondent started using TM only 
and stopped the use of modern 
medicine 
Nil  
9  
9 (25.7%  )  [12.5-43.3] 
Was using conventional medicine 
during the same period as he was using 
TM so that both will work together 
Nil  
6  
6 (17.1%  )  [6.6-33.6 ] 
Motivation/ perceptions of the choice of 
the use of traditional medicines 
Curiosity and belief Nil 12  12 (34.2%  )  [19.1-52.2 ] 
MM disappoint Nil 3  3 (8.6%  )  [1.8-23.1] 
 
 
Particular benefit obtained from the use 
of TM 
Yes, no more bleeding, nor blood and 
itching when urinating 
Nil  
12  
12 (34.3%  )  [19.1-52.2 ] 
None Nil 3  3 (8.6%  )  [1.8-23.1] 
Disease treatment and relieved  
symptoms 
18  Nil 18 (51.4%  )  [34-68.6] 
It didn't work well 2  Nil 2 ( 2.7% )  [0.7-19.7] 
Any unwanted effect from the used of 
any medicines either alone or in 
combination (CT and/or T) for 
Schistosomiasis 
Yes 8  Nil 8 (22.9%  )  [10.4-40.1] 
No 12  15  27 ( 77.1% )  [59.9-89.6] 
Experience on any unwanted effect  
from the TM use (specification) 
Running stomach (diarrhoea), vomiting 
and Nausea 
 
9  Nil 9 (25.7%  )  [12.5-43.3] 
None 11  Nil 11 (31.4%  )  [16.9-49.3] 
Satisfaction on the performance of 
TM/CT used for Schistosomiasis 
Satisfied 18  12  30 (85.7%  )  [69.7-95.2] 
No idea 2  3  5 ( 14.2% )  [4.8-30.3] 
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Category (variables) Patients seen only 
by THPs, n=20 
Patients seen by 
HCPs, n=15 
Total, N= 35 N (%) [CI 
95%] 
     
Use of either TM/both against 
Schistosomiasis or recommend it for 
someone with Schistosomiasis 
Yes 18  12  30 ( 85.7% )  [69.7-95.2] 
Not sure 2  3  5 (14.2%  )  [4.8-30.3] 
 
Choice of TM over CT 
Yes, Just went to Hospital for exam not 
treatment 
Nil 5  5 (14.2%   )  [4.8-30.3] 
Yes, Solution and no coming back of 
the infection 
Nil 7  7 ( 20% )  [8.4-36.9 ] 
No Nil 3  3 ( 8.6% )  [1.8-23.1] 
Mention to the HCPs of TM use for 
Schistosomiasis management 
Yes Nil 3  3 (8.6%  )  [1.8-23.1] 
No Nil 12  12 (34.3% )  [19.1-52.2 ] 
 
 
Patient disclosure to Doctor on TM use 
He said it doesn't work and might not 
be helpful 
Nil 1  1 (2.9%  )  [0.1-14.9] 
He said that traditional medicines can 
have side effects that won't be 
controlled if used together with 
traditional herbs 
 
 
Nil 
 
 
6  
6 (17.1%  )  [6.6-33.6] 
The HCP said that it destroyed organs 
or make the modern treatment not work 
properly 
 
Nil 
 
8  
8 (22.9%  )  [10.4-40.1] 
 
Traditional medicine supply 
From the market of traditional herbs Nil 5  5 (14.2%    )  [4.8-30.3] 
From the relations Nil 2  2 (2.7%  )  [0.7-19.7] 
From the TM practitioner Nil 8  8 (22.9%    )  [10.4-40.1] 
 
Cost of TM  for a year 
Almost R 1000 (84.75$) Nil 8  8 (22.9%    )  [10.4-40.1] 
Almost R 1500(127.11$) Nil 5  5 (14.2%    )  [4.8-30.3] 
Almost R 2000 (169.49$) Nil 2  2 (2.7%  )  [0.7-19.7] 
*Note: 1$=11.8R at the time of data collection
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Phase 2: Assessment of medical chart records of patients with a history of schistosomiasis  
Evidence of documentation of the use of TM for schistosomiasis and comorbidities among patients 
In phase two, medical chart records of patients with schistosomiasis were analyzed. Overall, 39 medical 
chart records were analyzed and none documented the use of TM. Out of 39 files retrieved, two medical 
records were from patients seen in phase one. The information given verbally to researchers on the use 
of traditional treatment was not reported in their medical chart records. These two above patients fell 
among seven cases of patients with a history of schistosomiasis and other comorbidities including HIV 
and other STIs.  Refer to table 3.6 below for details.
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Table 3. 6. Schistosomiasis with other associated conditions  
 
 
Categories  
The frequency of associated disease conditions to schistosomiasis Total N (%)  95% CI  
Frequency of 
schistosomiasis 
                 Sub-categories 
 
schistosomiasis 
alone 
11 None 11  (8.5%  )  [4.3-14.6 ] 
 
 
schistosomiasis 
associated with 
HIV 
5 Diarrhoea (3), Genital ulcers or 
itching(1)  and other (5) 
9 14 (10.8% )  [6-17.4 ] 
7 STI & TB(7) and other (31)   38 45 (34.6%)  [26.5– 43.5] 
3 other non-infectious diseases: 
Hypertension(3) and other (5) 
8 11 (8.5% )  [4.3-14.6] 
5 Hematuria (5), respiratory problem 
(2) and other (5) 
12 17 (13.1%)  [7.8-20.1] 
schistosomiasis 
associated with 
other diseases 
conditions 
2 Hypertension (2), Blood in urine 
(1), Genital ulcers or itching(1)   
and other (9) 
13 15 (11.5%)  [6.6 – 18.3] 
6 Hematuria (6), STI & TB (1)  and 
other (4) 
11 17 (13.1%)  [7.8 – 20.1] 
Total 39                                                          91 130  
*NB: More than one disease was documented per patients beside the 11 with schistosomiasis alone 
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Assessment of prescribed conventional medicines for schistosomiasis and comorbidities 
Table 7 below presents the most commonly prescribed medicines for patients with a history of 
schistosomiasis and comorbidities. The most frequent documented medicine for schistosomiasis was 
Praziquantel (Biltricide®). For infectious comorbidities, antiretroviral medicines (60/219, 27.39%) and 
antibiotics (44/219, 20.1%) were the most commonly prescribed medicines with Praziquantel 
(Biltricide®). See table 3.6 below for details. 
Table 3. 7. Conventional medicines prescribed to patients with a history of schistosomiasis and 
comorbidities 
The main treatment of 
schistosomiasis and 
comorbidities 
Sub-category Frequency 
N (%)  95% CI 
Praziquantel 
(Biltricide®)  alone 
None 11 (5.02%) [2.5-8.8 ] 
Praziquantel 
(Biltricide®)  
associated with ARVs  
Tenofovir (19),  Efavirenz (19), Emtricitabine (19) and 
others (3)    
60 (27.39%) [21.6-33.8 ] 
 Praziquantel 
(Biltricide®)  
associated with ATBs 
(TB/STI/other 
infection) 
Hydrochlorothiazide (7), Ceftriaxone (6), 
Azithromycin (6), Flagyl (Metronidazole) (5), 
Augmentin (3),  Amoxicillin (3),  Isoniazid (2), 
Doxycycline (2),  Flucloxacillin (2),  Fluconazole (2)  
and others (6)   
44 (20.1 %) [15.0-26.0] 
Praziquantel 
(Biltricide®)  
associated with other 
medicines 
Paracetamol /Panado (13), B-Complex /Zincplex 
(12), Buscopan (Hyoscine butylbromide) (12), 
Multivitamin (10), Brufen (Ibuprofen) (8), FeSO4 
(7), Folic Acid (6), Petogen (5), Pyridoxine (3), 
Calcium (3), Diphenhydramine (3), Illiadin nose 
drops (Oxymetazoline) (2), Epillim (Sodium 
valproate) (2) and others (18)  
104 (47.5%) [40.7-54.3 ] 
Total 219 
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DISCUSSION 
A cross-sectional study was conducted in the community, three hospitals, one community health clinic 
and six primary health clinics in the ILembe District in KwaZulu-Natal, South Africa.  
This study found that at least sixty per cent of the HCPs (76/124; 61.3%) reported that they did not 
know whether their patients used concurrently TM and CT for the treatment of schistosomiasis. In the 
light of this study finding, a similar study stated that patients who crossed the two healthcare systems 
did not fully disclose their use of TM to HCWs [33]. In addition, another study in Western Cape, South 
Africa reported that HCWs were stigmatizing the concurrent use of TM and CT in health conditions 
[34]. 
This study found that there was no relationship between the availability of Praziquantel (Biltricide®)  
in healthcare facilities and the concurrent use of TM and CT for the treatment of Schistosomiasis (X2 = 
3.042, p = 0.551). Thus, the availability of Praziquantel (Biltricide®) in the facilities does not imply the 
concurrent use of TM and CT by patients for the treatment of schistosomiasis in the study areas due to 
the belief on the use of TM.  This finding is in agreement with another study which demonstrated that 
Praziquantel was available in endemic areas of South Africa including KwaZulu-Natal [35].  Another 
study argued that patients crossed from the mainstream healthcare system to traditional medicine, 
despite the availability of conventional treatment [36]. The same authors further indicated that HCWs 
in charge had to be increased in endemic areas for follow-ups to avoid the risk of reinfection and which 
might be the reason why patients use to cross the two healthcare systems. These viewpoints above may 
justify the concurrent use of CT and TM in the management of schistosomiasis. Many studies have 
suggested that the treatment of NTDs has to be extended to the entire community considering socio-
cultural beliefs and accessibility [37, 38]. 
This study found that the maximum treatment duration and follow up for schistosomiasis was a month 
as reported the majority of respondents seen by THPs. Not much is known about the treatment duration 
for those crossing the two healthcare systems. This finding met the length of treatment duration of 
schistosomiasis using TM as reported in a study conducted in Mali where the treatment duration was 
reported to be 1 to 30 days for schistosomiasis to be treated depending on the plant used [39]. 
Some respondents seen by THPs in this study used medicinal plants for the management of 
schistosomiasis; they did not use orthodox conventional medicines while some respondents crossed the 
two systems. The use of  TM was previously reported for their anthelmintic activity for the management 
of schistosomiasis in Zimbabwe [40]. This was also supported by another study conducted in Cameroon 
on the antischistosomal activity of African medicinal plants [41]. 
Another finding from this study was a perceived credit to be given to traditional healers for the 
management of schistosomiasis. Traditional medicine representing a parallel healthcare system to 
orthodox medicine, the researchers in this study hold a view that collaboration between HCWs and 
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THPs should be improved. This is in line with another study which indicated that collaboration of THPs 
and HCWs was an important component of controlling the concurrent misuse of TM and conventional 
medicine by patients to avoid uncontrollable side effects [42]. 
A minority of patients seen by THPs in this study (8/20, 40%) reported unwanted effects citing running 
stomach (diarrhoea), vomiting and nausea after the use of TM for schistosomiasis. A study conducted 
in South Africa showed that the use of TM came with unwanted effects due to the way plants were used 
including their preparation and dosage[43]. The same authors also recommended that communication 
between users and prescribers was an important component in the healing process where people relied 
on TM as primary healthcare. 
This study reported that community clients consulting THPs collected their medicinal treatment mostly 
from THPs and the overall yearly cost reported was R1000 (84.75$). This finding is in agreement with 
another study conducted in South Africa showing that  TM was not a cheaper alternative easily 
accessible but expensive compared to local public healthcare facilities where treatment is free of charge 
sometime [44].              
Findings of this study revealed that schistosomiasis was associated mainly with sexually transmitted 
infections, mostly HIV.  It is also suggested in a study that Schistosoma infection might have an active 
role in HIV transmission and disease progression within low and middle-income settings [45]. A study 
showed that the co-infection of schistosomiasis with HIV had immunological consequences [46]. 
Another study conducted in Tanzania reported that co-infections of HIV and Schistosomiasis had an 
effect on the patient immune system [47].  
Strengths and limitations of this study 
This study investigated the traceability on the concurrent use of CT and TM in the management of 
schistosomiasis with comorbidities. It could be of interest for the improvement of the collaboration of 
THPs and HCWs in the management schistosomiasis.  However, a few limitations were due to relatively 
small sample size, the results possibly cannot be generalized to the entire population of patients with a 
history of schistosomiasis and comorbidities in South Africa. Therefore, similar studies are warranted 
in other endemic areas of South Africa to ascertain that patients are concurrently using TM and CT in 
the management of schistosomiasis known as a neglected tropical disease in the general population.  
 
 
CONCLUSION 
In this study, HCWs reported that they were not aware of whether their patients concurrently used TM 
and CT for the treatment of schistosomiasis. Furthermore, patients seen by THPs in this study relied on 
medicinal plants for the management of schistosomiasis; they did not use orthodox conventional 
medicines while a few of them crossed the two systems. This study found that respondents believed that 
credit could be given to traditional healers for the management of schistosomiasis. Future investigations 
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in endemic areas of South Africa should contribute to the knowledge of other medicinal plants used by 
THPs for schistosomiasis. 
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CHAPTER 5: SYNTHESIS CHAPTER - GENERAL DISCUSSION  
5.1. Synthesis & Discussion – the significance of major findings 
This chapter concludes this research followed by recommendations for future research.  
This study investigated the use of traditional medicine and prescribed antischistosomal medicines in 
communities with a high prevalence of schistosomiasis infections. Perspectives from traditional healers 
(22), patients are seen by THPs (20), patients who have visited healthcare facilities with possible use of 
TM (15) and healthcare workers (124) were assessed through interviews in the first phase of the study. 
Medical chart records were reviewed and analyzed in the second phase of the study. 
A systematic scoping review protocol was drawn up to map research areas in line with the treatment of 
schistosomiasis with comorbidities. This review protocol assessed the management of schistosomiasis 
in terms of volume, nature, and characteristics of existing data, with a view of identifying gaps in the 
current literature on this topic. This review protocol was in line with review studies reporting on the 
importance of mapping evidence on the use TM and CT in order to report the extent of knowledge about 
the appropriateness and potential interactions on patients (Agbabiaka et al., 2016, Agbabiaka et al., 
2017).  
5.1.1. Knowledge, perceptions and experiences of traditional health practitioners about managing 
female urogenital schistosomiasis 
a. This study found that THPs played a key role in the management of schistosomiasis in rural 
areas of the district of ILembe where they diagnosed symptoms of schistosomiasis based on 
their knowledge and experience. Another study in South Africa highlighted that THPs played 
a key role in the management schistosomiasis in rural endemic areas (Lothe et al., 2018). 
Although conventional treatment in public healthcare facilities was readily available and free, 
many female respondents, consulted by THPs, did not use treatment in the mainstream 
healthcare system. Studies conducted in schistosomiasis endemic areas have shown that the 
disease was perceived as a shameful disease for children (Koffi et al., 2018, Lothe et al., 2018). 
This perception and other cultural beliefs posed an obstacle to the elimination of the disease 
through the mainstream healthcare systems (Mwanga et al., 2015). This may suggest that health 
education initiatives should be developed to combat such beliefs in local communities.  
b. THPs indicated that TM was used in the study area for the management of schistosomiasis. 
Overall, 22 plant species belonging to 14 families were mentioned in this study to be used 
against schistosomiasis. Various studies have supported the potential activity of medicinal 
plants in schistosomiasis management (Maroyi, 2017, Muema et al., 2015). A study conducted 
in East Africa reported that about 19 medicinal plants were traditionally used in the 
management of schistosomiasis among which 5 were found to be used in Kenya citing: Dissotis 
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rotundifolia (Melistomataceae), Iboza multiflora (Labiatae), Macaranga kilimandscharia 
(Euphorbiaceae), Ozoroa mucronata (Amatanthaceae) and Rhynchosia hirta (Leguminosae) 
(Kokwaro, 1993). However, due to secrecy, THPs did not reveal their traditional recipes in this 
study.  
This study found that more than two plant species were widely combined in herbal treatment 
preparations administered by THPs who believed that combined treatments worked better when 
taken as per requirements. Synergistic strengths in antischistosomal activity were shown when 
medicinal plants extracts were combined in other studies (Ghareeb et al., 2018, Kyere-Davies 
et al., 2018).  On the same note, this study recommends further investigations for biological 
evaluation of some of the remedies [Senecio serratuloides (Asteraceae), Hypoxis 
hemerocallidea (Hypoxidaceae), Tylophora flanaganii (Apocynaceae), Rhoicissus 
digitata (Vitaceae)] used by THPs in the study area. 
 
c. This study found that THPs perceived some side effects after administration of traditional 
recipes as a good result for patients ' treatment. They believed that those symptoms experienced 
by patients such as constipation and stomach-aches were beneficial.  The study showed that 
feedback from a patient who did not urinate blood but experienced constipation were signs of 
healing while for other THPs, patients were sent to modern facilities to determine if the disease 
had been cured. Studies conducted in South Africa indicated that while people were aware of 
the potential consequences using TM alone or with other treatments of health issues, they 
believed they could be manageable (De Wet et al., 2016, Marais et al., 2015).  
5.1.2. A triangulation of information from healthcare workers and patients about the concurrent use 
of traditional medicine and conventional prescribed medicines for schistosomiasis. 
a. This study found that at least 60% of HCWs (76/124; 61.3%) reported not knowing if their 
patients used TM and CT to treat schistosomiasis at the same time. However, the 
availability of Praziquantel (Biltricide ®) in healthcare facilities and the concurrent use of 
TM and CT in the treatment of schistosomiasis are not related (X2 = 3.042, p = 0.551).  
These findings are in line with the finding of another study conducted in rural KwaZulu-
Natal showing that Praziquantel was available in healthcare facilities but was not 
administered properly to patients in fighting schistosomiasis (Kabuyaya et al., 2017). 
Consequently, the availability of Praziquantel (Biltricide ®) in the facilities did not imply 
the simultaneous use of TM and CT by patients in the treatment of schistosomiasis in the 
study areas because of their belief in the use of TM. A study conducted in Ghana showed 
that cultural beliefs play a key role in patients’ health-seeking behaviour in Africa 
explaining the concomitant use of CT and TM (Gyasi et al., 2016). The complex socio-
cultural orientation and belief paradigm depends on health-seeking behaviour. It was 
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suggested that to improve the provision of health services, it is wise to customize and assess 
the role of people's traditional structure and cultural beliefs in local communities (Gyasi et 
al., 2016). 
b. Another finding of this study indicated that THPs were credited by patients seen by them 
for the management of schistosomiasis. Traditional medicine, which represents a parallel 
health care system with orthodox medicine, believes that cooperation between HCWs and 
THPs should be improved. Various studies conducted in Africa have supported the 
collaborative engagement between THPs and HCWs in the management of various 
illnesses (Maimela et al., 2015, Moshabela et al., 2016, Musyimi et al., 2016).  
c.  Another finding of this study showed that patients who crossed the two healthcare systems 
did not disclose such infection to HCWs. A study on culture and clinical care found that 
some patients always felt that some illnesses were not well defined within the biomedical 
paradigm due to the folk beliefs of patients (Pachter, 1994). Good communication between 
THPs and HCWs might have a positive impact on the treatment –seeking behaviour and 
perceptions of sicknesses as well as the clinical care and physician-patient communication 
(Mwanga et al., 2004, Mwanga et al., 2015). The effectiveness of the collaboration between 
traditional practitioners and primary health care professionals in diseases management  
(Campbell-Hall et al., 2010). 
d. Findings from this study revealed that schistosomiasis was associated with sexually 
transmitted infections, mainly HIV and other STIs. In addition to antiretroviral therapy for 
patients consulted, antibiotics were prescribed. Schistosomiasis and HIV/AIDS is one of 
the biggest health problems in South Africa today, with the biggest and most high profile 
HIV epidemic in the world, an estimated 7 million people living with HIV in 2016 
(UNAIDS, 2017). The finding of this study was in line with a study reporting that the 
incidence of urogenital schistosomiasis and STIs infections was positively correlated which 
increased S. Haematobium infection prevalence with associated STIs (Molvik et al., 2017). 
 
5.2. General conclusion 
The present study shows that traditional medicine is a resource contributing to the management of 
schistosomiasis in rural areas of KwaZulu-Natal. Despite the challenge faced by the use of medicinal 
plants in the management of schistosomiasis, its implementation and integration in fighting the disease 
burden can have a positive effect as well as the collaboration of THPs and HCWs. However, healthcare 
workers are not informed whether their patients use concurrently TM and CT for the treatment of 
schistosomiasis. South Africa still has much to achieve in order to successfully control and decrease the 
prevalence of schistosomiasis in endemic areas. A well-structured schistosomiasis control program, 
therefore, has the potential to contribute to a reduction in the prevalence of HIV amongst women. TM 
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can be part of the curriculum for healthcare professionals in the management of schistosomiasis 
infection. Future investigations within the endemic areas of South Africa shall contribute to the 
knowledge of medicinal plants used by THPs for schistosomiasis. 
 
5.3. Recommendations for future research 
Traditional medicine has contributed to the management of schistosomiasis in rural settings of South 
Africa. This investigation was in line with other various studies highlighting the contribution of 
traditional medicine managing schistosomiasis in the primary healthcare system of rural areas. Not 
much is known on the properties of plants used, further studies on investigations are recommended on 
biological evaluation of some of the remedies used by THPs in the study area. On another note, due to 
the credit given by patients to THPs collaboration between THPS and HCWs to explore reasons for use, 
potential benefits or risks of the concurrent use of modern and traditional medicine in schistosomiasis 
management should be launched. Further studies are needed to investigate the effectiveness of African 
traditional medicine in the management of schistosomiasis.   Furthermore, there is a need of conducting 
studies with bigger sample size on the acceptability, affordability, availability and accessibility of the 
concurrent use of modern and traditional medicine at the national level in endemic settings to investigate 
on its impact in the management of schistosomiasis. 
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APPENDIX 3: ACCESS LETTER OF PERMISSION AND SUPPORT TO CONDUCT 
RESEARCH 
To the facility Manager 
……………………… 
ILembe Health District 
Private Bag ………….. 
 
Dear Sir / Madam 
RE: Application for support to conduct a study in your Facility 
I am a registered Master’s student in the Discipline of Pharmaceutical Sciences at the University of 
KwaZulu-Natal. My supervisor is Dr MANIMBULU NLOOTO. The title of my research proposal is 
“A triangulation study of the use of traditional medicine and prescribed antischistosomal medicines in 
communities with high prevalence schistosomiasis infections: perspectives from traditional healers, 
patients and healthcare workers”.  
I am hereby seeking your consent and support to successfully conduct my research project in the facility, 
under your responsibility and management. The survey will be conducted among Health care workers 
and patients in your facility. To assist you in reaching a decision, I have attached to this letter an 
information sheet and my full proposal. 
This study will be fully approved by the Biomedical Research Ethics Committee of the University of 
KwaZulu-Natal. This research study is registered with the postgraduate office of the School of Health 
Sciences, University of KwaZulu-Natal, Westville Campus.  
Should you require any further information, please do not hesitate to contact the Department or me. 
Contact details are as follows: Ms Phindile Nene, Research office (Telephone: 031 260 82 80, E-mail: 
Nenep1@ukzn.ac.za ), Dr Manimbulu Nlooto, Supervisor (Telephone: 031 260 70 30, Email: 
Nlooto@ukzn.ac.za), Mr Aganze Mushebenge, student (060 311 97 54, E-mail: 
aganzedar@Gmail.com). 
Your permission to conduct this study will be greatly appreciated. 
Yours sincerely, 
Mr. Aganze Gloire-Aimé Mushebenge (Student number: 217080760) 
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APPENDIX 5: INFORMED CONSENT FORMS TO PARTICIPATE IN RESEARCH 
UKZN BIOMEDICAL RESEARCH ETHICS COMMITTEE 
APPLICATION FOR ETHICS APPROVAL  
For research with human participants (Biomedical) 
A. INFORMATION SHEET 
Date: 
Greetings, 
My name is GLOIRE-AIME AGANZE MUSHEBENGE (217080760), Master’s student in UKZN, 
aganzedar@gmail.com (060 311 9754), under the supervision of Dr MANIMBULU NLOOTO, 
nlooto@ukzn.ac.za (076 091 1427), University of KwaZulu-Natal, School of Health Sciences, 
Discipline of Pharmaceutical Sciences.  
You are being invited to consider participating in a Master’s research that involves a 
triangulation study of the use of traditional medicine and prescribed antischistosomal medicines in 
communities with a high attempt to schistosomiasis infections: perspectives from traditional healers, 
patients and healthcare workers. The aim and purpose of this research are to evaluate the proportion 
of the use of traditional medicine and prescribed antischistosomal medicines in communities having a 
high proportion of Schistosomiasis infection in ILembe District, KwaZulu-Natal and to establish 
whether the unavailability of prescribed antischistosomal medicines leads to the use of traditional 
medicine. The study is expected to enrol 534 participants in total composed by 50 Traditional Healers 
Practitioners (THPs), 50-384 Patients (theirs), 384 Health care Professionals (HCPs) and 50-384 
Patients in different facilities in KwaZulu-Natal. It will involve the following procedures: research-
administered face-to-face interviews will be carried out in phase 1 of this study while phase 2 will 
consist of a medical chart review as a data collection technique method. Data will be collected five to 
six days a week over the data collection period. The duration of your participation, if you choose to 
participate and remain in the study, is expected to be (Maximum of 30 minutes). The study is funded 
by CHS scholarship. 
 The study may not involve risks and/or discomforts. It will not provide direct benefits to participants 
but feedback to community members can be given on the management of schistosomiasis. Findings of 
the research will be written in a final thesis and peer-reviewed publications related to our specific 
objectives. Anonymity will be maintained and participants will be guaranteed confidentiality. No name, 
no ID of participants will be disclosed to the third party or displayed on questionnaires and data 
collection forms. 
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This study has been ethically reviewed and approved by the UKZN Biomedical Research Ethics 
Committee (approval number:  Brec ref No: 477/17). 
In the event of any problems or concerns/questions you may contact the researcher at 
aganzedar@gmail.com (060 311 9754) or the UKZN Biomedical Research Ethics Committee, contact 
details as follows:  
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
 
B. CONSENT FORM  
I (Name) have been informed about the study entitled (provide details) by (provide the name of 
researcher/fieldworker). 
I understand the purpose and procedures of the study (add these again if appropriate). 
I have been given an opportunity to answer questions about the study and have had answers to my 
satisfaction. 
I declare that my participation in this study is entirely voluntary and that I may withdraw at any time 
without affecting any treatment or care that I would usually be entitled to. 
I have been informed about any available compensation or medical treatment if an injury occurs to me 
as a result of study-related procedures. 
 If I have any further questions/concerns or queries related to the study I understand that I may contact 
the researcher at (provide details). 
If I have any questions or concerns about my rights as a study participant, or if I am concerned about 
an aspect of the study or the researchers then I may contact: 
 BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban 4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za 
 ____________________      ____________________ 
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Signature of Participant                            Date 
___________________  _____________________ 
Signature of Witness                                Date 
(Where applicable)      
____________________   _____________________ 
Signature of Translator                            Date 
(Where applicable) 
 
 
APPENDIX 6:  QUESTIONNAIRE  
 
This questionnaire is designed to find out the treatment of schistosomiasis in employing alternative and 
complementary remedies in the treatment of it. The answers you give to the questions here will in no 
way influence how you are treated as an individual. The findings of this research will help us to 
understand the treatment of Schistosomiasis better and therefore help us to improve the care that we 
render to them. We implore you to give us as honest an answer to each question as possible. You may 
choose not to respond to any of the questions you are not comfortable with. We guarantee your 
confidentiality. 
Lemibuzo yakhelwe ukuthola ikhambi le-schistomiasis ekusebenziseni nasekuqhakambiseni 
ukwelashwa kwaso lesisifo. Izimpendulo zakho kulemibuzo angeke zibe nomthelela ekulashweni 
kwakho. Okutholakele kulolucwaningo kuzosisiza siqonde ukwelashwa okungcono kwe-
Schistosomiasis futhi kuzosisiza ekuthuthukiseni ukunakekela. Siyanxusa ukuba uphendule umbuzo 
ngamunye ngokwethembeka. Uvumelekile ukuba ungayiphenduli eminye imibuzo ongakhululekile 
ngayo. Siyakuqinisekisa ngemfihlo yakho. 
 
PHASE 1.A: INTERVIEWS WITH THPs 
A. DEMOGRAPHIC DATA  
1. Age: --------------                         2. Sex: Male--------                Female---------  
3. Marital status:  
(A) Married     (B) Not married        (C) Widow       (D) Divorced/Separated  
4. The highest level of education attained:  
    (A) None                     (B) Primary                       (C) Post-primary/Secondary  
(D) University/Polytechnic/College of education  
5. Profession/Occupation: ----------------------------------------------------------  
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7. Religion: (A) Traditional religion (B) Catholic (C) Pentecostal  
(D) Anglican      (E) Moslem                (F) others (specify) – 
B. RESPONDENT'S PERCEPTION TOWARDS SCHISTOSOMIASIS TREATMENT 
Source of traditional healing knowledge: 
……………………………………………………………………………………………… 
How long have you been healing people?  
……………………………………………………………………………………………… 
How do you diagnose Schistosomiasis?  
……………………………………………………………………………………………… 
Ailments treated and used remedies (used plant parts, methods of preparation and administration) 
……………………………………………………………………………………………… 
Do you use a combination of plants?    [Yes]                        [No]          (Healer) If yes, please mention 
some of them: ……………………………………………………………………………………… 
Are these plants easy to find? [Yes]       [No]           If not, why? 
……………………………………………………………………………………………… 
Side effects and assessment of the efficacy of medicine 
……………………………………………………………………………………………… 
What season do you receive more patients suffering from schistosomiasis? If any, please explain 
why?……………………………………………………………………………………………… 
Are Traditional medicine treatments affordable comparing to modern ones?  
……………………………………………………………………………………………… 
Do your patients use concurrently traditional and modern medicines for the treatment of 
Schistosomiasis? 
------------------------------------------------------------------------------------------------------------ 
 
ISIGABA 1.A: UKUXOXISANA  NAMA- THPs 
A. IDATHA YEMINININGWANE 
1. Iminyaka...         2. Ubulili         •Ungowesilisa...              ungowesifazane... 
3. Isimo sakho somshado  
(A) Ushadile.  (B) Awushadile.   (C) Ungumfelokazi (widow)/ ungumfelwa (Widower).    
(D) Wahlukanisa  
4. Izinga eliphakeme lemfundo owafinyelela kuyo  
    (A) Alikho    (B) Amabanga aphansi      (C)Imfundo yesibili      (D) Imfundo ephakeme  
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5. Umsebenzi wakho:……………………….. 
6. Inkolo: (A.) Inkolo yendabuko.      (B) ungumKatolika.       (C) UngumPentekoste.       
(D) UmSheshi.     (E) Moslemu.   (F) enye (cacisa) 
B. IMIBONO YOPHENDULAYO MAYELANA NGOKWELASHWA KWE-SCHISTOSOMIASIS  
Umthombo wolwazi lapho kuvela khona ulwazi lokwelapha ngokwesintu.  
------------------------------------------------------------------------------------------------------------ 
Usunesikhathi eside kangakanani ulapha abantu? 
------------------------------------------------------------------------------------------------------------ 
Uthola kanjani ukuthi umuntu uphethwe i-Schistosomiasis? 
------------------------------------------------------------------------------------------------------------ 
Ukwelashwa kwezifo nemithi esetshenzisiwe ( izingxenye noma izicubu zezitshalo ezisetshenzisiwe, 
indlela zokulungisa imithi). 
------------------------------------------------------------------------------------------------------------ 
Ingabe usebenzisa ingxube yezitshalo ezihlukene? [yebo] [chabo] Uma uthi yebo, ngicela uzisho 
lezozitshalo: 
------------------------------------------------------------------------------------------------------------ 
Ingabe kulula ukuthola lezozitshalo? [yebo] [chabo] Uma uthi chabo, usho ngani? 
------------------------------------------------------------------------------------------------------------ 
Imiphi imiphumela emibi eqhamukayo uma usebenzisa lamakhambi okulapha no kuhlolwa kwawo?---
-------------------------------------------------------------------------------------------------------- 
Iyiphi inkathi othola kuyo iziguli eziningi eziguliswa i-Schistosomiasis? 
------------------------------------------------------------------------------------------------------------ 
Ingabe imithi yokwelashwa yendabuko ingabizi ngokulinganisa nanamuhla? 
------------------------------------------------------------------------------------------------------------ 
Ingabe iziguli zakho zisebenzisa imithi yendabuko nemanje yokwelashwa kweSchistomiasis? 
------------------------------------------------------------------------------------------------------------ 
 
PHASE 1B: INTERVIEWS WITH PATIENTS SEEN BY THPs 
A. DEMOGRAPHIC DATA  
1. Age: --------------                         2. Sex: Male--------                Female---------  
3. Marital status:  
(A) Married     (B) Not married        (C) Widow       (D) Divorced/Separated  
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4. The highest level of education attained:  
    (A) Non                     (B) Primary                       (C) Post-primary/Secondary  
(D) University/Polytechnic/College of education  
5. Profession/Occupation: ----------------------------------------------------------  
6. Religion: (A) Traditional religion (B) Catholic (C) Pentecostal  
(D) Anglican      (E) Moslem                (F) others (specify) – 
B. RESPONDENT'S PERCEPTION TOWARDS SCHISTOSOMIASIS TREATMENT 
7. How long have you had this disease? ------------------------------------------------  
8. How long have you been on treatment for this disease? ----------------------------------  
9. What type of treatment are you currently receiving for this disease? --------------------------------------
------------------------------------------------------------------------------------------- 
10. How frequently have you been using TM in this Schistosomiasis?  
(A) Daily      (B) weekly      (C) Occasionally    (D) Only once  
11. What benefits were you hoping to get from the TM you used in this? (You can choose more than 
one)  
(A) It will directly treat/cure your disease  
 (B) It will relieve the symptoms of the Schistosomiasis 
 (C) Others (specify)  
12. Have you obtained any particular benefit from the TM you used?  
(A) Yes (specify) --------------------------------------------------------------------------  
(B) No  
13. Did you experience any unwanted effect from the TM you used?  
(A) Yes (specify) -----------------------------------------------------------------------------  
(B) No  
14. How satisfied are you with the performance of the TM you used in this Schistosomiasis?  
(A) Very satisfied (B) Satisfied (C) Disappointed  
15. Would you use TM against Schistosomiasis or recommend it for someone with Schistosomiasis?  
(A) Yes (B) No  
 
ISIGABA 1.B: UKUXOXISANA NESIGULI ESIBONWA I-THPs 
A. IDATHA YEMINININGWANE 
Iminyaka...         2. Ubulili         •Ungowesilisa...              ungowesifazane... 
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3. Isimo sakho somshado  
(A) Ushadile.  (B) Awushadile.   (C) Ungumfelokazi (widow)/ ungumfelwa (Widower).   (D) 
Wahlukanisa  
4. Izinga eliphakeme lemfundo owafinyelela kuyo  
 (A) Alikho    (B) Amabanga aphansi      (C)Imfundo yesibili      (D) Imfundo ephakeme  
5. Umsebenzi wakho: ……………………….. 
6.  Inkolo: (A.) Inkolo yendabuko.      (B) ungumKatolika.       (C) UngumPentekoste.       
(D) UmSheshi.     (E) Moslemu.   (F) enye (cacisa) 
B. IMIBONO YOPHENDULAYO MAYELANA NGOKWELASHWA KWE-SCHISTOSOMIASIS  
Sewunesikhathi esingakanani unalesisifo? ------------------------------------------------ 
Sewunesikhathi eside kangakanani usebenzisa lokhukwelashwa? --------------------------------------------
---- 
Iyiphi indlela yokwelashwa oyitholayo okwamanje? ------------------------------------------------------------
-------------------------------------------------------------------------------------------- 
Ubuwasebenzisa kangakanani amakhambi okwelapha i-Schistosomiasis?    
(A) ngosuku _ (B) ngesonto_ (C) Kanye 
Bewulindele ukuzuzani kulokhu ukwelashwa?  (ungakhetha kube kuningi) 
Kuzokwelapha isifo sakho ngqo 
Kuzodambisa izimpawu ze-Schistosomiasis 
Okunye (awukusho)  
Kukhona oke wakuzuza kulokhu ukwelapha? 
……………………………………………………………………………………………… 
Uke waba nemiphumela emibi oyithole kulokhu kwelashwa? 
……………………………………………………………………………………………… 
 Waneliseke kangakanani ngomsebenzi waloluhlobo lokwelashwa olusetshenzisiwe kwi- 
Schistosomiasis? 
Waneliseke kakhulu     B. Wanelisekile    C. Awanelisekanga / udumele 
15. Ungakusebenzisa yini lokhu ukwelapha okumelene ne- Schistosomiasis noma ukuncome kumuntu 
one- Schistosomiasis?      A) yebo      B) Cha 
 
PHASE 1C: INTERVIEW WITH HEALTH CARE WORKERS 
A. DEMOGRAPHIC DATA  
1. Age: --------------                         2. Sex: Male--------                Female---------  
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3. Marital status:  
(A) Married     (B) Not married        (C) Widow       (D) Divorced/Separated  
4. The highest level of education attained:  
    (A) Non                     (B) Primary                       (C) Post-primary/Secondary  
(D) University/Polytechnic/College of education  
5. Profession/Occupation: ----------------------------------------------------------  
7. Religion: (A) Traditional religion (B) Catholic (C) Pentecostal  
(D) Anglican      (E) Moslem                (F) others (specify) – 
8. Facility name and mailing address of the facility: 
9. Classification of the facility: ■ publicly ■ Private ■ NonGovernmental organization (NGO) 
10. Setting type: ■ Rural-Urban ■ Semi-urban 
B. RESPONDENT'S PERCEPTION TOWARDS SCHISTOSOMIASIS TREATMENT 
Is Praziquantel Available in the facility? 
……………………………………………………………………………………………… 
Are medicines purchased directly by the facility for distribution to patients? If “Yes”, are medicine 
purchases subsidized by the government? 
……………………………………………………………………………………………… 
What is the total number of visits to the health facility for outpatient services last month? 
……………………………………………………………………………………………… 
What is the total number of visits to the health facility for outpatient services yesterday? 
……………………………………………………………………………………………… 
How many of the patient visits made yesterday were for: 
……………………………………………………………………………………………… 
Where do you refer patients in the event of resistance to the treatment? 
……………………………………………………………………………………………… 
Does the facility keep a record of patient visits? 
……………………………………………………………………………………………… 
How are records kept? 
■Patient files                     ■Registry system                        ■Other (specify:  
Are patient files retrieved and consulted each time they visit the facility? 
■Yes, patient files usually/always consulted  
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■Yes, patient files consulted, but only when necessary 
■No, patient files not consulted 
Do your patients use concurrently traditional and modern medicines for the treatment of 
Schistosomiasis? If yes, what do you think about this use? 
……………………………………………………………………………………………… 
 
ISIGABA 1.C: UKUXOXISANA NABASEBENZI BEZEMPILO 
A. IDATHA YEMINININGWANE 
Iminyaka...         2. Ubulili         •Ungowesilisa...              ungowesifazane... 
3. Isimo sakho somshado  
(A) Ushadile.  (B) Awushadile.   (C) Ungumfelokazi (widow)/ ungumfelwa (Widower).   (D) 
Wahlukanisa  
4. Izinga eliphakeme lemfundo owafinyelela kuyo  
 (A) Alikho    (B) Amabanga aphansi      (C)Imfundo yesibili      (D) Imfundo ephakeme  
5. Umsebenzi wakho: ……………………….. 
6.  Inkolo: (A.) Inkolo yendabuko.      (B) ungumKatolika.       (C) UngumPentekoste.       
(D) UmSheshi.     (E) Moslemu.   (F) enye (cacisa) 
Igama lesikhungo nekheli laso. 
.ukwahlukaniswa kwesikhungo •esomphakathi • esizimele  • akusona esikahulumeni  
Indawo ekuso.      • emakhaya    •edolobheni 
B. IMIBONO YABAPHENDULAYO MAYELANA NGOKWELASHWA KWE-
SCHISTOSOMIASIS  
Kungabe i- Praziquantel iyatholakala yini kulesisikhungo? 
……………………………………………………………………………………………… 
Kungabe imithi ithengwa isikhungo ukuze inikwe iziguli? Uma uthi yebo; kungabe uhulumeni 
uyayikhipha yini imali yokuxhasa ukuthengwa kwemithi?  
……………………………………………………………………………………………… 
Ngenyanga edlule belingakanani inani lokufika kweziguli emakhaya kulesisikhungo sezempilo? 
……………………………………………………………………………………………… 
Izolo belingakanani inani lokufika kweziguli emakhaya  lapha kulesisikhungo sezempilo? 
……………………………………………………………………………………………… 
 Bangaki ukuvakashelwa kwesiguli okwenziwe izolo kwaba: 
……………………………………………………………………………………………… 
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Nizidlulisela kuphi iziguli uma kwenzeka zingelapheki? 
……………………………………………………………………………………………… 
Kungabe lesisikhungo siyawagcina amarekhodi okuvakasha kweziguli?  
……………………………………………………………………………………………… 
Amarekhodi agcinwa kanjani?  
Ifayela yeziguli 
Uhlelo lokubhalisa 
Okunye (cacisa)  
Kungabe lamafayela eziguli ayabuyiswa njalo uma zivakasha kulesisikhungo? 
Yebo, amafayela eziguli ahlezi ebhekwa 
Yebo, amafayela eziguli ayabuyiswa sikhona isidingo 
Chabo, amafayela awabuyiswa 
Kungabe iziguli zenu zisebenzisa imithi yendabuko nemithi yesimanje ngesikhathi esisodwa 
ekulashweni kwe-Schistosomiasis? Uma kunjalo, ucabangani ngalokhu ukusetshenziswa? 
……………………………………………………………………………………………… 
 
PHASE 1D: INTERVIEWS WITH PATIENTS SEEN BY BOTH THPs AND HEALTHCARE 
WORKERS 
 A. DEMOGRAPHIC DATA  
1. Age: --------------                         2. Sex: Male--------                Female---------  
3. Marital status:  
(A) Married     (B) Not married        (C) Widow       (D) Divorced/Separated  
4. The highest level of education attained:  
    (A) Non                     (B) Primary                       (C) Post-primary/Secondary  
(D) University/Polytechnic/College of education  
5. Profession/Occupation: ----------------------------------------------------------  
6. Religion: (A) Traditional religion (B) Catholic (C) Pentecostal  
(D) Anglican      (E) Moslem                (F) others (specify) – 
B. RESPONDENT'S PERCEPTION TOWARDS SCHISTOSOMIASIS TREATMENT 
7. Type of Schistosomiasis? ------------------------------------------------- (Please confirm from case note)  
8. How long have you had this disease? ------------------------------------------------  
9. How long have you been on treatment for this disease? ----------------------------------  
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10. What types of treatment have you received in the past for this disease?  
(A) Praziquantel     (B) Others (specify) 
11. What type of treatment are you currently receiving for this disease? -------------------------------------
-------------------------------------------------------------------------------------------- 
12. Have you used anything other than that given to you by a medical doctor /Pharmacist or nurses to 
treat schistosomiasis?  
(A)Yes                      (B) No 
13. If you have used any Conventional Medicine (CM) in this Schistosomiasis, for how long have you 
used it? --------------  
14. How frequently have you been using Conventional Medicine in this Schistosomiasis?  
(A) Daily      (B) weekly      (C) Occasionally    (D) Only once  
15. Which of the following sentences explains how you have been using Conventional and M and 
Traditional medicine (TM)?  
(A). You started TM only when you stopped CM  
(B) You started CM only when you finished TM  
(C) You were using CM during the same period as you were using TM so that both will work to help 
each other  
16. What are your reasons for deciding to use TM (you can choose more than one)  
(A). You were disappointed that conventional treatment is not working  
(B). Conventional treatment is too toxic or too mutilating  
(C). You think TM is more in keeping with your beliefs and your inner self  
(D). you want to take control of your treatment and your faith in your own hands  
(E). Conventional treatment is too mechanistic/technological and lacks the human touch  
(F) You are just trying everything that can help  
(G) Others (specify please)  
17. Have you obtained any particular benefit from the TM you used?  
(A) Yes (specify) --------------------------------------------------------------------------  
(B) No  
18. Did you experience any unwanted effect from the CM and TM you used in this Schistosomiasis?  
(A) Yes (specify) -----------------------------------------------------------------------------  
(B) No  
19. How satisfied are you with the performance of the CM you used in this Schistosomiasis?  
(A) Very satisfied (B) Satisfied (C) Disappointed  
122 
 
20. Would you use both against Schistosomiasis or recommend it for someone with Schistosomiasis?  
(A) Yes (B) No  
21. Have you had to abandon CM since you started using TM?  
(A) Yes (B) NO  
22. Did you mention to the doctor in charge of this your Schistosomiasis management that you have 
used/are using TM? (A) Yes  (B) No  
23. If your doctor is not aware that you have used/are using TM, what is it that makes you feel unwilling 
to discuss it with him/her? -------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------ 
24. How do you get your supply of TM?  
(A) From friends                         (B) From relations  
(C) From TM practitioner  
(D) You buy from the market  
(E) From your church  
(F) Others (specify) -----------------------------------------------------------------  
25. How much do you estimate that you have spent on TM in the last one year? -------------- 
 
ISIGABA 1D. UKUXOXA NEZIGULI EZIBONWA AMA-THPs NABASEBENZI BEZEMPILO. 
A. IDATHA YEMINININGWANE 
Iminyaka...         2. Ubulili         •Ungowesilisa...              ungowesifazane... 
3. Isimo sakho somshado  
(A) Ushadile.  (B) Awushadile.   (C) Ungumfelokazi (widow)/ungumfelwa (Widower).   (D) 
Wahlukanisa  
4. Izinga eliphakeme lemfundo owafinyelela kuyo  
 (A) Alikho    (B) Amabanga aphansi      (C)Imfundo yesibili      (D) Imfundo ephakeme  
5. Umsebenzi wakho: ……………………….. 
6.  Inkolo: (A.) Inkolo yendabuko.      (B) ungumKatolika.       (C) UngumPentekoste.       
(D) UmSheshi.     (E) Moslemu.   (F) enye (cacisa) 
B. IMIBONO YOPHENDULAYO MAYELANA NGOKWELASHWA KWE-SCHISTOSOMIASIS  
7. Uhlobo lweSchistosomiasis? ------------------------------------------------- ( Sicela uqinisekise kusuka 
kwesaziso senkantolo) 
8. Kuze kube nini usulele lesi sifo? ………………………………………………… 
9. Kuze kube nini uye waba ukwelashwa kwalesi sifo?…………………………………… 
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10. Yiziphi izinhlobo zokwelashwa ozitholile esikhathini esidlule ukuze lokhu kukhishwe? 
(A) Praziquantel 
(B) Abanye (chaza) 
11. Yiluphi uhlobo lwezokwelapha okwamanje oluthola lesi sifo? -------------------------------------------
------- -------------------------------------------------- ---------------------------------------------------- 
12. Ingabe usetshenzisile noma yini enye ngaphandle kokunikezwa udokotela wezeMpilo / 
Uchwepheshe wezeMpilo noma abahlengikazi ukuphatha i-schistosomiasis? 
(A) Yebo (B) Cha 
13. Uma ususebenzise noma yimaphi ama-Medicinal Conventional (CM) kule Schistosomiasis, 
usebenzise isikhathi eside kangakanani?  
……………………………………………………………………………………………… 
14. Sekuyisikhathi esingakanani usebenzise iMedicalal Medicine kule Schistosomiasis? 
(A) Nsuku zonke (B) masonto onke (C) Ngezinye izikhathi (D) Kanye kuphela 
15. Yimiphi eminye imisho elandelayo echaza ukuthi usebentise kanjani imithi ejwayelekile kanye 
neyomuthi wendabuko (TM)? 
(A). Uqale i-TM kuphela uma umise i-CM 
(B) Uqale i-CM kuphela uma uqedile i-TM 
(C) Usebenzisa i-CM ngesikhathi esifanayo njengoba usebenzisa i-TM ukuze bobabili basebenze 
ukusizana 
16. Yiziphi izizathu zakho zokunquma ukusebenzisa i-TM (ungakhetha okungaphezu kweyodwa) 
(A). Wadumala ukuthi ukwelashwa okuvamile akusebenzi 
(B). Ukwelashwa okuvamile kuyingozi kakhulu noma kudubula kakhulu 
(C). Ucabanga ukuthi i-TM ihamba ngokuvumelana nezinkolelo zakho kanye nomuntu ongaphakathi 
(D). Ufuna ukulawula ukwelashwa kwakho nokholo lwakho ezandleni zakho 
(E). Ukwelashwa okuvamile kuyindlela enkulu yokusebenza / ezobuchwepheshe futhi ayinakho 
ukuthintwa kwabantu 
(F) Uzama nje konke okungasiza 
(G) Abanye (chaza ngenhla) 
17. Uke wathola yini inzuzo ethile evela TM oyisebenzisayo? 
(A) Yebo (chaza) ------------------------------------------- ------------------------------- 
(B) Cha 
18. Uke wahlangabezana nanoma iyiphi impendulo engadingeki evela ku-CM no-TM oyisebenzisayo 
kule Schistosomiasis? 
(A) Yebo (chaza) ------------------------------------------- ---------------------------------- 
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(B) Cha 
19. Waneliseke kangakanani ngokusebenza kwe-CM oyisebenzisayo kule Schistosomiasis? 
(A) Inelisekile kakhulu (B) Inelisekile (C) Inqatshiwe 
20. Ungayisebenzisa kokubili ngokumelene neSchistosomiasis noma uyincoma kumuntu 
onamaSchistosomiasis? 
(A) Yebo (B) Cha 
21. Ingabe kufanele ulahle i-CM kusukela uqale ukusebenzisa i-TM? 
(A) Yebo (B) Cha 
22. Ingabe ukhulume nodokotela ophethe lokhu ukuphathwa kweSchistosomiasis yakho 
oyisebenzisayo / usebenzisa i-TM?           (A) Yebo            (B) Cha 
23. Uma udokotela wakho engazi ukuthi usetshenzisile / usebenzisa i-TM, yini eyenza uzizwe ungafuni 
ukuxoxa naye? -------------------------------------------------- -------------------------------------------------- ---
----------------------------------------------- -------------------------------------------------- 
24. Uthola kanjani uhlelo lwakho lwe-TM? 
(A) Kusuka kubangani 
(B) Kusuka ebuhlotsheni 
(C) kusuka kumsebenzi we-TM 
(D) Uthenga emakethe 
(E) Kusuka esontweni lakho 
(F) Abanye (chaza) ------------------------------------------- ---------------------- 
25. Ulinganisela kangakanani ukuthi uchithe ku-TM ngonyaka owodwa wokugcina? -------------- 
……………………………………………………………………………………………… 
 
APPENDIX 7: MEDICAL CHART REVIEW BASED ON TM/CM MEDICATION THERAPY IN 
THE MANAGEMENT OF SCHISTOSOMIASIS 
A. DEMOGRAPHIC DATA  
Age:                                                                  Ethnicity: 
Sex:                                                                  Marital status: 
Brief medical history (when relevant): 
  
SCHISTOSOMIASIS TREATMENT  
Therapeutic claims and the corresponding level of evidence (Reliability) 
Yes  No 
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Quality medication therapies 
(A) Very satisfied          (B) Satisfied                 (C) Disappointed  
Precautions: risks associated with the use of TM/CM medication therapies 
Yes                No 
All other medicines used (including self-medication) with administration details. 
……………………………………………………………………………………………… 
Adverse events and their causality. Date of onset (or duration from first administration to the onset of 
the event), description with symptoms and signs, severity and seriousness, results of clinical 
investigations and tests, course and outcome; and, if appropriate, consider challenge/rechallenge with 
the same product. 
……………………………………………………………………………………………… 
Potent and/or toxic TM/CM medication therapies 
……………………………………………………………………………………………… 
Interactions and contraindications (The combination of several TM/CM medication therapies and/or the 
concurrent use of conventional drugs may magnify or oppose the effect of the treatments) 
…………………………………………………………………………………………… 
Posology of TM/CM medication therapies 
……………………………………………………………………………………………… 
Methods of administration of TM/CM medication therapies 
……………………………………………………………………………………………… 
Self-medication of TM/CM medication therapies Yes                No 
Therapeutic claims of the use of concurrent use of conventional drugs TM/CM medication therapies 
……………………………………………………………………………………………… 
 
UHLO LOKUHLOLA EKULASHWENI KWE-SCHISTOSOMIASIS  
A. IDATHA YEMINININGWANE 
Iminyaka:                           uhlanga: 
Ubulili:                                isimo sakho somshado: 
Umlando wokwelashwa (uma kuhambelana): 
 
B. NGOKWELASHWA KWE-SCHISTOSOMIASIS.  
Izimangalo zokwelapha kanye nezinga elihambiselana nobufakazi 
Yebo 
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Chabo 
Izinga lemithi yokwelapha  
A) Nganelisekile kakhulu.   (B)Nganelisekile (C) Anganelisekanga  
Izinyathelo zokuphepha: izingozi ezihambisana nokusetshenziswa kwemithi yokwelapha. 
Yebo 
Cha 
Yonke eminye imithi esetshenzisiwe (nokuzelapha) nemininingwane ekuphathweni kwayo 
……………………………………………………………………………………………… 
Izigameko ezingezinhle ezavela. Usuku kuqala, incazelo kanye nezimpawu, ubukhulu kanye 
nobunzima, imiphumela yophenyo lwasemtholampilo kanye nokuhlolwa, indlela nomphumela, futhi, 
uma kufaneleka, cabanga ngeRechallenge ne Dechallenge ngomkhiqizo ofanayo.  
……………………………………………………………………………………………… 
 
Imithi yokwelapha enamandla noma inobuthi  
……………………………………………………………………………………………… 
Ukuxhumana (ingxube yemithi yokwelapha eminingi noma ukusebenzisa kanyekanye lemishanguzo 
kungenzeka kukhulise noma kuphikise imiphumela yokwelapha.)  
……………………………………………………………………………………………… 
Iposology yokwelapha 
……………………………………………………………………………………………… 
Izindlela zokuphatha imithi yokwelapha  
……………………………………………………………………………………………… 
Imithi yokuzelapha  
Yebo 
 Cha 
Izimangalo ekusebenziseni kanyekanye imithi evamile yokwelapha  
……………………………………………………………………………………………… 
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APPENDIX 8: CERTIFICATE OF ETHICS TRAINING 
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APPENDIX 9: CONFERENCE PRESENTATION 
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